Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	O
I	B
aldosterone	I
receptors	I
in	O
peripheral	O
mononuclear	O
leucocytes	O
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	B
receptor	I
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	O
mononuclear	O
leucocytes	O
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I	O
-	O
II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow	O
-	O
up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate	O
/	O
marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B
receptor	I
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR	O
/	O
EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High	O
-	O
risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion	B
-	I
associated	I
regulatory	I
protein	I
.	O

The	O
vpr	B
product	I
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	O
cells	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B
protein	I
.	O

The	O
vpr	B
product	I
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	O
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

The	O
suppression	O
of	O
basophils	O
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O

The	O
37.5	O
%	O
reduction	O
in	O
dose	O
produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	O
cell	O
return	O
to	O
blood	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng	O
/	O
ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng	O
/	O
ml	O
.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
`	O
`	O
dose	O
-	O
sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
II	O
rex	O
gene	O
are	O
not	O
required	O
for	O
p24rex	B
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-	O
acting	O
regulatory	O
genes	O
,	O
tax	O
and	O
rex	O
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	B
gene	I
product	I
(	O
HTLV	B
-	I
I	I
p40tax	I
and	O
HTLV	B
-	I
II	I
p37tax	I
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	O
gene	O
encodes	O
two	O
protein	O
products	O
,	O
p27rex	B
/	I
p21rex	I
and	O
p26rex	B
/	I
p24rex	I
in	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
,	O
respectively	O
.	O

Rex	B
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	B
/	I
pol	I
and	O
singly	O
spliced	O
env	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	O
gene	O
is	O
critical	O
for	O
Rex	B
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV	O
-	O
I	O
rex	O
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B
,	O
and	O
by	O
analogy	O
HTLV	O
-	O
II	O
p24rex	B
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	O
/	O
rex	O
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	O
gene	O
on	O
Rex	B
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B
of	O
HTLV	O
-	O
II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	O
gene	O
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

[	O
Glucocorticoid	B
receptors	I
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang	O
-	O
deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang	O
-	O
deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	B
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	B
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/-	O
413	O
and	O
4433	O
+	O
/-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/-	O
962	O
and	O
5622	O
+	O
/-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

GCR	B
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/-	O
370	O
,	O
4986	O
+	O
/-	O
419	O
and	O
4524	O
+	O
/-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

Type	B
-	I
II	I
estrogen	I
binding	I
sites	I
in	O
a	O
lymphoblastoid	O
cell	O
line	O
and	O
growth	O
-	O
inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti	O
-	O
estrogen	O
and	O
bioflavonoids	O
.	O

Type	B
-	I
II	I
estrogen	I
-	I
binding	I
sites	I
(	O
type	B
-	I
II	I
EBS	I
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	O
lymphoblastoid	O
cell	O
line	O
IM-9	O
using	O
a	O
whole	O
-	O
cell	O
assay	O
with	O
(	O
6	O
,	O
7	O
-	O
3H	O
)	O
estradiol	O
(	O
3H	O
-	O
E2	O
)	O
as	O
tracer	O
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type	B
-	I
II	I
EBS	I
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose	O
-	O
dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type	B
-	I
II	I
EBS	I
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type	B
-	I
II	I
EBS	I
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell	O
-	O
cycle	O
analysis	O
showed	O
that	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti	O
-	O
estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	O
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type	B
-	I
II	I
EBS	I
.	O

Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O

Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	O
mononuclear	O
leukocytes	O
.	O

Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B
1	I
receptors	I
in	O
human	O
mononuclear	O
leukocytes	O
.	O

11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd	O
-	O
C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O

With	O
hot	O
acetic	O
+	O
p	O
-	O
toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd	O
-	O
C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Pd	O
-	O
C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	O
mononuclear	O
leukocytes	O
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B
1	I
receptor	I
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Specific	O
depletion	O
of	O
the	O
B	O
-	O
cell	O
population	O
induced	O
by	O
aberrant	O
expression	O
of	O
human	O
interferon	O
regulatory	O
factor	O
1	O
gene	O
in	O
transgenic	O
mice	O
.	O

Interferons	B
(	O
IFNs	B
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B
proteins	I
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	B
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	B
factor	I
,	O
IRF-1	B
(	O
interferon	B
regulatory	I
factor	I
1	I
)	O
,	O
which	O
binds	O
to	O
type	O
I	O
IFN	O
and	O
some	O
IFN	O
-	O
inducible	O
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	B
gene	O
is	O
both	O
virus	O
and	O
IFN	B
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	O
gene	O
is	O
functioning	O
in	O
IFN	B
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	O
IRF-1	O
gene	O
linked	O
to	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B	O
-	O
cell	O
population	O
.	O

In	O
fact	O
,	O
transgenic	O
bone	O
marrow	O
cells	O
cocultured	O
with	O
a	O
bone	O
marrow	O
-	O
derived	O
stromal	O
cell	O
line	O
revealed	O
an	O
altered	O
B	O
-	O
cell	O
maturation	O
pattern	O
.	O

Functional	O
analysis	O
of	O
cis	O
-	O
linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	B
proteins	I
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA	O
-	O
DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell	O
-	O
specific	O
transcription	O
.	O

This	O
`	O
`	O
octamer	O
`	O
`	O
in	O
the	O
context	O
of	O
DRA	B
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	B
(	O
OTF-1	B
)	O
and	O
lymphoid	B
-	I
specific	I
(	I
OTF-2	I
)	I
`	I
`	I
octamer	I
''	I
binding	I
proteins	I
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
`	B
`	I
octamer	I
''	I
complex	I
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-	O
acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II	O
-	O
negative	O
HeLa	O
cells	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
`	O
`	O
octamer	O
''	O
does	O
not	O
utilize	O
OTF-2	B
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Inhibition	O
of	O
protein	B
phosphatases	I
by	O
okadaic	O
acid	O
induces	O
AP1	B
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	B
phosphatases	I
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B
1	I
and	I
2A	I
phosphatases	I
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	B
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	B
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto	O
-	O
oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	B
further	O
enhanced	O
the	O
induction	O
of	O
AP1	B
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto	O
-	O
oncogenes	O
including	O
c	O
-	O
jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c	O
-	O
fos	O
and	O
fra-1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c	O
-	O
jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c	O
-	O
jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c	O
-	O
jun	O
transcription	O
.	O

The	O
induction	O
of	O
AP1	B
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	B
phosphatases	I
1	I
and	I
2A	I
(	O
PP1	B
and	O
PP2A	B
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	B
factor	I
AP1	B
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T	B
-	I
cell	I
-	I
specific	I
membrane	I
proteins	I
allows	O
the	O
identification	O
of	O
transcription	B
factors	I
that	O
control	O
the	O
expression	O
of	O
these	O
T	O
-	O
cell	O
genes	O
.	O

Such	O
transcription	B
factors	I
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T	O
-	O
cell	O
phenotype	O
by	O
functioning	O
as	O
'	O
master	O
regulators	O
of	O
T	O
-	O
cell	O
differentiation	O
'	O
.	O

HTLV-1	B
Tax	I
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
T	O
-	O
cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	B
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	B
proteins	I
,	O
c	B
-	I
Fos	I
,	O
Fra-1	B
,	O
c	B
-	I
Jun	I
,	O
JunB	B
,	O
and	O
JunD	B
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	B
transcription	I
factor	I
,	O
Tax1	B
.	O

By	O
using	O
the	O
human	O
T	O
-	O
cell	O
line	O
(	O
JPX-9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	B
,	O
c	B
-	I
Jun	I
,	O
and	O
JunD	B
was	O
also	O
transactivated	O
by	O
Tax1	B
.	O

Moreover	O
,	O
Tax1	B
activated	O
expression	O
of	O
two	O
other	O
transcription	B
factors	I
having	O
zinc	B
finger	I
motifs	I
,	O
Egr-1	B
and	O
Egr-2	B
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	B
transcription	I
factors	I
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Lymphocyte	O
glucocorticoid	B
receptor	I
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	B
glucocorticoid	I
receptor	I
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	B
receptor	I
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	B
receptor	I
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand	O
-	O
induced	O
plasticity	O
of	O
glucocorticoid	B
receptor	I
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	B
receptor	I
numbers	O
during	O
depression	O
.	O

Glucocorticoid	B
receptors	I
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age	O
-	O
related	O
decrease	O
in	O
the	O
number	O
of	O
GR	B
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	B
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	B
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	B
.	O

Eight	O
patients	O
with	O
dermatomyositis	O
/	O
polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	B
in	O
MNL	O
could	O
be	O
down	O
-	O
regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	B
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	B
in	O
MNL	O
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0	O
/	O
G1	O
switch	O
gene	O
containing	O
a	O
CpG	O
-	O
rich	O
island	O
encodes	O
a	O
small	B
basic	I
protein	I
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
(	O
G0S	O
genes	O
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	B
-induced	O
switch	O
of	O
lymphocytes	O
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	O
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	O
genes	O
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	O
mRNA	O
increases	O
transiently	O
within	O
1	O
-	O
2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B
or	O
cycloheximide	O
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full	O
-	O
length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino	B
-	I
acid	I
basic	I
protein	I
has	O
two	O
potential	O
alpha	B
-	I
helical	I
domains	I
separated	O
by	O
a	O
hydrophobic	B
region	I
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta	O
-	O
sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	B
kinase	I
C	I
and	O
casein	B
kinase	I
II	I
.	O

The	O
gene	O
contains	O
a	O
CpG	B
-	I
rich	I
island	I
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19	O
/	O
(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	O
sites	O
for	O
CCAAT	B
-	I
box	I
binding	I
factors	I
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	O
sites	O
for	O
transcription	B
factors	I
AP1	B
,	O
AP2	B
,	O
and	O
AP3	B
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	B
receptor	I
alpha	I
chain	I
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

The	O
two	B
nuclear	I
proteins	I
NF	B
-	I
kappa	I
B	I
(	O
consisting	O
of	O
subunits	O
p50	B
an	O
dp65	B
)	O
and	O
the	O
DNA	B
-	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	B
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T	O
-	O
cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	B
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B
and	O
NF	B
-	I
kappa	I
B	I
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B
(	I
IL-2	I
)	I
receptor	I
alpha	I
chain	I
(	O
IL-2R	B
alpha	I
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O

These	O
findings	O
show	O
that	O
nuclear	B
NF	I
-	I
kappa	I
B	I
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	B
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	B
is	O
a	O
competitive	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B
and	O
IL-2	B
alpha	I
genes	O
during	O
the	O
immune	O
response	O
.	O

Binding	O
of	O
erythroid	B
and	I
non	I
-	I
erythroid	I
nuclear	I
proteins	I
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	O
-	O
encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-392	O
to	O
-177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
86	O
(	O
1989	O
)	O
5306	O
-	O
5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-	O
cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	O
to	O
-251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	B
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B
receptors	I
.	O

Interrelations	O
between	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well	O
-	O
documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T	O
-	O
cell	O
proliferation	O
,	O
pokeweed	B
mitogen	I
(	O
PWM	B
)	O
-driven	O
B	O
-	O
cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B
receptor	I
function	O
,	O
dose	O
-	O
response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B
-induced	O
T	O
-	O
cell	O
mitogenesis	O
,	O
PWM	B
-generated	O
B	O
-	O
cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B
-induced	O
B	O
-	O
cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B
receptor	I
function	O
.	O

The	O
decrease	O
in	O
PWM	B
-generated	O
B	O
-	O
cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid	O
-	O
mediated	O
induction	O
of	O
interleukin-1	B
receptor	I
synthesis	O
.	O

Leukotriene	O
B4	O
stimulates	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
transcription	O
and	O
AP-1	B
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	B
mediator	I
,	O
on	O
the	O
expression	O
of	O
the	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	B
factors	I
binding	O
specifically	O
to	O
the	O
AP-1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
gene	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
c	O
-	O
jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral	O
-	O
blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c	O
-	O
fos	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	O
-	O
fos	O
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	O
-	O
jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
7-fold	O
and	O
the	O
c	O
-	O
jun	O
gene	O
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	B
factors	I
binding	O
to	O
the	O
AP-1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1	B
-binding	O
activity	O
of	O
nuclear	B
proteins	I
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	B
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	B
factors	I
such	O
as	O
AP-1	B
-binding	O
proto	B
-	I
oncogene	I
products	I
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	B
D	I
receptor	I
in	O
human	O
HL60	O
leukemia	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA	O
-	O
relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	B
affinity	I
receptors	I
(	O
VDR	B
)	O
for	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B
3H	I
]	I
calcitriol	I
/	I
VDR	I
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(	O
-9	O
)	O
M	O
/	O
l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	B
3H	I
]	I
calcitriol	I
/	I
VDR	I
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites	O
/	O
nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	O
cells	O
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites	O
/	O
nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	B
radiolabeled	I
VDR	I
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	B
by	O
24	O
h	O
.	O

Radiolabeled	B
VDR	I
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse	O
/	O
chase	O
-	O
experiments	O
)	O
.	O

No	O
difference	O
of	O
VDR	B
retention	O
in	O
pulse	O
and	O
pulse	O
/	O
chase	O
-	O
experiments	O
was	O
seen	O
in	O
PBL	O
,	O
where	O
VDR	B
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

Radiolabeled	B
hormone	I
/	I
receptor	I
complexes	I
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

The	O
activity	O
of	O
DNA	B
relaxing	I
enzymes	I
(	O
e.g	O
.	O
topoisomerases	B
I	I
and	I
II	I
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation	O
-	O
assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v	O
/	O
v	O
)	O
in	O
HL60	O
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	O
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	O
treated	O
controls	O
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	B
proteins	I
after	O
hormone	O
binding	O
.	O

Translocated	B
hormone	I
/	I
receptor	I
complexes	I
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	B
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	B
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA	O
-	O
unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

Specific	O
NF	B
-	I
kappa	I
B	I
subunits	I
act	O
in	O
concert	O
with	O
Tat	B
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
a	O
protein	B
complex	I
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	B
-	I
I	I
gene	I
product	I
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
family	I
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF	B
-	I
kappa	I
B	I
subunits	I
to	O
act	O
with	O
Tat	B
-	I
I	I
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	B
(	I
100	I
)	I
DNA	I
binding	I
subunit	I
,	O
together	O
with	O
p65	B
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	B
-	I
I	I
to	O
stimulate	O
the	O
expression	O
of	O
HIV	O
-	O
CAT	O
plasmid	O
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	B
forms	I
of	O
p105	B
NF	B
-	I
kappa	I
B	I
or	O
rel	B
,	O
in	O
combination	O
with	O
p65	B
or	O
full	B
-	I
length	I
c	I
-	I
rel	I
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	B
(	I
100	I
)	I
and	O
p65	B
NF	B
-	I
kappa	I
B	I
can	O
act	O
in	O
concert	O
with	O
the	O
tat	B
-	I
I	I
gene	I
product	I
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer	O
/	O
promoter	O
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	O
kappa	O
enhancer	O
(	O
or	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer	O
/	O
promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility	O
/	O
cell	O
type	O
specificity	O
.	O

Oct2	B
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B	O
-	O
cell	O
-	O
restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte	B
-	I
specific	I
transcription	I
factor	I
Oct2	B
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	B
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	O
octamer	O
enhancer	O
element	O
in	O
HeLa	O
cells	O
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B
isoforms	I
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B	O
-	O
cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B
isoforms	I
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B	B
-	I
cell	I
-	I
specific	I
cofactor	I
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B
or	O
the	O
Oct2	B
protein	I
in	O
Oct2	B
-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy	B
-	I
terminal	I
domain	I
of	O
Oct2	B
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B
protein	I
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine	B
-	I
rich	I
activation	I
domain	I
present	O
in	O
the	O
amino	B
-	I
terminal	I
portion	I
of	I
Oct2	I
and	O
the	O
POU	B
domain	I
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

TAR	O
-independent	O
transactivation	O
by	O
Tat	B
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	B
protein	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	B
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	B
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS	O
-	O
derived	O
cells	O
Tat	B
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	O
-independent	O
pathway	O
.	O

A	O
Tat	O
-	O
responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial	O
-	O
derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat	O
-	O
responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV-1	O
enhancer	O
,	O
or	O
NF	O
-	O
kappa	O
B	O
domain	O
.	O

DNA	O
band	O
-	O
shift	O
analysis	O
reveals	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	O
-	O
deleted	O
mutants	O
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	B
p24	I
antigen	I
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Natural	O
variants	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG	O
-	O
motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	O
-	O
motif	O
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild	O
-	O
type	O
plasmid	O
were	O
cotransfected	O
into	O
T	O
-	O
cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG	O
-	O
monomer	O
virus	O
outcompeted	O
the	O
CTG	O
-	O
dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation	O
-	O
induced	O
activation	O
of	O
the	O
protein	B
kinase	I
C	I
signaling	O
pathway	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein	B
-	I
tyrosine	I
kinase	I
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B	O
-	O
lymphocyte	O
precursors	O
,	O
irradiation	O
with	O
gamma	O
-	O
rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine	B
-	I
specific	I
protein	I
kinases	I
,	O
including	O
protein	B
kinase	I
C	I
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
.	O

All	O
of	O
the	O
radiation	O
-	O
induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein	B
-	I
tyrosine	I
kinase	I
inhibitors	I
genistein	I
and	I
herbimycin	I
A	I
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	B
kinase	I
C	I
signaling	O
cascade	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation	O
-	O
induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

The	O
zinc	B
finger	I
transcription	I
factor	I
Egr-1	B
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL-60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	B
,	O
a	O
zinc	B
finger	I
transcription	I
factor	I
.	O

The	O
Egr-1	O
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	O
cells	O
,	O
but	O
active	O
in	O
U-937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	B
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL-60	O
cells	O
constitutively	O
expressing	O
an	O
Egr-1	O
transgene	O
(	O
HL-60Egr-1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	B
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	O
to	O
-130	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	B
acetyltransferase	I
reporter	O
gene	O
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	O
and	O
-130	O
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
cell	O
line	O
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65	O
:	O
2436	O
-	O
2444	O
,	O
1991	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	O
to	O
-	O
184	O
,	O
-183	O
to	O
-166	O
,	O
-165	O
to	O
-148	O
,	O
and	O
-148	O
to	O
-130	O
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	O
RD	O
cells	O
with	O
CEMx174	O
cells	O
.	O

In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	O
and	O
-76	O
and	O
between	O
-75	O
and	O
-58	O
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
-	O
and	O
Sp1-binding	O
sites	O
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Three	O
mutants	O
(	O
-201	O
/	O
-184	O
NXS	O
,	O
-165	O
/	O
-148	O
NXS	O
,	O
and	O
-147	O
/	O
-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201	O
/	O
-184	O
NXS	O
and	O
-183	O
/	O
-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type	O
-	O
specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF	B
-	I
kappa	I
B	I
and	O
SP1-binding	O
sites	O
but	O
also	O
for	O
several	O
regions	O
between	O
-201	O
and	O
-130	O
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Human	O
CD4	O
lymphocytes	O
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	B
protein	I
pml	B
/	I
RAR	I
alpha	I
present	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	O
cells	O
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B
point	I
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1	O
/	O
25	O
)	O
encompassing	O
the	O
fusion	B
region	I
of	O
the	O
hybrid	O
molecule	O
pml	B
/	I
RAR	I
alpha	I
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
recognized	O
by	O
human	O
T	O
lymphocytes	O
in	O
vitro	O
.	O

CD4	O
+	O
lymphocytes	O
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1	O
/	O
25	O
in	O
an	O
HLA	B
-	I
DR	I
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
or	O
by	O
APC	O
expressing	O
the	O
HLA	B
-	I
DR11	I
restricting	I
molecule	I
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B
and	O
RAR	B
alpha	I
proteins	I
were	O
not	O
recognized	O
.	O

One	O
clone	O
(	O
DEG5	O
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	O
cells	O
pulsed	O
with	O
BCR1	O
/	O
25	O
.	O

The	O
autologous	O
DE	O
LCL	O
containing	O
a	O
transduced	O
pml	O
/	O
RAR	O
alpha	O
fusion	O
gene	O
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml	B
/	I
RAR	I
alpha	I
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	O
anti	O
-	O
BCR1	O
/	O
25	O
T	O
cell	O
clones	O
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	B
type	I
-	I
pml	I
/	I
RAR	I
alpha	I
fusion	I
protein	I
of	O
APL	O
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	O
CD4	O
+	O
lymphocytes	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid	O
-	O
specific	O
promoter	O
.	O

Mammal	B
pyruvate	I
kinases	I
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	O
the	O
erythroid	B
(	O
R	B
-	I
PK	I
)	O
or	O
the	O
hepatic	B
(	I
L	I
-	I
PK	I
)	I
isozymes	I
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	O
and	O
trans	O
-	O
acting	O
elements	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	O
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R	O
-	O
PK	O
DNA	O
fragment	O
extending	O
from	O
-870	O
to	O
+	O
54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-62	O
to	O
+	O
54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC	B
/	I
Sp1	I
family	I
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	B
factor	I
GATA-1	I
.	O

Although	O
the	O
-20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	B
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC	B
/	I
Sp1	I
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
R	B
-	I
PK	I
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R	O
-	O
PK	O
promoter	O
in	O
HeLa	O
cells	O
.	O

Cell	O
type-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
CD20	B
/	I
B1	I
antigen	I
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	O
(	O
B1	O
)	O
gene	O
encodes	O
a	O
B	B
cell	I
-	I
specific	I
protein	I
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	O
promoter	O
-	O
CAT	O
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B
in	O
pre	O
-	O
B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter	O
-	O
CAT	O
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	O
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	B
proteins	I
suggesting	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
were	O
Oct-1	B
and	O
Oct-2	B
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
confirmed	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
were	O
Oct-1	B
and	O
Oct-2	B
.	O

The	O
affinity	O
of	O
the	O
BAT	B
box	I
binding	I
proteins	I
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	B
box	I
binding	I
proteins	I
dissociated	O
from	O
the	O
BAT	O
box	O
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	O
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	O
cells	O
.	O

The	O
BAT	O
box	O
and	O
Oct-2	B
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B
in	O
the	O
pre	O
-	O
B	O
cell	O
line	O
,	O
PB-697	O
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	O
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	O
mRNA	O
and	O
a	O
BAT	O
box	O
-	O
deleted	O
CD20-CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	B
box	I
binding	I
proteins	I
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B
and	O
perhaps	O
CD21	B
.	O

NF	B
-	I
kappa	I
B	I
controls	O
expression	O
of	O
inhibitor	O
I	B
kappa	I
B	I
alpha	I
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B
kappa	I
B	I
alpha	I
.	O

Phorbol	O
ester	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
induction	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B
kappa	I
B	I
alpha	I
and	O
the	O
activation	O
of	O
I	B
kappa	I
B	I
alpha	O
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65-kilodalton	B
transactivating	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	B
kappa	I
B	I
alpha	I
with	O
p65	B
restores	O
intracellular	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	B
-	I
kappa	I
B	I
controls	O
the	O
expression	O
of	O
I	B
kappa	I
B	I
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	O
B	O
-	O
cells	O
.	O

Lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

Two	O
stable	O
B	O
cell	O
lines	O
were	O
established	O
:	O
R59Z	O
activator	O
cells	O
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	B
1	I
trans	I
-	I
activator	I
(	O
Zta	B
)	O
.	O

R7	O
-	O
57	O
reporter	O
cells	O
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	O
origin	O
of	O
EBV	O
replication	O
(	O
ori	O
Lyt	O
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans	O
-	O
activation	O
converted	O
the	O
recombinant	O
ori	O
Lyt	O
element	O
in	O
R7	O
-	O
57	O
reporter	O
cells	O
.	O

BZLF	B
1	I
,	O
transiently	O
expressed	O
in	O
R7	O
-	O
57	O
reporter	O
cells	O
,	O
was	O
the	O
only	O
EBV	B
trans	I
-	I
activator	I
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans	O
-	O
cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	O
1-expressing	O
R59Z	O
activator	O
cells	O
with	O
the	O
R7	O
-	O
57	O
reporter	O
line	O
.	O

No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	O
cells	O
nor	O
by	O
coincubation	O
of	O
BZLF	B
1	I
-containing	O
cell	O
lysates	O
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	O
to	O
reporter	O
cells	O
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	O
gene	O
BZLF	O
1	O

Immobilization	O
and	O
recovery	O
of	O
fusion	B
proteins	I
and	O
B	O
-	O
lymphocyte	O
cells	O
using	O
magnetic	O
separation	O
.	O

A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	B
proteins	I
and	O
selected	O
human	O
B	O
lymphocytes	O
has	O
been	O
developed	O
.	O

Using	O
magnetic	O
beads	O
with	O
attached	O
DNA	O
containing	O
the	O
Escherichia	O
coli	O
lac	O
operator	O
,	O
fusion	B
proteins	I
comprising	O
the	O
DNA	O
-	O
binding	O
lac	O
repressor	O
could	O
be	O
affinity	O
-	O
purified	O
and	O
recovered	O
by	O
gentle	O
elution	O
conditions	O
,	O
such	O
as	O
with	O
a	O
lactose	O
analogue	O
or	O
by	O
enzymatic	O
means	O
using	O
either	O
deoxyribonuclease	B
(	O
DNase	B
)	O
or	O
restriction	B
endonucleases	I
.	O

The	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
DNA	B
-	I
binding	I
protein	I
can	O
be	O
used	O
for	O
affinity	O
purification	O
of	O
fusion	B
proteins	I
as	O
exemplified	O
by	O
the	O
specific	O
and	O
gentle	O
recovery	O
of	O
beta	B
-	I
galactosidase	I
and	O
alkaline	B
phosphatase	I
from	O
bacterial	O
lysates	O
using	O
immunomagnetic	O
separation	O
.	O

The	O
approach	O
was	O
further	O
extended	O
to	O
cell	O
separation	O
by	O
the	O
efficient	O
recovery	O
and	O
elution	O
of	O
human	O
CD37	O
B	O
lymphocytes	O
from	O
peripheral	O
blood	O
.	O

[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	O
]	O

Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	O
biology	O
since	O
genes	O
association	O
with	O
eosinophils	O
such	O
as	O
interleukin-5	B
or	O
eosinophil	B
granule	I
proteins	I
(	O
EPO	B
,	O
ECP	B
,	O
EDN	B
,	O
MBP	B
,	O
and	O
CLC	B
)	O
,	O
were	O
isolated	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
has	O
not	O
been	O
determined	O
.	O

The	O
mechanism	O
by	O
which	O
eosinophil	O
-	O
specific	O
genes	O
encoding	O
primary	O
and	O
secondary	B
granule	I
proteins	I
(	O
e.g	O
.	O
ECP	B
,	O
EDN	B
,	O
EPO	B
,	O
MBP	B
,	O
and	O
CLC	B
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
I	O
described	O
the	O
characterization	O
of	O
genes	O
encoding	O
eosinophil	B
granule	I
proteins	I
and	O
the	O
mRNA	O
expression	O
of	O
GATA-1	B
binding	I
transcription	I
factor	I
during	O
eosinophil	O
differentiation	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	B
and	O
activation	O
of	O
c	B
-	I
Rel	I
and	O
related	O
NF	B
-	I
kappa	I
B	I
proteins	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA	O
-	O
binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
transcription	I
factor	I
family	I
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS	O
-	O
generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c	B
-	I
Rel	I
/	I
p50	I
heterodimers	I
as	O
well	O
as	O
p50	B
/	I
p65	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
kappa	O
B	O
DNA	O
-	O
binding	O
complexes	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	B
ester	I
-	I
sensitive	I
protein	I
kinase	I
C	I
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c	B
-	I
Rel	I
,	O
p105	B
,	O
and	O
p50	B
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP-1	O
cells	O
.	O

LPS	O
activation	O
of	O
THP-1	O
cells	O
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B
(	O
an	O
I	B
kappa	I
B	I
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	O
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	B
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c	B
-	I
Rel	I
/	I
p50	I
and	O
p50	B
/	I
p65	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B
.	O

Regulation	O
of	O
lymphoid	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
enhancer	O
by	O
ETS	O
-	O
domain	O
proteins	O
.	O

The	O
enhancer	O
for	O
the	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
(	O
IgH	B
)	O
activates	O
a	O
heterologous	O
gene	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
of	O
B	O
lymphocyte	O
differentiation	O
.	O

A	O
lymphoid	O
-	O
specific	O
element	O
,	O
microB	O
,	O
is	O
necessary	O
for	O
enhancer	O
function	O
in	O
pre	O
-	O
B	O
cells	O
.	O

A	O
microB	B
binding	I
protein	I
is	O
encoded	O
by	O
the	O
PU.1	O
/	O
Spi-1	O
proto	O
-	O
oncogene	O
.	O

Another	O
sequence	O
element	O
,	O
microA	O
,	O
was	O
identified	O
in	O
the	O
mu	O
enhancer	O
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	O
proto	O
-	O
oncogene	O
.	O

The	O
microA	O
motif	O
was	O
required	O
for	O
microB	O
-	O
dependent	O
enhancer	O
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	O
B	O
cell	O
-	O
specific	O
enhancer	O
is	O
composed	O
of	O
both	O
the	O
PU.1	O
and	O
Ets-1	O
binding	O
sites	O
.	O

Co	O
-	O
expression	O
of	O
both	O
PU.1	B
and	O
Ets-1	B
in	O
nonlymphoid	O
cells	O
trans	O
-	O
activated	O
reporter	O
plasmids	O
that	O
contained	O
the	O
minimal	O
mu	O
enhancer	O
.	O

These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	B
family	I
in	O
the	O
activation	O
of	O
IgH	O
gene	O
expression	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
-	O
transduction	O
pathway	O
emanating	O
from	O
the	O
T	B
-	I
cell	I
receptor	I
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second	O
-	O
messenger	O
Ca2	O
+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL-2	B
,	O
among	O
which	O
are	O
calmodulin	B
,	O
calcineurin	B
and	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
.	O

Hence	O
,	O
Ca2	O
+	O
binds	O
to	O
calmodulin	B
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	B
to	O
calcineurin	B
;	O
the	O
activated	O
calcineurin	B
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	B
subunit	I
of	I
NF	I
-	I
AT	I
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	B
transcriptional	I
activator	I
.	O

As	O
described	O
by	O
Jun	B
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	B
receptors	I
called	O
immunophilins	B
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	B
prolyl	I
cis	I
-	I
trans	I
isomerase	I
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin	B
-	I
drug	I
complexes	I
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	B
activity	O
of	O
calcineurin	B
.	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B
factors	I
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B
factors	I
(	O
MyoD	B
,	O
myogenin	B
,	O
myf5	B
,	O
and	O
myf6	B
)	O
that	O
are	O
`	B
`	I
basic	I
helix	I
-	I
loop	I
-	I
helix	I
''	I
proteins	I
that	O
bind	O
to	O
the	O
promoters	O
of	O
muscle	O
-	O
specific	O
genes	O
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B
binding	I
basic	I
domain	I
of	O
MyoD	B
confers	O
c	O
-	O
myc	O
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	B
domains	I
of	O
all	O
the	O
myogenic	B
factors	I
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B
transcription	I
factors	I
.	O

The	O
SCL	B
protein	I
displays	O
cell	O
-	O
specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	B
protein	I
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	O
cell	O
lines	O
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	B
protein	I
was	O
detected	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
mast	O
and	O
early	O
myeloid	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	O
leukemia	O
cell	O
lines	O
which	O
are	O
known	O
to	O
harbor	O
SCL	O
gene	O
rearrangements	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B
weight	I
species	I
of	I
24	I
and	I
22	I
kDa	I
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell	O
-	O
specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	O
gene	O
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	O
lines	O
(	O
GP+E-86	O
,	O
AT2.5	O
,	O
M1	O
)	O
but	O
only	O
the	O
22	B
kDa	I
form	I
in	O
the	O
myeloid	O
cell	O
line	O
,	O
WEHI-3B	O
/	O
D+	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
SCL	B
protein	I
in	O
the	O
lymphoid	O
cell	O
lines	O
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B
transcription	O
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B
protein	I
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	O
mRNA	O
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B
protein	I
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

Activation	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoter	O
in	O
T	O
cells	O
requires	O
cooperative	O
binding	O
of	O
Elf-1	B
and	O
AP-1	B
transcription	B
factors	I
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T	O
-	O
lymphocyte	O
activation	O
.	O

The	O
GM	O
-	O
CSF	O
gene	O
is	O
not	O
expressed	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	B
surface	I
T	I
-	I
cell	I
receptor	I
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
TATA	O
box	O
(	O
bp	O
-34	O
to	O
-52	O
)	O
,	O
herein	O
called	O
purine	O
box	O
1	O
(	O
PB1	O
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T	B
-	I
cell	I
nuclear	I
protein	I
complex	I
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
following	O
T	O
-	O
cell	O
activation	O
.	O

The	O
PB1	O
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	O
and	O
murine	O
GM	O
-	O
CSF	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	O
element	O
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	B
nuclear	I
protein	I
-	I
binding	I
complex	I
that	O
is	O
not	O
present	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
following	O
T	O
-	O
cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	O
is	O
composed	O
of	O
adjacent	O
binding	O
sites	O
for	O
Ets	B
and	O
AP-1	B
transcription	B
factors	I
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	O
and	O
AP-1	O
sites	O
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	B
nuclear	I
protein	I
complex	I
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
activated	O
T	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Stress	O
response	O
of	O
senescent	O
T	O
lymphocytes	O
:	O
reduced	O
hsp70	B
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	O
human	O
T	O
lymphocyte	O
cultures	O
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	O
passage	O
cells	O
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

A	O
second	O
feature	O
of	O
senescent	O
T	O
cells	O
is	O
the	O
dramatic	O
reduction	O
in	O
hsp70	B
production	O
in	O
response	O
to	O
heat	O
shock	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	O
heat	O
shock	O
element	O
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	O
T	O
cells	O
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

This	O
suggests	O
that	O
for	O
senescent	O
T	O
cells	O
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	B
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

The	O
interleukin-8	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B
cytokine	I
,	O
interleukin-8	B
(	O
IL-8	B
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	O
promoters	O
,	O
the	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	B
-	I
JunD	I
or	O
c	B
-	I
Fos	I
antibody	I
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B
B	I
-	I
like	I
site	I
binding	I
complexes	I
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B
against	O
the	O
human	B
Rel	I
family	I
proteins	I
(	O
c	B
-	I
Rel	I
,	O
p65	B
,	O
p50	B
,	O
and	O
p49	B
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	B
-	I
kappa	I
B	I
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	O
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	O
kappa	O
B	O
site	O
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B
factors	I
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	O
NF	O
-	O
AT	O
and	O
NFIL-2A	O
sites	O
and	O
Ig	O
kappa	O
B	O
site	O
,	O
but	O
also	O
the	O
IL-8	B
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O

Activation	O
of	O
a	O
novel	O
serine	B
/	I
threonine	I
kinase	I
that	O
phosphorylates	O
c	B
-	I
Fos	I
upon	O
stimulation	O
of	O
T	O
and	O
B	O
lymphocytes	O
via	O
antigen	O
and	O
cytokine	B
receptors	I
.	O

Ligation	O
of	O
Ag	B
receptors	I
in	O
T	O
and	O
B	O
lymphocytes	O
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B
tyrosine	I
and	I
serine	I
/	I
threonine	I
kinases	I
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine	B
/	I
threonine	I
kinase	I
that	O
phosphorylated	O
the	O
proto	B
-	I
oncogene	I
product	I
,	O
c	B
-	I
Fos	I
,	O
and	O
is	O
termed	O
Fos	B
kinase	I
.	O

Fos	B
kinase	I
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	B
and	I
CD2	I
receptors	I
in	O
Jurkat	O
and	O
normal	O
human	O
T	O
lymphocytes	O
and	O
in	O
response	O
to	O
IL-6	B
and	O
anti	B
-	I
IgM	I
in	O
the	O
human	O
B	O
cell	O
lines	O
AF10	O
and	O
Ramos	O
,	O
respectively	O
.	O

The	O
phorbol	O
ester	O
,	O
PMA	O
,	O
was	O
also	O
a	O
potent	O
inducer	O
of	O
Fos	B
kinase	I
activity	O
in	O
all	O
of	O
the	O
above	O
populations	O
,	O
suggesting	O
that	O
PKC	B
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
this	O
enzyme	B
.	O

Fos	B
kinase	I
phosphorylates	O
c	B
-	I
Fos	I
at	O
a	O
site	O
near	O
the	O
C	B
-	I
terminus	I
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B
359	I
-	I
370	I
,	O
RKGSSSNEPSSD	B
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c	B
-	I
Fos	I
phosphorylation	O
.	O

Fos	B
kinase	I
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine	B
/	I
threonine	I
kinases	I
,	O
including	O
protein	B
kinase	I
A	I
,	O
protein	B
kinase	I
C	I
,	O
casein	B
kinase	I
II	I
,	O
MAP	B
kinases	I
,	O
p70S6	B
K	I
and	O
p90RSK	B
.	O

Fos	B
kinase	I
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M	O
(	O
r	O
)	O
=	O
65	O
,	O
000	O
and	O
isoelectric	O
point	O
=	O
6.1	O
.	O

Fos	B
kinase	I
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c	B
-	I
Fos	I
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	O
.	O

A	O
novel	O
heterodimerization	B
partner	I
for	O
thyroid	B
hormone	I
receptor	I
.	O

Peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
.	O

Retinoid	B
-	I
like	I
receptors	I
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B
with	O
other	O
nuclear	B
hormone	I
receptors	I
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
(	O
PPAR	B
)	O
as	O
a	O
new	O
thyroid	B
hormone	I
receptor	I
(	I
THR	I
)	I
auxiliary	I
nuclear	I
protein	I
,	O
heterodimerizing	O
with	O
THR	B
in	O
solution	O
.	O

Although	O
these	O
heterodimers	B
do	O
not	O
recognize	O
a	O
classical	O
thyroid	O
hormone	O
response	O
element	O
(	O
TRE	O
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	O
)	O
,	O
PPAR	B
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH	O
-	O
dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	B
beta	I
-	I
PPAR	I
but	O
not	O
the	O
THR	B
alpha	I
-	I
PPAR	I
heterodimer	I
with	O
a	O
novel	O
TRE	O
(	O
DR+2	O
)	O
.	O

The	O
critical	O
region	O
of	O
THR	B
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B
box	I
of	O
the	O
DNA	B
binding	I
domain	I
.	O

Hence	O
,	O
PPAR	B
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	B
isotype	I
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	O
gene	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte	O
-	O
mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia	O
/	O
reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14	O
-	O
18	O
Torr	O
,	O
led	O
to	O
time	O
-	O
dependent	O
release	O
of	O
IL-8	B
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	B
.	O

Production	O
of	O
IL-8	B
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	O
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	B
transcription	O
,	O
based	O
on	O
nuclear	O
run	O
-	O
on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	O
for	O
macrophage	B
chemotactic	I
protein-1	I
,	O
another	O
member	O
of	O
the	O
chemokine	B
superfamily	I
of	O
proinflammatory	B
cytokines	I
.	O

IL-8	O
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF	O
-	O
kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	B
antigen	I
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30	O
-	O
40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	B
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	B
family	I
related	O
to	O
IL-8	B
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Patterns	O
of	O
Pan	B
expression	O
and	O
role	O
of	O
Pan	B
proteins	I
in	O
endocrine	O
cell	O
type	O
-	O
specific	O
complex	O
formation	O
.	O

The	O
Pan	O
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	B
and	O
Pan-2	B
(	O
also	O
known	O
as	O
E47	B
and	O
E12	B
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	B
proteins	I
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	O
lines	O
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B
proteins	I
have	O
suggested	O
that	O
significant	O
E2A	B
protein	I
expression	O
is	O
restricted	O
to	O
B	O
-	O
lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	B
antibody	I
,	O
Yae	B
,	O
which	O
is	O
specific	O
for	O
Pan	B
/	I
E2A	I
proteins	I
,	O
and	O
have	O
used	O
the	O
Yae	B
antibody	I
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan	O
/	O
E2A	B
protein	I
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan	O
/	O
E2A	B
proteins	I
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B
proteins	I
in	O
GH	O
/	O
PRL-	O
and	O
insulin	O
-	O
producing	O
,	O
B-	O
and	O
T	O
-	O
lymphocyte	O
cells	O
.	O

IEF-1	B
,	O
a	O
pancreatic	O
beta	O
-	O
cell	O
type	O
-	O
specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B
molecules	I
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta	O
-	O
cells	O
share	O
identical	O
Pan	B
/	I
E2A	I
complexes	I
,	O
native	O
-	O
Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta	O
-	O
cells	O
detect	O
Pan	B
proteins	I
in	O
distinct	O
cell	B
type	I
-	I
specific	I
complexes	I
.	O

Novel	O
aldosterone	B
receptors	I
:	O
specificity	O
-	O
conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra	O
-	O
renal	O
,	O
nonepithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non	O
-	O
genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium	B
/	I
proton	I
-	I
exchanger	I
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate	O
/	O
calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
-	O
related	O
rapid	O
responses	O
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	O
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
receptor	B
protein	I
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two	O
-	O
step	O
model	O
for	O
non	O
-	O
genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity	O
-	O
conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

Multiple	O
prolactin	O
-	O
responsive	O
elements	O
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	O
regulatory	O
factor-1	O
gene	O
.	O

The	O
interferon	O
regulatory	O
factor-1	O
(	O
IRF-1	O
)	O
gene	O
is	O
both	O
an	O
immediate	O
-	O
early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	O
by	O
PRL	B
in	O
rat	O
Nb2	O
T	O
lymphocytes	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B
,	O
we	O
cloned	O
the	O
rat	O
IRF-1	O
gene	O
and	O
functionally	O
characterized	O
the	O
IRF-1	O
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	O
T	O
cells	O
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	O
5'-flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	B
enzyme	I
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	O
,	O
0.6	O
,	O
and	O
0.2	O
kb	O
5'-flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	B
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	O
to	O
respond	O
to	O
PRL	B
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	O
PRL	O
response	O
elements	O
may	O
require	O
an	O
interaction	O
with	O
promoter	O
-	O
proximal	O
elements	O
.	O

By	O
assaying	O
CAT	B
enzyme	I
activity	O
across	O
a	O
24-h	O
PRL	B
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	B
responses	O
of	O
the	O
IRF-1	O
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF-1	B
5'-flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0.2-kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
induced	O
by	O
PRL	B
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-	O
CAT	B
construct	O
was	O
inducible	O
by	O
PRL	B
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	B
-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	O
gene	O
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL	O
-	O
responsive	O
elements	O
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	O
promoter	O
region	O
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

HLA	O
-	O
DR-	O
,	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16-	O
myeloid	O
/	O
natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French	O
-	O
American	O
-	O
British	O
acute	O
myeloid	O
leukemia	O
-	O
M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+	O
/	O
-	O
,	O
HLA	B
-	I
DR	I
-	O
,	O
CD16	B
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	B
(	I
CD33	I
,	I
CD13	I
,	I
CD15	I
)	I
and	I
NK	I
cell	I
-	I
associated	I
(	I
CD56	I
)	I
antigens	I
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B
(	O
neural	B
cell	I
adhesion	I
molecule	I
)	O
in	O
leukemic	O
blasts	O
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B
,	O
no	O
case	O
expressed	O
CD2	B
,	O
CD3	B
,	O
or	O
CD8	B
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
beta	I
,	I
gamma	I
,	I
delta	I
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B
variant	I
(	O
FAB	B
AML	I
-	I
M3v	I
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic	O
/	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
fusion	O
transcript	O
in	O
RT	O
-	O
PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	O
17q	O
:	O
1	O
with	O
del	O
(	O
17	O
)	O
(	O
q25	O
)	O
and	O
the	O
other	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q23	O
;	O
q21	O
)	O
and	O
the	O
promyelocytic	O
leukemia	O
zinc	O
finger	O
/	O
RAR	O
alpha	O
fusion	O
transcript	O
.	O

All	O
cases	O
tested	O
(	O
6	O
/	O
20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16	B
-acute	O
leukemias	O
and	O
normal	O
CD56	O
+	O
,	O
CD16-	O
NK	O
precursor	O
cells	O
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	O
CD56	O
+	O
,	O
CD33	O
+	O
,	O
CD16-	O
counterpart	O
cell	O
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	O
and	O
NK	O
cell	O
lineages	O
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid	O
/	O
NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA	O
-	O
nonresponsive	O
cases	O
from	O
ATRA	O
-	O
responsive	O
true	O
APL	O
.	O

Upregulation	O
of	O
bcl-2	O
by	O
the	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
membrane	I
protein	I
LMP1	B
:	O
a	O
B	O
-	O
cell	O
-	O
specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
to	O
induction	O
of	O
cell	B
surface	I
markers	I
.	O

An	O
ability	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
membrane	I
protein	I
LMP1	B
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	O
of	O
the	O
bcl-2	O
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1	O
+	O
clones	O
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107	O
-	O
1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	B
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2	O
+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
and	O
upregulation	O
of	O
the	O
cell	B
adhesion	I
molecule	I
ICAM-1	B
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B	O
-	O
cell	O
lines	O
carrying	O
an	O
LMP1	B
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	O
to	O
express	O
LMP1	B
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK	B
-	I
kappa	I
B	I
and	O
upregulation	O
of	O
ICAM-1	B
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	B
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B	O
-	O
cell	O
lines	O
tested	O
showed	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
response	O
to	O
LMP1	B
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	B
and	O
Bcl-2	B
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-	O
B	O
-	O
cell	O
lines	O
showed	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
ICAM-1	B
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl-2	B
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	B
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	B
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B
signal	O
transduction	O
,	O
other	O
cell	B
-	I
specific	I
factors	I
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B
protein	I
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
in	O
relation	O
to	O
CD4	B
cell	O
number	O
and	O
antibody	O
titres	O
to	O
EBV	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti	B
-	I
Z	I
Epstein	I
-	I
Barr	I
replicative	I
activator	I
(	O
ZEBRA	B
)	O
,	O
anti	B
-	I
early	I
antigen	I
(	O
EA	B
)	O
,	O
anti	B
-	I
viral	I
capsid	I
antigen	I
(	O
VCA	B
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4	B
+	I
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	B
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

METHODS	O
:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein	O
-	O
Barr	O
early	O
region	O
(	O
EBER	O
)	O
RNA	O
-	O
positive	O
]	O
.	O

Immunohistochemistry	O
was	O
performed	O
with	O
anti	B
-	I
ZEBRA	I
,	O
anti	B
-	I
EA	I
-	I
restricted	I
,	I
anti	I
-	I
VCA	I
antibodies	I
and	O
in	O
situ	O
hybridization	O
with	O
BHLF1	O
/	O
NotI	O
oligoprobes	O
on	O
tumour	O
samples	O
.	O

Results	O
were	O
statistically	O
correlated	O
with	O
those	O
of	O
CD4	B
+	I
cell	O
counts	O
(	O
17	O
out	O
of	O
17	O
)	O
and	O
with	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
13	O
out	O
of	O
17	O
)	O
assessed	O
using	O
standard	O
immunofluorescence	O
method	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
procedure	O
using	O
recombinant	B
ZEBRA	I
protein	I
and	O
synthetic	O
peptides	O
as	O
antigens	B
.	O

RESULTS	O
:	O
BZLF1	B
(	O
ZEBRA	B
)	O
or	O
early	B
gene	I
products	I
(	O
EA	B
-	I
R	I
and	O
EA	B
-	I
D	I
/	I
BHLF1	I
/	I
NotI	I
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01	O
-	O
5	O
%	O
)	O
of	O
tumour	O
cells	O
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4	B
+	I
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Anti-	O
ZEBRA	B
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
ARNHL	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	B
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Displacement	O
of	O
an	O
E	B
-	I
box	I
-	I
binding	I
repressor	I
by	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
:	O
implications	O
for	O
B	O
-	O
cell	O
specificity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

The	O
activity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
is	O
restricted	O
to	O
B	O
cells	O
,	O
although	O
it	O
binds	O
both	O
B	B
-	I
cell	I
-	I
restricted	I
and	I
ubiquitous	I
transcription	I
factors	I
.	O

Activation	O
of	O
the	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
upon	O
overexpression	O
of	O
the	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
protein	I
E2A	B
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	B
to	O
its	O
cognate	O
E	O
box	O
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	B
from	O
that	O
same	O
site	O
.	O

We	O
have	O
identified	O
a	O
`	B
`	I
two	I
-	I
handed	I
''	I
zinc	I
finger	I
protein	I
,	O
denoted	O
ZEB	B
,	O
the	O
DNA	O
-	O
binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B
repressor	I
.	O

By	O
employing	O
a	O
derivative	O
E	O
box	O
that	O
binds	O
ZEB	B
but	O
not	O
E2A	B
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B
is	O
active	O
in	O
B	O
cells	O
and	O
the	O
IgH	O
enhancer	O
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B
proteins	I
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	O
activity	O
is	O
the	O
B	O
-	O
cell	O
-	O
specific	O
displacement	O
of	O
a	O
ZEB	B
-	I
like	I
repressor	I
by	O
bHLH	B
proteins	I
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	O
and	O
interleukin	B
2	I
-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV	O
-	O
infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	O
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	O
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free	O
-	O
radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	O
cells	O
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	O
cells	O
.	O

Both	O
antioxidants	O
inhibited	O
TNF	B
-or	O
PMA	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
U1	O
cells	O
,	O
as	O
well	O
as	O
the	O
sustained	O
NF	B
-	I
kappa	I
B	I
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV	O
-	O
infected	O
U937	O
cells	O
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	O
cells	O
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	O
infected	O
U937	O
cells	O
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK	B
-	I
kappa	I
B	I
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	O
PBMC	O
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant	O
-	O
based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

A	O
low	O
NM23.H1	O
gene	O
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis	O
-	O
suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	B
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	B
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	O
gene	O
in	O
cell	O
lines	O
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease	O
-	O
free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	O
lines	O
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	O
lines	O
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24	O
-	O
58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	O
lines	O
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6	O
-	O
15	O
months	O
)	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	B
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid	O
-	O
induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat	O
-	O
activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1-infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B
(	O
IFN	B
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV-1-infected	O
cells	O
,	O
HIV-1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
of	O
the	O
HIV-1	O
LTR	O
significantly	O
inhibited	O
Tat	B
-mediated	O
transactivation	O
in	O
T	O
-	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	O
line	O
,	O
U937	O
.	O

Replacement	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
in	O
the	O
HIV-1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5'-flanking	O
region	O
of	O
IFN	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN	O
-	O
stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat	B
-mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	O
gene	O
directed	O
high	O
levels	O
of	O
IFN	B
synthesis	O
in	O
Tat	O
-	O
expressing	O
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B
necrosis	I
factor	I
alpha	I
-mediated	O
activation	O
.	O

ISG15-LTR	O
-	O
IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	O
and	O
U937	O
cells	O
.	O

Selected	O
transfected	O
clones	O
produced	O
low	O
levels	O
of	O
IFN	B
A	I
(	O
IFNA	B
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B
and	O
interleukin-2	B
receptor	I
upon	O
stimulation	O
with	O
phytohemagglutinin	B
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA	O
-	O
producing	O
cells	O
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	O
cells	O
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	O
cells	O
transduced	O
with	O
the	O
IFNA	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	B
synthesis	O
to	O
HIV-1-infected	O
cells	O
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	B
synthesis	O
results	O
in	O
a	O
long	O
-	O
lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B
receptor	I
on	O
peripheral	O
blood	O
lymphocytes	O
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
expression	O
of	O
the	O
progesterone	B
receptor	I
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
was	O
analysed	O
,	O
using	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
Abbott	O
PgR	O
-	O
EIA	O
monoclonal	O
)	O
,	O
in	O
order	O
to	O
evaluate	O
its	O
prognostic	O
character	O
in	O
the	O
context	O
of	O
spontaneous	O
abortion	O
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non	O
-	O
pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

In	O
addition	O
,	O
a	O
human	O
breast	O
carcinoma	O
cell	O
line	O
(	O
ZR-75	O
-	O
1	O
)	O
,	O
which	O
expresses	O
the	O
progesterone	B
receptor	I
,	O
was	O
analysed	O
throughout	O
.	O

The	O
ZR-75	O
-	O
1	O
cell	O
line	O
showed	O
an	O
expression	O
of	O
642	O
fmol	O
/	O
mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol	O
/	O
mg	O
.	O

Lymphocytes	O
of	O
non	O
-	O
pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre	O
-	O
term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+	O
/-	O
1	O
,	O
3	O
+	O
/-	O
2	O
and	O
5	O
+	O
/-	O
4	O
fmol	O
/	O
mg	O
respectively	O
.	O

These	O
results	O
show	O
that	O
there	O
is	O
no	O
evidence	O
of	O
specific	O
expression	O
of	O
the	O
progesterone	B
receptor	I
in	O
pregnancy	O
and	O
exclude	O
any	O
prognostic	O
character	O
in	O
spontaneous	O
abortion	O
.	O

A	O
role	O
for	O
the	O
progesterone	B
receptor	I
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	O
blood	O
lymphocytes	O
is	O
also	O
excluded	O
.	O

Characterization	O
of	O
the	O
CD48	O
gene	O
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
and	O
contains	O
an	O
essential	O
NF	O
-	O
kappa	O
B	O
site	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	O
B	O
cells	O
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	B
,	O
characteristically	O
expressed	O
on	O
normal	O
activated	O
B	O
cells	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	O
element	O
in	O
the	O
CD48	O
gene	O
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV	O
-	O
positive	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV	O
-	O
negative	O
B	O
-	O
cell	O
lines	O
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	O
phenotype	O
.	O

An	O
NF	B
-	I
kappa	I
B	I
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	B
protein	I
complex	I
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF	B
-	I
kappa	I
B1	I
(	O
p50	B
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV	B
-	I
encoded	I
latent	I
membrane	I
protein	I
1	I
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B
NF	O
-	O
kappa	O
B	O
site	O
but	O
not	O
the	O
intact	O
element	O
,	O
suggesting	O
that	O
the	O
latent	B
membrane	I
protein	I
1	I
-driven	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	O
B	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O

Activation	O
of	O
human	O
thymocytes	O
after	O
infection	O
by	O
EBV	O
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	B
receptor	I
,	O
CR2	B
/	I
CD21	I
,	O
on	O
a	O
population	O
of	O
immature	O
thymocytes	O
,	O
T	O
lymphoblastoid	O
cell	O
lines	O
,	O
and	O
childhood	O
acute	O
T	O
lymphoblastic	O
leukemia	O
cells	O
suggested	O
that	O
EBV	O
-	O
receptor	O
interactions	O
on	O
T	O
cells	O
may	O
be	O
of	O
importance	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	O
,	O
immature	O
cells	O
expresses	O
CD21	B
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	O
thymocytes	O
in	O
vitro	O
.	O

Triggering	O
through	O
CD2	B
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	O
cells	O
.	O

However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	B
caused	O
thymocytes	O
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	B
cytokines	I
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	B
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	B
mAb	I
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95	O
-	O
8	O
.	O

Immature	O
thymocytes	O
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	O
genome	O
and	O
its	O
transcriptional	O
activity	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95	B
-	I
8	I
,	O
EBNA-2	O
transcripts	O
were	O
identified	O
within	O
infected	O
thymocyte	O
populations	O
.	O

In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	O
.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	O
,	O
an	O
early	O
gene	O
that	O
characterizes	O
EBV	O
-	O
infected	O
B	O
cells	O
after	O
disruption	O
of	O
latency	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
consequences	O
of	O
EBV	O
infection	O
of	O
T	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
may	O
lead	O
to	O
failure	O
of	O
normal	O
T	O
cell	O
repertoire	O
development	O
,	O
autoimmunity	O
,	O
or	O
malignancy	O
.	O

Protein	B
kinase	I
C	I
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	O
in	O
activated	O
T	O
cells	O
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
downstream	O
of	O
p21ras	O
,	O
in	O
activating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	B
is	O
an	O
effector	B
of	O
p21ras	O
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	B
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	B
is	O
not	O
downstream	O
of	O
p21ras	O
in	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
and	O
AP-1	B
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL-2	B
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF	B
-	I
kappa	I
B	I
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	O
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	B
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	B
during	O
T	O
cell	O
activation	O
.	O

Detection	O
of	O
the	O
chromosome	O
16	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcript	O
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	O
beta	O
and	O
MYH11	O
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	O
transcripts	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
by	O
RT	O
-	O
PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty	O
-	O
three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	O
abnormal	O
eosinophils	O
(	O
AML	O
M4	O
`	O
`	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT	O
-	O
PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	O
eosinophils	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	O
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT	O
-	O
PCR	O
positive	O
.	O

Follow	O
-	O
up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	O
16	O
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	O
beta	O
-	O
MYH11	O
transcripts	O
in	O
the	O
absence	O
of	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT	O
-	O
PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	O
transcript	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM	B
-	I
CSF	I
,	O
IL-3	B
,	O
M	B
-	I
CSF	I
receptor	I
(	O
C	B
-	I
FMS	I
)	O
,	O
early	O
growth	O
response	O
gene-1	O
(	O
EGR-1	O
)	O
and	O
M	O
-	O
CSF	O
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	O
,	O
GM	O
-	O
CSF	O
,	O
FMS	O
and	O
EGR-1	O
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	O
clones	O
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M	O
-	O
CSF	O
gene	O
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	O
and	O
the	O
EGR-1	O
genes	O
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M	O
-	O
CSF	O
and	O
FMS	O
genes	O
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	B
growth	I
factors	I
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

A	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
in	O
the	O
progesterone	O
receptor	O
gene	O
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	B
receptor	I
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	O
leucocyte	O
genomic	O
DNAs	O
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	O
progesterone	O
receptor	O
(	O
hPR	O
)	O
cDNA	O
probe	O
identified	O
a	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	O
,	O
represented	O
by	O
a	O
2.7	O
kb	O
fragment	O
;	O
and	O
T2	O
,	O
represented	O
by	O
a	O
1.9	O
kb	O
fragment	O
and	O
characterised	O
by	O
an	O
additional	O
TaqI	O
restriction	O
site	O
with	O
respect	O
to	O
T1	O
.	O

An	O
over	O
-	O
representation	O
of	O
T2	O
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish	O
/	O
German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	O
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy	O
-	O
Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	O
cDNA	O
region	O
-	O
specific	O
probes	O
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	O
G	O
of	O
the	O
hPR	O
gene	O
.	O

IL-1	B
receptor	I
and	O
TCR	B
signals	O
synergize	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	B
receptor	I
(	O
IL-1R	B
)	O
-	O
and	O
TCR	B
-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	B
I	I
IL-1R	I
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

The	O
synergistic	O
antigen	B
receptor	I
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B
kinase	I
C	I
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	B
rather	O
than	O
by	O
antigen	B
receptor	I
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF	B
-	I
kappa	I
B	I
functional	O
activity	O
is	O
independent	O
of	O
I	B
kappa	I
B	I
alpha	I
(	O
MAD3	B
)	O
-	O
NF	B
-	I
kappa	I
B	I
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B
kappa	I
B	I
nuclear	O
translocation	O
.	O

The	O
IL-1	B
-induced	O
NF	B
-	I
kappa	I
B	I
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	B
induces	O
both	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	B
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF	B
-	I
kappa	I
B	I
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	B
-induced	O
NF	B
-	I
kappa	I
B	I
-dependent	O
gene	O
transcription	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	B
kinase	I
C	I
-	I
alpha	I
,	I
-epsilon	I
,	I
and	I
-zeta	I
in	O
T	O
cell	O
activation	O
.	O

T	O
cells	O
express	O
multiple	O
isotypes	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B
isotypes	I
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC	B
-	I
alpha	I
,	I
-epsilon	I
,	I
or	I
-zeta	I
have	O
been	O
transfected	O
into	O
T	O
cells	O
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	B
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B
active	I
PKCs	I
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B
.	O

The	O
data	O
indicate	O
that	O
PKC	B
-	I
epsilon	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC	B
-	I
alpha	I
but	O
not	O
-zeta	B
,	O
can	O
regulate	O
the	O
transcription	B
factors	I
AP-1	B
and	O
nuclear	O
factor	B
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT-1	I
)	O
.	O

The	O
ability	O
of	O
PKC	B
-	I
epsilon	I
to	O
induce	O
transactivation	O
of	O
NF	B
-	I
AT-1	I
and	O
AP-1	B
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B
activated	I
p21ras	I
.	O

PKC	B
-	I
epsilon	I
,	O
but	O
not	O
PKC	B
-	I
alpha	I
nor	O
activated	O
p21ras	B
,	O
was	O
able	O
to	O
induce	O
NF	B
-	I
KB	I
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B
whereas	O
none	O
of	O
the	O
activated	B
PKC	I
isotypes	I
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	B
and	O
p21ras	B
were	O
able	O
to	O
induce	O
CD69	B
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B
isotypes	I
in	O
T	O
cells	O
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B
Ras	I
and	O
PKC	B
mutants	I
suggest	O
that	O
PKC	B
-	I
alpha	I
,	O
p21ras	B
,	O
and	O
PKC	B
-	I
epsilon	I
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Identification	O
of	O
two	O
novel	O
regulatory	O
elements	O
within	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
A	O
gamma	O
-	O
globin	O
gene	O
.	O

Interaction	O
between	O
the	O
stage	O
selector	O
element	O
(	O
SSE	O
)	O
in	O
the	O
proximal	O
gamma	O
-	O
globin	O
promoter	O
and	O
hypersensitivity	O
site	O
2	O
in	O
the	O
locus	O
control	O
region	O
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE	O
-	O
like	O
element	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
gamma	O
-	O
gene	O
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
gene	O
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	O
erythroid	O
cell	O
line	O
,	O
K562	O
,	O
we	O
have	O
shown	O
that	O
the	O
core	O
enhancer	O
of	O
hypersensitivity	O
site	O
2	O
can	O
preferentially	O
interact	O
with	O
the	O
proximal	O
gamma	O
-	O
promoter	O
in	O
the	O
absence	O
of	O
the	O
SSE	O
,	O
completely	O
silencing	O
a	O
linked	O
beta	O
-	O
promoter	O
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma	O
-	O
gene	O
5'-untranslated	O
region	O
(	O
UTR	O
)	O
led	O
to	O
derepression	O
of	O
beta	O
-	O
promoter	O
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma	O
-	O
promoter	O
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	O
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	O
+	O
13	O
to	O
+	O
15	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B
and	I
erythroid	I
-	I
specific	I
protein	I
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	O
was	O
localized	O
to	O
tandem	O
GATA	O
-	O
like	O
sites	O
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	B
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	O
of	O
the	O
gamma	O
-	O
gene	O
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

MIP1	B
alpha	I
nuclear	I
protein	I
(	O
MNP	B
)	O
,	O
a	O
novel	O
transcription	B
factor	I
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP-1	O
alpha	O
gene	O
.	O

Murine	B
macrophage	I
inflammatory	I
protein	I
1	I
alpha	I
(	O
MIP-1	B
alpha	I
)	O
and	O
its	O
human	B
equivalent	I
(	O
GOS19	B
,	O
LD78	B
,	O
or	O
AT464	B
)	O
are	O
members	O
of	O
the	O
-C	B
-	I
C	I
family	I
of	O
low	B
-	I
molecular	I
-	I
weight	I
chemokines	I
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	B
-	I
derived	I
MIP-1	I
alpha	I
/	I
GOS19	I
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B
alpha	I
/GOS19	B
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B
factors	I
(	O
the	O
ICK-1	B
family	I
)	O
affect	O
the	O
GOS19	O
promoter	O
.	O

One	O
member	O
,	O
ICK-1A	B
,	O
behaves	O
as	O
a	O
strong	B
negative	I
regulator	I
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP-1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK-1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	B
-	I
migrating	I
protein	I
-	I
DNA	I
complexes	I
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	B
protein	I
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	B
factor	I
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

The	O
transcription	B
factor	I
,	O
Nm23H2	B
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	O
site	O
on	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	O
site	O
on	O
the	O
silent	O
normal	O
c	O
-	O
myc	O
allele	O
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
SDS	O
-	O
gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c	O
-	O
myc	O
PuF	O
site	O
.	O

Transfection	O
experiments	O
with	O
c	O
-	O
myc	O
promoter	O
constructs	O
in	O
both	O
DHL-9	O
and	O
Raji	O
cells	O
revealed	O
that	O
the	O
PuF	O
site	O
functioned	O
as	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
cells	O
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	O
silent	O
c	O
-	O
myc	O
allele	O
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

Modulation	O
of	O
transcription	B
factor	I
NF	I
kappa	I
B	I
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV	O
-	O
infected	O
individuals	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Molt-4	O
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
NF	I
kappa	I
B	I
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA	O
-	O
binding	O
and	O
transactivating	O
activity	O
of	O
NF	B
kappa	I
B	I
.	O

Because	O
inhibition	O
of	O
DNA	O
-	O
binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	B
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
directly	O
in	O
cell	O
-	O
free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	B
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	O
cells	O
also	O
.	O

NF	B
kappa	I
B	I
controls	O
many	O
immunologically	O
important	O
genes	O
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Thapsigargin	O
induces	O
IL-2	B
receptor	I
alpha	I
-	I
chain	I
in	O
human	O
peripheral	O
and	O
Jurkat	O
T	O
cells	O
via	O
a	O
protein	B
kinase	I
C	I
-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-ATPase	I
,	O
depletes	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2	O
+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	B
in	O
Jurkat	O
T	O
cells	O
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B
alpha	I
protein	I
as	O
well	O
as	O
IL-2R	O
alpha	O
mRNA	O
in	O
Jurkat	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	B
alpha	I
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	B
kappa	I
B	I
in	O
Jurkat	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B
alpha	I
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B
alpha	I
through	O
distinct	O
pathways	O
.	O

PMA	B
-but	I
not	I
TG	I
-	I
induced	I
IL-2R	I
alpha	I
is	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
H7	O
,	O
whereas	O
TG	B
-but	I
not	I
PMA	I
-	I
induced	I
IL-2R	I
alpha	I
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B
alpha	I
in	O
human	O
T	O
cells	O
through	O
a	O
PKC	B
-independent	O
pathway	O
.	O

Interleukin	B
4	I
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B
(	I
Stat	I
)	I
protein	I
which	O
interacts	O
with	O
an	O
interferon	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B
kinase	I
3	I
and	O
interleukin-4	B
Stat	I
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL-4	B
in	O
the	O
human	O
B	O
cell	O
line	O
,	O
BL-2	O
.	O

Utilizing	O
a	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	B
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	O
cells	O
.	O

This	O
factor	O
was	O
designated	O
IL-4	B
NAF	I
(	O
IL-4-induced	B
nuclear	I
-	I
activating	I
factors	I
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B
phosphoprotein	I
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
Stat	I
)	I
protein	I
,	O
we	O
determined	O
whether	O
antibodies	B
to	I
Stat	I
proteins	I
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B
to	I
IL-4	I
Stat	I
,	O
also	O
known	O
as	O
Stat6	B
,	O
but	O
not	O
antibodies	B
to	O
other	O
Stat	B
proteins	I
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B
NAF	I
complex	I
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B
protein	I
,	O
IL-4	B
induced	O
robust	O
Janus	B
kinase	I
3	I
(	O
JAK3	B
)	O
activity	O
in	O
BL-2	O
cells	O
.	O

Cotransfection	O
of	O
JAK3	B
with	O
IL-4	B
Stat	I
into	O
COS-7	O
cells	O
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
and	O
comigrated	O
with	O
IL-4	B
NAF	I
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	B
NAF	I
is	O
IL-4	B
Stat	I
,	O
which	O
is	O
activated	O
by	O
JAK3	B
in	O
response	O
to	O
IL-4	B
receptor	O
engagement	O
.	O

Interleukin	B
12	I
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B
in	O
human	O
lymphocytes	O
.	O

Interleukin	B
12	I
(	O
IL-12	B
)	O
is	O
an	O
important	O
immunoregulatory	B
cytokine	I
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B
receptor	I
superfamily	I
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL-12	B
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
family	I
tyrosine	I
kinase	I
JAK2	B
and	O
Tyk2	B
,	O
implicating	O
these	O
kinases	B
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B
.	O

Recently	O
,	O
transcription	B
factors	I
known	O
as	O
STATs	B
(	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B
that	O
bind	O
hematopoietin	B
receptors	I
and	O
activate	O
JAK	B
kinases	I
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	B
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	B
family	I
member	I
,	O
STAT4	B
,	O
and	O
show	O
that	O
STAT4	B
expression	O
is	O
regulated	O
by	O
T	O
-	O
cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B
stimulates	O
formation	O
of	O
a	O
DNA	B
-	I
binding	I
complex	I
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B
proteins	I
and	O
that	O
this	O
complex	O
contains	O
STAT4	B
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	B
phosphorylation	O
by	O
IL-12	B
,	O
identify	O
a	O
rapid	O
signal	O
-	O
transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	B
-induced	O
gene	O
expression	O
.	O

Overexpression	O
of	O
DR	B
-	I
nm23	I
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	O
gene	O
family	O
,	O
inhibits	O
granulocyte	O
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	O
myeloid	O
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	O
clone	O
,	O
DR	B
-	I
nm23	I
,	O
differentially	O
expressed	O
in	O
a	O
blast	O
-	O
crisis	O
cDNA	O
library	O
,	O
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	O
metastatic	O
suppressor	O
genes	O
,	O
nm23-H1	O
and	O
nm23-H2	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B
zipper	I
-	I
like	I
and	O
the	O
RGD	B
domain	I
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B
and	O
in	O
the	O
COOH	B
-	I
terminal	I
portion	I
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B
function	O
.	O

DR	O
-	O
nm23	O
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	O
purified	O
CD34	O
+	O
cells	O
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	O
precursor	O
32Dc13	O
cell	O
line	O
,	O
which	O
is	O
growth	O
-	O
factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR	B
-	I
nm23	I
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Transcription	B
factors	I
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	O
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time	O
-	O
frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	O
gene	O
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B
factors	I
AP-1	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
NF	B
-	I
AT	I
and	O
Oct1	B
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	O
mRNA	O
and	O
secretion	O
of	O
IL-2	B
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B
factor	I
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
extracted	O
from	O
mitogen	O
-	O
stimulated	O
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF	O
-	O
AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	B
proteins	I
,	O
such	O
as	O
transcription	B
factors	I
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	O
lymphocytes	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	B
-	I
gamma	I
production	O
induced	O
by	O
IL-2	B
and	O
IL-12	B
in	O
a	O
human	O
NK	O
cell	O
line	O
.	O

Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
is	O
an	O
important	O
immunoregulatory	B
protein	I
produced	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
(	O
LGL	O
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	B
(	O
ILs	B
)	O
,	O
IL-2	B
and	O
IL-12	B
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN	B
-	I
gamma	I
gene	O
expression	O
in	O
both	O
T	O
cells	O
and	O
LGL	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	O
cell	O
lines	O
that	O
produce	O
IFN	B
-	I
gamma	I
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
line	O
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	O
line	O
NK3.3	O
derived	O
from	O
human	O
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL-2	B
and	O
IL-12	B
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN	B
-	I
gamma	I
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B
and	O
IL-12	B
synergized	O
in	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
and	O
GM	B
-	I
CSF	I
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
mRNAs	O
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B
growth	I
factor	I
-	I
beta	I
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	B
and	O
IL-12	B
on	O
NK3.3	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B
kinase	I
C	I
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B
induction	O
of	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
cytoplasmic	O
mRNA	O
.	O

In	O
contrast	O
,	O
IL-12	B
induction	O
of	O
IFN	O
-	O
gamma	O
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B
kinase	I
C	I
.	O

Furthermore	O
,	O
both	O
transforming	B
growth	I
factor	I
-	I
beta	I
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B
and	O
IL-12	B
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	O
gene	O
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	B
but	O
not	O
IL-12	B
induced	O
nuclear	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP1	B
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B
binding	I
protein	I
complexes	I
is	O
correlated	O
with	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B
and	O
IL-12	B
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
and	O
GM	B
-	I
CSF	I
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	O
cell	O
line	O
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

Restoration	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
ZEBRA	I
protein	I
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	B
activation	I
regions	I
.	O

The	O
ZEBRA	B
protein	I
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B
proteins	I
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	B
is	O
a	O
bZIP	B
transcriptional	I
activator	I
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	O
response	O
elements	O
within	O
EBV	O
promoters	O
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	O
lytic	O
origin	O
.	O

We	O
have	O
employed	O
the	O
ZEBRA	B
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B
activation	I
domain	I
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B
domain	I
)	O
.	O

The	O
ZEBRA	B
activation	I
region	I
was	O
replaced	O
with	O
the	O
potent	O
acid	B
activation	I
region	I
from	O
the	O
herpes	B
simplex	I
virus	I
VP16	I
protein	I
or	O
with	O
the	O
activation	B
region	I
of	O
the	O
EBV	B
R	I
protein	I
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell	O
-	O
type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B
's	O
ability	O
to	O
induce	O
early	B
antigen	I
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B
domain	I
present	I
within	O
ZEBRA	B
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B
factors	I
of	O
activated	O
T	O
cells	O
,	O
NFATp	B
and	O
NFATc	B
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	B
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B
factor	I
of	O
activated	O
T	O
cells	O
(	O
NFATp	B
)	O
,	O
a	O
cyclosporin	B
A	I
(	I
CsA	I
)	I
-sensitive	I
factor	I
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B
,	O
mediates	O
CD16	B
-induced	O
activation	O
of	O
cytokine	B
genes	I
in	O
human	O
NK	O
cells	O
.	O

CD16	B
(	O
Fc	B
gamma	I
RIIIA	I
)	O
-induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	B
ligands	O
induces	O
NFAT	B
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	B
cell	I
NFAT	I
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	B
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	B
and	O
NFATc	B
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	B
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B
and	I
NFATc-	I
specific	I
antibodies	I
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	B
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	O
express	O
NFATc	B
constitutively	O
,	O
but	O
NFATc	O
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	B
recognizing	O
the	O
T	B
cell	I
NFATc	I
revealed	O
no	O
detectable	O
NFATc	B
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	O
ester	O
-	O
stimulated	O
cells	O
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	B
-	I
sensitive	I
transcription	I
factors	I
,	O
NFATp	B
and	O
NFATc	B
,	O
are	O
expressed	O
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	O
mRNA	O
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B
receptor	I
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	O
cells	O
(	O
U937	O
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	O
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein	O
-	O
labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double	O
-	O
labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B
receptor	I
expression	O
in	O
U937	O
cells	O
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up	O
-	O
regulation	O
of	O
GR	O
mRNA	O
while	O
no	O
enhanced	O
GR	B
expression	O
was	O
perceived	O
with	O
RA	O
/	O
VD	O
treatment	O
.	O

Up	O
-	O
regulation	O
of	O
high	O
-	O
affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	O
T	O
lymphocytes	O
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
in	O
a	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+	O
/-	O
0.53	O
nmol	O
/	O
L	O
,	O
mean	O
+	O
/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2	O
+	O
ionophore	O
A23187	O
.	O

Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	B
receptor	I
,	O
but	O
also	O
suggest	O
that	O
T	O
cells	O
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal	O
-	O
induced	O
activation	O
.	O

Attenuation	O
of	O
gamma	B
interferon	I
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	B
kinases	I
and	O
Stat1	B
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B
interferon	I
is	O
impaired	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B
interferon	I
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B
protein	I
tyrosine	I
kinases	I
,	O
including	O
the	O
Janus	B
kinases	I
Jak1	B
and	O
Jak2	B
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factor	I
Stat1	I
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B
interferon	I
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B
and	O
Jak2	B
and	O
phosphorylation	O
of	O
Stat1	B
was	O
developed	O
in	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
differentiated	O
U-937	O
cells	O
.	O

Analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B
interferon	I
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	O
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon	O
-	O
treated	O
cells	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
increased	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
U-937	O
cells	O
incubated	O
with	O
gamma	B
interferon	I
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	O
cells	O
were	O
also	O
obtained	O
with	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	O
mononuclear	O
phagocytes	O
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B
interferon	I
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	B
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B
interferon	I
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Regulation	O
of	O
IkB	B
alpha	I
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	B
(	I
2	I
+	I
)	I
-dependent	I
phosphatase	I
calcineurin	B
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B
-induced	O
activation	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
in	O
T	O
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
calcineurin	B
is	O
also	O
sufficient	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
PKC	O
-	O
dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B
alpha	I
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B
alpha	I
phosphorylation	O
.	O

While	O
PKC	B
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B
alpha	I
in	O
T	O
cell	O
lines	O
,	O
co	O
-	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B
alpha	I
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B
alpha	I
in	O
Jurkat	O
T	O
or	O
in	O
U937	O
cells	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	B
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA	O
-	O
induced	O
IkB	B
alpha	I
phosphorylation	O
/	O
degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B
alpha	I
induced	O
by	O
TNF	B
-	I
alpha	I
,	O
a	O
PKC	B
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B
,	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF	B
-	I
alpha	I
not	O
at	O
the	O
level	O
of	O
IkB	B
alpha	I
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B
calcineurin	B
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B
alpha	I
phosphorylation	O
and	O
degradation	O
.	O

Cupric	O
ion	O
blocks	O
NF	B
kappa	I
B	I
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O

A	O
transcription	B
factor	I
NF	B
kappa	I
B	I
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B
protein	I
I	I
kappa	I
B	I
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
to	O
release	O
NF	B
kappa	I
B	I
.	O

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B
kappa	I
B	I
induced	O
by	O
TNF	B
-	I
alpha	I
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B
-	I
alpha	I
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B
kappa	I
B	I
from	O
I	B
kappa	I
B	I
alpha	I
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B
kappa	I
B	I
-	I
I	I
kappa	I
B	I
complex	I
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
was	O
observed	O
upon	O
TNF	B
-	I
alpha	I
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	B
kappa	I
B	I
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O

ETS1	B
transactivates	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
one	O
such	O
cytokine	B
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	B
kappa	I
B	I
,	O
AP-1	B
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	B
family	I
of	O
transcription	B
factors	I
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	B
and	O
ELF1	B
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-47	O
to	O
-40	O
upstream	O
of	O
the	O
GM	O
-	O
CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	B
,	O
but	O
not	O
ELF1	B
,	O
can	O
transactivate	O
GM	B
-	I
CSF	I
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	B
-	I
like	I
factors	I
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-GGAA-	O
to	O
-GGAT-	O
prevents	O
the	O
binding	O
of	O
ETS	B
-	I
like	I
factors	I
with	O
the	O
exception	O
of	O
ETS1	B
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	B
-	I
CSF	I
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	B
activate	O
signal	B
transducer	I
and	I
activation	I
of	I
transcription	I
(	I
STAT	I
)	I
transcription	I
factors	I
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	O
cell	O
priming	O
cultures	O
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B
production	O
and	O
STAT	B
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B
(	I
IFN	I
)	I
-gamma	I
,	O
but	O
not	O
interleukin	B
(	I
IL	I
)	I
4	I
,	O
production	O
by	O
effector	O
cells	O
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B
and	O
IL-10	B
and	O
inhibition	O
of	O
IL-12	B
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

SFs	O
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B
factor	I
Stat1	I
,	O
but	O
not	O
Stat3	B
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN	B
-	I
gamma	I
production	O
.	O

Active	O
Stat3	B
,	O
but	O
not	O
Stat1	B
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

MEK1	B
and	O
the	O
extracellular	B
signal	I
-	I
regulated	I
kinases	I
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL-2	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

TCR	B
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	B
kinase	I
Raf-1	B
.	O

Active	O
Raf-1	B
phosphorylates	O
and	O
activates	O
the	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
/	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
kinase	I
1	I
(	O
MEK1	B
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	B
kinases	I
/	I
extracellular	I
signal	I
regulated	I
kinases	I
,	O
ERK1	B
and	O
ERK2	B
.	O

Raf-1	B
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	B
and	O
ERK	B
activities	O
also	O
stimulate	O
IL-2	O
gene	O
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf-1	B
or	O
MEK1	B
in	O
Jurkat	O
T	O
cells	O
enhanced	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF	B
-	I
AT	I
activity	O
.	O

Expression	O
of	O
MEK1-interfering	B
mutants	I
inhibited	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	B
and	O
Raf-1	B
to	O
costimulate	O
NF	B
-	I
AT	I
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	B
kinase	I
-	I
specific	I
phosphatase	I
,	O
MKP-1	B
,	O
which	O
blocks	O
ERK	B
activation	O
,	O
inhibited	O
IL-2	O
promoter	O
and	O
NF	B
-	I
AT	I
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	B
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	B
kinase	I
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	B
,	O
MEK1	B
,	O
and	O
ERK1	B
and	O
ERK2	B
functions	O
in	O
the	O
stimulation	O
IL-2	O
gene	O
transcription	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
NF	B
-	I
AT	I
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	B
.	O

An	O
inhibitory	O
,	O
`	O
`	O
dominant	O
-	O
negative	O
,	O
''	O
form	O
of	O
the	O
calcineurin	B
catalytic	I
(	I
A	I
)	I
subunit	I
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	B
-	I
binding	I
domain	I
,	O
autoinhibitory	B
domain	I
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B
(	I
B	I
)	I
subunit	I
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
`	O
`	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
''	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	B
-	I
AT	I
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	B
-	I
labeled	I
BKO	I
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B
B	I
subunit	I
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B
subunit	I
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	B
-	I
AT	I
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
`	O
`	O
rescued	O
''	O
by	O
overexpression	O
of	O
transfected	O
B	B
subunit	I
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	B
active	I
dimer	I
of	O
calcineurin	B
A	I
and	I
B	I
subunits	I
.	O

Inhibition	O
of	O
vitamin	B
D	I
receptor	I
-	I
retinoid	I
X	I
receptor	I
-	I
vitamin	I
D	I
response	I
element	I
complex	I
formation	O
by	O
nuclear	O
extracts	O
of	O
vitamin	O
D	O
-	O
resistant	O
New	O
World	O
primate	O
cells	O
.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

We	O
hypothesized	O
that	O
an	O
intracellular	B
vitamin	I
D	I
binding	I
protein	I
(	O
IDBP	B
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	O
cells	O
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone	O
-	O
resistant	O
state	O
in	O
NWP	O
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	B
complex	I
binding	O
to	O
the	O
consensus	O
response	O
elements	O
present	O
in	O
the	O
enhancer	O
regions	O
of	O
steroid	O
-	O
responsive	O
genes	O
.	O

We	O
employed	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
to	O
screen	O
for	O
the	O
presence	O
of	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
vitamin	O
D	O
response	O
element	O
(	O
VDRE	O
)	O
.	O

Nuclear	O
and	O
post	O
-	O
nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
and	O
wild	O
type	O
phenotypes	O
,	O
respectively	O
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	O
of	O
the	O
human	O
osteocalcin	O
and	O
the	O
mouse	O
osteopontin	O
gene	O
promoters	O
.	O

A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR	B
-	I
RXR	I
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O

In	O
addition	O
,	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	O
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR	B
-	I
RXR	I
-	I
VDRE	I
complex	I
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	O
type	O
cell	O
line	O
or	O
with	O
the	O
post	O
-	O
nuclear	O
extract	O
of	O
the	O
vitamin	O
D	O
-	O
resistant	O
cell	O
line	O
.	O

We	O
conclude	O
that	O
a	O
VDRE	B
-	I
binding	I
protein	I
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	B
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	O
vitamin	O
D	O
-	O
resistant	O
NWP	O
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR	B
-	I
RXR	I
heterodimer	O
binding	O
to	O
the	O
VDRE	O
.	O

Glucocorticoids	O
induced	O
down	O
-	O
regulation	O
of	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
in	O
asthma	O
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
the	O
AP-1	B
complex	I
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes	O
,	O
including	O
glucocorticoid	B
receptor	I
itself	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
expression	O
of	O
mRNA	O
for	O
glucocorticoid	B
receptor	I
in	O
human	O
blood	O
monocytes	O
obtained	O
from	O
seven	O
unstable	O
untreated	O
asthmatic	O
patients	O
who	O
were	O
subsequently	O
treated	O
with	O
high	O
doses	O
of	O
parenteral	O
corticosteroid	O
(	O
methyl	O
prednisolone	O
120	O
mg	O
/	O
day	O
)	O
for	O
10	O
days	O
.	O

mRNA	O
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	B
transcriptase	I
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+	O
/-	O
4.93	O
versus	O
95.57	O
+	O
/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down	O
-	O
regulation	O
for	O
the	O
glucocorticoid	B
receptor	I
mRNA	O
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

Differential	O
regulation	O
of	O
IL-6	O
gene	O
transcription	O
and	O
expression	O
by	O
IL-4	B
and	O
IL-10	B
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL-4	B
and	O
IL-10	B
inhibit	O
the	O
cytokine	B
production	O
and	O
mRNA	O
expression	O
by	O
monocytes	O
/	O
macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL-6	O
gene	O
expression	O
by	O
IL-4	B
and	O
IL-10	B
,	O
we	O
studied	O
IL-6	B
production	O
,	O
expression	O
level	O
of	O
IL-6	O
mRNA	O
,	O
IL-6	B
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappaB	I
and	O
NF	B
-	I
IL-6	I
,	O
and	O
IL-6	O
mRNA	O
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP-1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	B
or	O
IL-10	B
.	O

Both	O
IL-4	B
and	O
IL-10	B
were	O
seen	O
to	O
inhibit	O
IL-6	B
production	O
and	O
the	O
expression	O
of	O
IL-6	O
mRNA	O
in	O
both	O
monocytic	O
cell	O
lines	O
studied	O
.	O

In	O
chloramphenicol	B
acetyltransferase	I
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
plasmid	O
containing	O
the	O
IL-6	O
gene	O
promoter	O
,	O
IL-4	B
,	O
but	O
not	O
IL-10	B
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	B
,	O
but	O
not	O
IL-10	B
,	O
inhibited	O
nuclear	O
NF	B
-	I
kappaB	I
activity	O
,	O
and	O
that	O
IL-4	B
and	O
IL-10	B
did	O
not	O
affect	O
NF-	O
IL-6	B
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	B
enhanced	O
the	O
degradation	O
of	O
IL-6	O
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	B
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL-6	O
gene	O
by	O
affecting	O
NF	B
-	I
kappaB	I
binding	O
activity	O
,	O
while	O
IL-10	B
may	O
inhibit	O
the	O
IL-6	O
mRNA	O
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	B
and	O
IL-10	B
inhibit	O
IL-6	B
production	O
by	O
different	O
mechanisms	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

Cyclic	O
AMP	O
-responsive	O
element	O
-dependent	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
zebra	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
-	O
positive	O
B	O
cells	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate	O
-	O
early	O
EBV	O
Zebra	O
gene	O
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768	O
-	O
6777	O
,	O
1993	O
)	O
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	O
gene	O
transcription	O
through	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
located	O
within	O
the	O
Zebra	O
promoter	O
(	O
Zp	O
)	O
.	O

Using	O
human	O
B-	O
or	O
T	O
-	O
cell	O
lines	O
transfected	O
with	O
ZpCat	O
reporter	O
gene	O
constructs	O
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	O
domain	O
of	O
Zp	O
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

Mutation	O
of	O
the	O
consensus	O
AP-1	O
/	O
CRE	O
site	O
within	O
ZII	O
abolished	O
the	O
inducibility	O
of	O
Zp	O
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	O
domain	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
minimal	O
promoter	O
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	O
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	O
but	O
not	O
by	O
AP-1	O
consensus	O
sequences	O
.	O

Antibodies	O
against	O
CRE	B
-	I
binding	I
(	I
CREB	I
)	I
protein	I
but	O
not	O
against	O
c	B
-	I
Fos	I
or	O
c	B
-	I
Jun	I
were	O
able	O
to	O
supershift	O
the	O
DNA	B
-	I
protein	I
complex	I
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	B
factor	I
which	O
binds	O
to	O
ZII	O
as	O
a	O
member	O
of	O
the	O
CREB	B
family	I
of	I
proteins	I
.	O

Finally	O
,	O
transfection	O
of	O
CREB	B
protein	I
and	O
protein	O
kinase	O
A	O
expression	O
vectors	O
were	O
found	O
to	O
activate	O
Zp	O
in	O
Jurkat	O
cells	O
,	O
suggesting	O
that	O
phosphorylated	O
form	O
of	O
CREB	B
protein	I
can	O
play	O
a	O
determining	O
role	O
in	O
the	O
EBV	O
reactivation	O
process	O
.	O

Expression	O
of	O
c	B
-	I
fos	I
and	I
c	I
-	I
jun	I
proteins	I
and	O
AP-1	B
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	O
cells	O
and	O
phytohemagglutinin	O
-	O
stimulated	O
lymphocytes	O
.	O

The	O
protein	O
products	O
of	O
the	O
c	O
-	O
fos	O
(	O
p62c	B
-	I
fos	I
)	O
and	O
c	O
-	O
jun	O
(	O
p39c	B
-	I
jun	I
)	O
genes	O
are	O
members	O
of	O
the	O
AP-1	B
transcription	I
factor	I
family	I
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	O
systems	O
:	O
a	O
continuously	O
growing	O
myeloid	O
leukemic	O
cell	O
line	O
,	O
HL60	O
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto-	O
hemagglutinin	O
(	O
PHA	O
)	O
-stimulated	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP-1	B
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	B
and	I
Jun	I
family	I
proteins	I
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c	B
-	I
fos	I
,	O
p39c	B
-	I
jun	I
,	O
and	O
AP-1	B
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	O
cells	O
and	O
in	O
PHA	O
-	O
stimulated	O
PBL	O
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	B
binding	O
activity	O
from	O
p62c	B
-	I
fos	I
,	O
and	O
p39c	B
-	I
jun	I
AP-1	B
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2	O
/	O
M	O
-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S	O
-	O
phase	O
enriched	O
samples	O
of	O
HL60	O
cells	O
,	O
while	O
levels	O
of	O
nuclear	B
p62c	I
-	I
fos	I
and	I
p39c	I
-	I
jun	I
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c	B
-	I
fos	I
and	O
p39c	B
-	I
jun	I
,	O
but	O
AP-1	B
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	B
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP-1	B
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c	B
-	I
jun	I
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	B
p62c	I
-	I
fos	I
and	I
p39c	I
-	I
jun	I
were	O
present	O
in	O
HL60	O
cells	O
and	O
PHA	O
-	O
stimulated	O
PBL	O
.	O

However	O
,	O
no	O
cytoplasmic	B
p62c	I
-	I
fos	I
was	O
detected	O
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	B
p39c	I
-	I
jun	I
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	B
may	O
occur	O
under	O
certain	O
circumstances	O
.	O

Soluble	B
tumor	I
necrosis	I
factor	I
receptors	I
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine	O
-	O
induced	O
HIV-1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	B
human	I
tumor	I
necrosis	I
factor	I
(	I
TNF	I
)	I
binding	I
protein-1	I
(	O
r	B
-	I
h	I
TBP-1	I
)	O
and	O
recombinant	B
human	I
soluble	I
dimeric	I
TNF	I
receptor	I
(	O
rhu	B
TNFR	I
:	I
Fc	I
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	B
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine	O
-	O
induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1-infected	O
promonocytic	O
U1	O
cells	O
with	O
r	B
-	I
h	I
-	I
TBP-1	I
or	O
rhu	B
TNFR	I
:	I
Fc	I
reduced	O
PMA	O
-	O
induced	O
HIV-1	B
p24	I
antigen	I
production	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	B
antigen	I
production	O
in	O
T	O
-	O
lymphocytic	O
ACH-2	O
cells	O
was	O
47	O
%	O
with	O
r	B
-	I
hTBP-1	I
and	O
42	O
%	O
with	O
rhu	B
TNFR	I
:	I
Fc	I
.	O

r	B
-	I
hTBP-1	I
and	O
rhu	B
TNFR	I
:	I
Fc	I
also	O
decreased	O
p24	B
antigen	I
synthesized	O
by	O
U1	O
cells	O
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	B
(	I
PHA	I
)	I
-induced	I
supernatant	I
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
,	O
interleukin-6	B
,	O
and	O
TNF	B
.	O

Addition	O
of	O
r	B
-	I
hTBP-1	I
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	B
antigen	I
production	O
by	O
15	O
%	O
.	O

U1	O
cells	O
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng	O
/	O
ml	O
endogenous	B
TBP-1	I
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r	B
-	I
hTBP-1	I
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r	B
-	I
hTBP-1	I
and	O
rhu	B
TNFR	I
:	I
Fc	I
blocked	O
PMA	O
induction	O
of	O
nuclear	B
factor	I
(	I
NK	I
)	I
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
in	O
U1	O
cells	O
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli	O
-	O
induced	O
HIV-1	O
expression	O
and	O
NK-	B
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

Reversible	O
differentiation	O
of	O
human	O
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B
light	I
chain	I
kinase	I
.	O

Human	O
monoblastic	O
leukemia	O
U937	O
cells	O
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H	O
-	O
hexahydro-1	O
,	O
4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	B
light	I
chain	I
kinase	I
,	O
induces	O
differentiation	O
of	O
monocytoid	O
leukemia	O
cell	O
lines	O
U937	O
and	O
THP-1	O
but	O
not	O
of	O
myeloblastic	O
leukemic	O
ML-1	O
cell	O
or	O
erythroleukemia	O
K562	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML-9	O
also	O
induced	O
alpha	B
-	I
naphthyl	I
acetate	I
esterase	I
(	O
ANAE	B
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML-9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML-9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML-9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation	O
-	O
associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	O
cells	O
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	O
monoblastic	O
cells	O
,	O
THP-1	O
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	O
cells	O
but	O
increased	O
the	O
expression	O
of	O
monocyte	B
-	I
macrophage	I
lineage	I
-	I
associated	I
surface	I
antigen	I
,	O
CD14	B
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
myc	O
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
,	O
but	O
ML-9	O
did	O
not	O
affect	O
the	O
expression	O
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti	O
-	O
cancer	O
drug	O
such	O
as	O
1-beta	O
-	O
D	O
-	O
arabino	O
-	O
furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	B
growth	I
factor	I
-	I
beta	I
1	I
(	O
TGF	B
-	I
beta	I
1	I
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	O
cells	O
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML-9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

The	O
myeloid	O
-	O
cell	O
-	O
specific	O
c	O
-	O
fes	O
promoter	O
is	O
regulated	O
by	O
Sp1	B
,	O
PU.1	B
,	O
and	O
a	O
novel	O
transcription	B
factor	I
.	O

The	O
protein	O
product	O
of	O
the	O
c	O
-	O
fps	O
/	O
fes	O
(	O
c	O
-	O
fes	O
)	O
proto	O
-	O
oncogene	O
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	O
cells	O
(	O
macrophages	O
and	O
neutrophils	O
)	O
.	O

mRNA	O
for	O
c	O
-	O
fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	O
cells	O
and	O
vascular	O
endothelial	O
cells	O
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13-kilobase	O
-	O
pair	O
(	O
kb	O
)	O
human	O
c	O
-	O
fes	O
transgene	O
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
human	O
c	O
-	O
fes	O
gene	O
have	O
not	O
been	O
defined	O
.	O

Transient	O
-	O
transfection	O
experiments	O
demonstrated	O
that	O
plasmids	O
containing	O
446	O
bp	O
of	O
c	O
-	O
fes	O
5'-flanking	O
sequences	O
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	O
cells	O
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	O
human	O
c	O
-	O
fes	O
locus	O
contained	O
positive	O
cis	O
-	O
acting	O
elements	O
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	O
sequences	O
.	O

DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	B
nuclear	I
proteins	I
(	O
-408	O
to	O
-386	O
,	O
-293	O
to	O
-254	O
,	O
-76	O
to	O
-65	O
,	O
and	O
-34	O
to	O
+	O
3	O
)	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Plasmids	O
containing	O
151	O
bp	O
of	O
5'-flanking	O
sequences	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
gene	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	O
region	O
contains	O
nuclear	O
protein	O
binding	O
sites	O
for	O
Sp1	B
,	O
PU.1	B
,	O
and/or	O
Elf-1	B
,	O
and	O
a	O
novel	B
factor	I
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1	O
/	O
Elf-1	O
sites	O
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

Mutation	O
of	O
the	O
PU.1	B
/Elf-1	B
site	O
or	O
the	O
3	O
'	O
site	O
(	O
FP4	O
-	O
3	O
'	O
)	O
within	O
the	O
context	O
of	O
the	O
c	O
-	O
fes	O
promoter	O
resulted	O
in	O
substantially	O
reduced	O
activity	O
in	O
transient	O
transfections	O
.	O

Furthermore	O
,	O
transient	O
-	O
cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	B
(	O
and	O
not	O
Elf-1	B
)	O
can	O
transactivate	O
the	O
c	O
-	O
fes	O
promoter	O
in	O
nonmyeloid	O
cell	O
lines	O
.	O

We	O
conclude	O
that	O
the	O
human	O
c	O
-	O
fes	O
gene	O
contains	O
a	O
strong	O
myeloid	O
-	O
cell	O
-	O
specific	O
promoter	O
that	O
is	O
regulated	O
by	O
Sp1	B
,	O
PU.1	B
,	O
and	O
a	O
novel	O
transcription	B
factor	I
.	O

Transcriptional	O
activation	O
of	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
genes	O
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
tax	I
protein	I
.	O

The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
-	I
encoded	I
tax	I
protein	I
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
genes	O
transcribed	O
by	O
RNA	B
polymerase	I
II	I
.	O

We	O
find	O
that	O
both	O
chromatin	O
and	O
cell	O
extracts	O
derived	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1-infected	O
human	O
T	O
lymphocytes	O
support	O
higher	O
levels	O
of	O
5S	O
rRNA	O
and	O
tRNA	O
gene	O
transcription	O
than	O
chromatin	O
or	O
extracts	O
from	O
uninfected	O
T	O
lymphocytes	O
.	O

The	O
viral	B
protein	I
Tax	I
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	O
II	O
gene	O
transcription	O
,	O
as	O
purified	B
Tax	I
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Both	O
limiting	O
-	O
component	O
transcription	O
assays	O
and	O
DNA	O
binding	O
assays	O
identified	O
the	O
class	B
III	I
gene	I
transcription	I
factor	I
TFIIIB	B
as	O
the	O
principle	O
target	O
of	O
Tax	B
activity	O
.	O

Surprisingly	O
,	O
we	O
find	O
that	O
Tax	B
increases	O
the	O
effective	O
concentration	O
of	O
active	B
TFIIIB	I
molecules	I
.	O

These	O
data	O
suggest	O
that	O
Tax	B
stimulates	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
gene	O
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	B
initiation	I
complex	I
assembly	O
.	O

Induction	O
of	O
CIITA	B
and	O
modification	O
of	O
in	O
vivo	O
HLA	O
-	O
DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN	B
-	I
gamma	I
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA	O
-	O
DR	O
-	O
constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN	B
-	I
gamma	I
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	B
class	I
II	I
induction	O
is	O
studied	O
in	O
a	O
`	O
`	O
physiologic	O
''	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B
trans	I
-	I
activator	I
,	O
a	O
crucial	O
MHC	B
class	I
II	I
gene	I
regulatory	I
factor	I
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	B
factors	I
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	B
I	I
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN	B
-	I
gamma	I
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	B
factors	I
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II	O
-	O
constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	O
lymphoma	O
line	O
Raji	O
and	O
normal	O
tonsil-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	O
,	O
either	O
IFN	B
-	I
gamma	I
-induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	B
trans	I
-	I
activator	I
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN	B
-	I
gamma	I
-induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c	O
-	O
jun	O
and	O
suppress	O
IL-2	O
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
AP-1	B
and	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
.	O

The	O
present	O
results	O
show	O
that	O
Jurkat	O
T	O
cells	O
acutely	O
exposed	O
to	O
micromolar	O
concentrations	O
of	O
H2O2	O
exhibit	O
substantial	O
increases	O
in	O
AP-1	B
binding	O
activity	O
and	O
the	O
expression	O
of	O
c	O
-	O
jun	O
but	O
not	O
c	O
-	O
fos	O
mRNA	O
.	O

The	O
preferential	O
induction	O
of	O
c	O
-	O
jun	O
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	O
transcripts	O
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA	O
/	O
PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c	O
-	O
jun	O
promoter	O
via	O
the	O
proximal	O
jun1	O
tumor	O
promoter	O
-	O
responsive	O
element	O
(	O
TRE	O
)	O
-like	O
promoter	O
element	O
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	O
AP-1	O
TRE	O
and	O
jun	O
TRE	O
-	O
like	O
motifs	O
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA	O
/	O
PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c	B
-	I
Fos	I
,	O
c	B
-	I
Jun	I
,	O
and	O
JunD	B
.	O

However	O
,	O
PHA	O
/	O
PMA	O
but	O
not	O
oxidative	O
signals	O
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	O
constructs	O
containing	O
the	O
AP-1-TRE	O
,	O
NF	O
-	O
AT	O
,	O
and	O
IL-2	O
promoter	O
regions	O
along	O
with	O
IL-2	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF	B
-	I
AT	I
and	O
IL-2	O
reporters	O
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	O
mRNA	O
in	O
cells	O
stimulated	O
with	O
PHA	O
/	O
PMA	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF	B
-	I
AT	I
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	B
complexes	I
rather	O
than	O
the	O
binding	O
of	O
preformed	O
NF	B
-	I
AT	I
complexes	I
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	O
cell	O
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP-1	B
regulation	O
of	O
c	O
-	O
jun	O
from	O
transcriptional	O
up	O
-	O
regulation	O
of	O
IL-2	B
via	O
NF	B
-	I
AT	I
.	O

HIV-1	B
tat	I
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B
cell	I
-	I
specific	I
transcription	I
factor	I
and	O
downregulates	O
MIP-1	O
alpha	O
gene	O
expression	O
in	O
activated	O
T	O
-	O
cells	O
.	O

MIP-1	B
alpha	I
is	O
a	O
secreted	O
chemokine	B
which	O
can	O
inhibit	O
hematopoietic	O
stem	O
cells	O
and	O
modulate	O
inflammatory	O
responses	O
.	O

It	O
is	O
also	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
CD8	O
+	O
T	O
-	O
cells	O
.	O

The	O
expression	O
of	O
MIP-1	B
alpha	I
is	O
induced	O
during	O
cellular	O
activation	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
and	O
monocytes	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	O
B	O
-	O
cells	O
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	B
factor	I
family	I
(	O
the	O
MNP	B
family	I
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP-1	B
alpha	I
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	O
B	O
cells	O
.	O

Monocytes	O
and	O
transformed	O
B	O
-	O
cells	O
normally	O
express	O
MNP-1	B
strongly	O
and	O
MNP-2	B
weakly	O
,	O
while	O
T	O
-	O
cells	O
strongly	O
express	O
only	O
MNP-2	B
.	O

Recently	O
,	O
we	O
reported	O
that	O
HIV-1	B
tat	I
downregulates	O
MIP-1	B
alpha	I
expression	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	B
in	O
Jurkat	O
T	O
-	O
cells	O
expressing	O
HIV-1	B
tat	I
.	O

Expression	O
of	O
neither	O
HTLV-1	B
tax	I
in	O
Jurkat	O
T	O
-	O
cells	O
nor	O
EBV	O
in	O
B	O
-	O
cells	O
had	O
any	O
effect	O
on	O
MNP-1	B
or	O
MNP-2	B
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	B
tat	I
.	O

We	O
propose	O
that	O
HIV-1	B
tat	I
may	O
inhibit	O
MIP-1	B
alpha	I
expression	O
by	O
inducing	O
MNP-1	B
expression	O
in	O
T	O
-	O
cells	O
,	O
probably	O
by	O
either	O
competing	O
with	O
MNP-2	B
for	O
binding	O
to	O
the	O
MIP-1	O
alpha	O
promoter	O
or	O
by	O
sequestering	O
it	O
into	O
inactive	O
forms	O
.	O

Cooperation	O
between	O
core	B
binding	I
factor	I
and	O
adjacent	O
promoter	O
elements	O
contributes	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	B
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
is	O
mediated	O
via	O
cis	O
-	O
acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	O
and	O
Elf-1	O
sites	O
in	O
the	O
IL-3	O
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell	O
-	O
specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL-3	O
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act-1	O
.	O

Together	O
the	O
Act-1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	O
in	O
fibroblasts	O
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL-3	O
promoter	O
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL-3	B
is	O
not	O
specified	O
by	O
the	O
activity	O
of	O
a	O
single	O
tissue	O
-	O
specific	O
element	O
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G	B
-	I
protein	I
-	I
coupled	I
chemoattractant	I
receptors	I
.	O

Receptors	O
for	O
leukocyte	B
chemoattractants	I
,	O
including	O
chemokines	B
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G	B
-	I
protein	I
-	I
coupled	I
serpentine	I
receptors	I
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	B
factors	I
,	O
such	O
as	O
NF	B
kappa	I
B	I
and	O
AP-1	B
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G	B
-	I
protein	I
coupling	O
and	O
the	O
activation	O
of	O
protein	B
kinases	I
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF	B
-	I
alpha	I
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate	O
-	O
early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	B
cytokines	I
and	O
chemokines	B
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	B
and	O
chemokine	B
gene	O
expression	O
.	O

Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T	O
-	O
cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL	O
-	O
mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	O
adenovirus	O
type	O
5	O
E1A	O
-	O
region	O
(	O
Ad5E1A234	O
-	O
243	O
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor	O
-	O
eradicating	O
CTL	O
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A	O
-	O
expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T	O
-	O
cell	O
-	O
mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A	B
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A	O
-	O
peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	B
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B
,	O
induced	O
Ad5E1A	B
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B
-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti	O
-	O
tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide	O
-	O
based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T	O
-	O
cell	O
-	O
mediated	O
autoimmune	O
diseases	O
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	O
gene	O
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c	B
-	I
Fos	I
,	O
FosB	B
,	O
and	O
JunB	B
in	O
anergic	O
T	O
helper	O
1	O
cells	O
.	O

Anergic	O
CD4	O
+	O
Th	O
cells	O
do	O
not	O
produce	O
IL-2	B
when	O
challenged	O
with	O
Ag	O
-	O
pulsed	O
accessory	O
cells	O
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	O
T	O
cells	O
are	O
defective	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	O
DNA	O
enhancer	O
elements	O
:	O
NF	B
-	I
AT	I
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	B
NFATp	I
,	I
Fos	I
,	I
and	I
Jun	I
protein	I
complex	I
)	O
and	O
Activator	B
Protein-1	I
(	O
AP-1	B
)	O
(	O
that	O
binds	O
Fos	B
and	I
Jun	I
heterodimers	I
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA	O
-	O
protein	O
interactions	O
in	O
anergic	O
T	O
cells	O
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	B
family	O
members	O
c	B
-	I
Fos	I
,	O
FosB	B
,	O
and	O
JunB	B
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR	B
/	I
CD3	I
-signaling	O
defect	O
because	O
CD3	B
cross	O
-	O
linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular	O
-	O
free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	B
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	O
and	O
anergic	O
T	O
cells	O
.	O

Thus	O
,	O
defective	O
IL-2	O
gene	O
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	B
Fos	I
and	I
Jun	I
family	I
members	I
in	O
anergic	O
T	O
cells	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
gene	O
family	O
member	O
NFATc	B
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	B
A	I
(	I
CsA	I
)	I
/FK506-sensitive	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	B
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non	O
-	O
T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	B
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	B
proteins	I
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	B
,	O
of	O
the	O
NFAT	B
gene	I
family	I
member	I
NFATc	B
(	O
designated	O
here	O
NFATc.alpha	B
)	O
.	O

The	O
amino	B
acid	I
sequence	I
of	O
NFATc.beta	B
differs	O
from	O
that	O
of	O
NFATc	B
.	O

alpha	O
in	O
the	O
first	O
NH2-terminal	B
29	I
residues	I
and	O
contains	O
an	O
additional	O
region	O
of	O
142	B
residues	I
at	O
the	O
COOH	B
terminus	I
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2.7	O
and	O
4.5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc.beta	O
-	O
specific	O
probe	O
detected	O
only	O
the	O
4.5-kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	B
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	O
NFAT	O
-	O
driven	O
reporter	O
gene	O
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	B
neither	O
bound	O
to	O
the	O
kappa3	O
element	O
(	O
an	O
NFAT	O
-	O
binding	O
site	O
)	O
in	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
nor	O
activated	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

JNK	B
(	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	O
lymphocytes	O
.	O

AP-1	B
has	O
been	O
shown	O
to	O
behave	O
as	O
a	O
redox	B
-	I
sensitive	I
transcription	I
factor	I
that	O
can	O
be	O
activated	O
by	O
both	O
oxidant	O
and	O
antioxidant	O
stimuli	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	B
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	B
(	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
)	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B
against	O
the	O
T	B
cell	I
receptor	I
-	I
CD3	I
complex	I
and	O
to	O
CD28	B
.	O

The	O
activation	O
of	O
JNK	B
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N	O
-	O
acetylcysteine	O
)	O
was	O
sustained	O
.	O

The	O
kinetics	O
of	O
JNK	B
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c	O
-	O
jun	O
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
JNK	B
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2	O
+	O
,	O
protein	B
kinase	I
C	I
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	O
to	O
inhibit	O
the	O
activation	O
mediated	O
by	O
PDTC	O
.	O

Transfection	O
of	O
trans	O
-	O
dominant	O
negative	O
expression	O
vectors	O
of	O
ras	O
and	O
raf	O
,	O
together	O
with	O
AP-1-dependent	O
reporter	O
constructs	O
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti	B
-	I
ERK	I
(	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
)	I
antibodies	I
,	O
indicated	O
that	O
the	O
Ras	O
/	O
Raf	O
/	O
ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

However	O
,	O
the	O
combined	O
treatment	O
with	O
PDTC	O
and	O
PMA	O
,	O
two	O
agents	O
that	O
synergize	O
on	O
AP-1	B
activation	O
,	O
resulted	O
in	O
the	O
persistent	O
phosphorylation	O
of	O
ERK-2	B
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	B
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B
B	I
-	I
cell	I
specific	I
transcriptional	I
coactivator	I
Bob1	B
.	O

From	O
a	O
murine	O
B	O
-	O
cell	O
cDNA	O
-	O
library	O
we	O
have	O
cloned	O
a	O
cDNA	O
encoding	O
the	O
murine	B
B	I
-	I
cell	I
specific	I
coactivator	I
mBob1	B
.	O

The	O
protein	O
is	O
the	O
murine	O
homologue	O
to	O
the	O
recently	O
described	O
human	B
coactivator	I
Bob1	I
(	O
hBob1	B
)	O
,	O
also	O
referred	O
to	O
as	O
OBF-1	B
or	O
OCA	B
-	I
B	I
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	B
mBob1	I
clone	I
.	O

Analysis	O
of	O
its	O
intron	O
-	O
exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C	B
-	I
terminal	I
splice	I
variant	I
.	O

mBob1	B
is	O
B	O
-	O
cell	O
restricted	O
,	O
and	O
is	O
found	O
in	O
all	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

mBob1	B
interacts	O
with	O
the	O
octamer	B
transcription	I
factors	I
Oct-1	B
and	O
Oct-2	B
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic	O
/	O
fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	B
growth	I
factor	I
(	O
HGF	B
)	O
requirement	O
of	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
purified	O
from	O
embryonic	O
-	O
fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	B
(	O
Epo	B
)	O
for	O
colony	O
formation	O
by	O
early	O
erythroid	O
progenitors	O
(	O
burst	O
-	O
forming	O
units	O
-	O
erythroid	O
[	O
BFU	O
-	O
E	O
]	O
)	O
has	O
been	O
confirmed	O
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	B
,	O
FL	O
monocytic	O
progenitors	O
(	O
colony	O
-	O
forming	O
unit	O
monocyte	O
[	O
CFU	O
-	O
M	O
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes	O
-	O
macrophages	O
;	O
these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

On	O
this	O
basis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

Both	O
compounds	O
modulate	O
the	O
growth	O
of	O
purified	O
FL	O
HPCs	O
,	O
which	O
show	O
a	O
dose	O
-	O
dependent	O
shift	O
from	O
mixed	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
colony	O
formation	O
.	O

Studies	O
on	O
unicellular	O
and	O
paired	O
daughter	O
cell	O
culture	O
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA	O
-	O
induced	O
down	O
-	O
modulation	O
of	O
multipotent	O
/erythroid	O
/	O
monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	O
HPCs	O
)	O
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	O
HPCs	O
(	O
high	O
-	O
proliferative	O
potential	O
colony	O
-	O
forming	O
cells	O
[	O
HPP	O
-	O
CFCs	O
]	O
)	O
and	O
putative	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
;	O
assayed	O
in	O
Dexter	O
-	O
type	O
long	O
-	O
term	O
culture	O
)	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP	O
-	O
CFC	O
colonies	O
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	O
proliferation	O
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	O
transduced	O
with	O
dominant	O
negative	O
ATRA	O
receptor	O
(	O
RAR	O
)	O
gene	O
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA	O
/	O
9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR	B
/	I
RXR	I
heterodimer	I
,	O
ie	O
,	O
inhibition	O
of	O
HSC	O
/	O
primitive	O
HPC	O
proliferation	O
and	O
induction	O
of	O
CFU	O
-	O
GEMM	O
/	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
M	O
shift	O
from	O
the	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
the	O
granulocytic	O
-	O
neutrophilic	O
differentiation	O
program	O
.	O

The	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
,	O
but	O
not	O
its	O
regulatory	B
domain	I
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B
production	O
.	O

The	O
lymphoid	B
src	I
kinase	I
pp56	B
(	I
lck	I
)	I
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	O
lymphocyte	O
responses	O
,	O
including	O
CD4	B
-mediated	O
enhancement	O
of	O
Ag	O
-	O
induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	B
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	B
(	I
lck	I
)	I
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B
regulatory	B
domain	I
is	O
sufficient	O
to	O
mediate	O
CD4	B
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	B
and	I
catalytic	I
domains	I
of	O
pp56	B
(	I
lck	I
)	I
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B
:	O
TCR	O
-	O
induced	O
IL-2	B
production	O
.	O

Two	O
pp56	B
(	I
lck	I
)	I
mutants	I
lacking	O
either	O
the	O
entire	O
catalytic	B
domain	I
or	O
the	O
entire	O
NH2	B
regulatory	B
domain	I
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR	O
-	O
regulated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
region	O
of	O
the	O
IL-2	O
promoter	O
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	B
regulatory	O
,	O
domain	O
of	O
pp56	B
(	I
lck	I
)	I
was	O
able	O
to	O
induce	O
NF	B
-	I
AT	I
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
was	O
able	O
to	O
induce	O
IL-2	B
cytokine	B
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
pp56	B
(	I
lck	I
)	I
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	B
(	I
lck	I
)	I
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	B
regulatory	B
domain	I
is	O
sufficient	O
to	O
mediate	O
CD4	B
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B
domain	I
of	O
pp56	B
(	I
lck	I
)	I
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	B
production	O
,	O
mimicking	O
TCR	B
ligation	O
.	O

Lack	O
of	O
IL-12	B
signaling	O
in	O
human	O
allergen	O
-	O
specific	O
Th2	O
cells	O
.	O

IL-12	B
is	O
a	O
powerful	O
skewer	O
of	O
CD4	O
+	O
T	O
cell	O
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN	B
-	I
gamma	I
production	O
in	O
naive	O
Th	O
cells	O
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	B
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1	O
/	O
Th0	O
responses	O
by	O
inducing	O
IFN	B
-	I
gamma	I
production	O
in	O
memory	O
Th2	O
cells	O
.	O

To	O
this	O
aim	O
,	O
allergen	O
-	O
specific	O
CD4	O
+	O
T	O
cell	O
clones	O
(	O
TCC	O
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	O
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	B
profile	O
,	O
and	O
the	O
production	O
of	O
IFN	B
-	I
gamma	I
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	B
.	O

Only	O
those	O
TCC	O
with	O
low	O
IFN	B
-	I
gamma	I
levels	O
in	O
the	O
absence	O
of	O
IL-12	B
responded	O
to	O
IL-12	B
by	O
additional	O
enhancement	O
of	O
IFN	B
-	I
gamma	I
production	O
.	O

The	O
IL-12	B
nonresponsiveness	O
of	O
the	O
Th2	O
clones	O
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	B
-induced	O
phosphorylation	O
of	O
STAT4	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-4	I
)	O
,	O
a	O
transcription	B
factor	I
that	O
is	O
typically	O
involved	O
in	O
IL-12	B
signaling	O
.	O

Consequently	O
,	O
IL-12	B
also	O
failed	O
to	O
induce	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
STAT4-containing	B
complexes	I
in	O
the	O
nuclei	O
of	O
these	O
Th2	O
clones	O
.	O

All	O
TCC	O
expressed	O
equal	O
levels	O
of	O
the	O
low	B
-	I
affinity	I
IL-12R	I
beta1	I
subunit	I
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen	O
-	O
specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	B
profiles	O
do	O
not	O
respond	O
to	O
IL-12	B
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN	B
-	I
gamma	I
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	O
Th	O
cells	O
within	O
the	O
allergen	O
-	O
specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	B
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	O
cells	O
.	O

Activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
via	O
T	B
cell	I
receptor	I
requires	O
a	O
Raf	B
kinase	I
and	O
Ca2	O
+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	B
and	O
calcineurin	B
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B
activate	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	B
kinase	I
C	I
activator	O
PMA	O
in	O
combination	O
with	O
Ca2	O
+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	B
stimulation	O
,	O
bypassing	O
the	O
TCR	B
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	B
-	I
kappaB	I
following	O
TCR	B
stimulation	O
.	O

TCR	B
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	O
T	O
cells	O
with	O
PHA	B
or	O
anti	B
-	I
CD3	I
Abs	I
,	O
and	O
NF	B
-	I
kappaB	I
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	B
-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B
kinase	I
C	I
is	O
involved	O
in	O
TCR	B
-mediated	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
PHA	B
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B
-induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	B
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	B
kinase	I
.	O

The	O
TCR	B
-mediated	O
activation	O
of	O
NF	B
-	I
kappaB	I
was	O
also	O
dependent	O
on	O
a	O
Ca2	O
+	O
influx	O
,	O
because	O
the	O
Ca2	O
+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2	O
+	O
influx	O
,	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B
largely	O
substituted	O
for	O
the	O
Ca2	O
+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B
and	O
calcineurin	B
synergistically	O
induced	O
kappaB	B
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B
and	O
the	O
phosphatase	B
.	O

Differentiation	O
-	O
dependent	O
expression	O
of	O
a	O
human	B
carboxylesterase	I
in	O
monocytic	O
cells	O
and	O
transcription	B
factor	I
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	B
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte	O
/	O
macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	B
carboxylesterase	I
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA	O
-	O
treated	O
THP-1	O
cells	O
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-1	O
to	O
-275	O
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	B
factors	I
,	O
is	O
bound	O
by	O
nuclear	B
factors	I
Sp1	B
and	O
IRBP	B
but	O
not	O
by	O
C	B
/	I
EBPs	I
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	O
cells	O
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	B
and	O
IRBP	B
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation	O
-	O
dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Identification	O
of	O
Bcd	O
,	O
a	O
novel	O
proto	O
-	O
oncogene	O
expressed	O
in	O
B	O
-	O
cells	O
.	O

A	O
novel	O
B	O
-	O
cell	O
derived	O
(	O
Bcd	O
)	O
oncogene	O
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

The	O
Bcd	O
proto	O
-	O
oncogene	O
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	O
'	O
UTR	O
.	O

It	O
predicts	O
for	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

ORF1	O
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	O
ORF2	O
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

Predicted	B
peptide	I
sequence	I
of	O
ORF2	O
contained	O
a	O
zinc	B
finger	I
domain	I
which	O
showed	O
significant	O
homology	O
to	O
GC	B
box	I
binding	I
proteins	I
BTEB2	B
and	O
SP1	B
.	O

Transfection	O
of	O
an	O
expression	O
vector	O
containing	O
ORF2	O
but	O
not	O
full	O
length	O
cDNA	O
was	O
able	O
to	O
transform	O
NIH3T3	O
cells	O
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Bcd	O
mRNA	O
transcripts	O
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	O
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

Within	O
the	O
PBL	O
,	O
Bcd	O
gene	O
expression	O
was	O
restricted	O
to	O
CD19	O
+	O
B	O
-	O
cells	O
and	O
absent	O
from	O
CD14	O
+	O
monocytes	O
and	O
T	O
-	O
cells	O
.	O

Bcd	O
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	O
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	O
human	O
B	O
-	O
cell	O
lines	O
and	O
not	O
in	O
50	O
%	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O

However	O
,	O
stimulation	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	O
cells	O
was	O
associated	O
with	O
induction	O
of	O
Bcd	O
gene	O
expression	O
.	O

The	O
Bcd	O
gene	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B	O
-	O
cell	O
growth	O
and	O
development	O
.	O

Shared	O
gamma	B
(	I
c	I
)	I
subunit	I
within	O
the	O
human	B
interleukin-7	I
receptor	I
complex	I
.	O

A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
mutations	O
in	O
the	O
gamma	B
(	I
c	I
)	I
receptor	I
subunit	I
cause	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
.	O

The	O
gamma	B
(	I
c	I
)	I
subunit	I
can	O
be	O
employed	O
in	O
receptor	B
complexes	I
for	O
IL-2	B
,	I
-4	I
,	I
-7	I
,	I
-9	I
,	I
and	I
-15	I
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	B
(	I
c	I
)	I
chain	I
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X	O
-	O
SCID	O
patients	O
.	O

Interestingly	O
,	O
gene	O
disruption	O
of	O
either	O
IL-7	B
or	O
the	O
IL-7	B
receptor	I
(	I
IL-7R	I
)	I
alpha	I
subunit	I
in	O
mice	O
leads	O
to	O
immunological	O
defects	O
that	O
are	O
similar	O
to	O
human	O
X	O
-	O
SCID	O
.	O

These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	B
(	I
c	I
)	I
in	O
the	O
IL-7R	B
complex	I
.	O

In	O
the	O
present	O
study	O
,	O
structure	O
/	O
function	O
analyses	O
of	O
the	O
IL-7R	B
complex	I
using	O
a	O
chimeric	B
receptor	I
system	O
demonstrated	O
that	O
gamma	B
(	I
c	I
)	I
is	O
indeed	O
critical	O
for	O
IL-7R	B
function	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	B
domain	I
of	O
gamma	B
(	I
c	I
)	I
is	O
necessary	O
for	O
IL-7R	B
signal	O
transduction	O
.	O

Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	B
(	I
c	I
)	I
cytoplasmic	B
domain	I
by	O
a	O
severely	B
truncated	I
erythropoeitin	I
receptor	I
does	O
not	O
affect	O
measured	O
IL-7R	B
signaling	O
events	O
.	O

These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	B
(	I
c	I
)	I
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	B
complex	I
,	O
while	O
IL-7R	B
alpha	I
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	B
signaling	I
molecules	I
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X	O
-	O
SCID	O
is	O
due	O
primarily	O
to	O
gamma	B
(	I
c	I
)	I
-mediated	O
defects	O
in	O
the	O
IL-7	B
/IL-7R	B
system	O

Generation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
against	O
immunorecessive	B
epitopes	I
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Since	O
the	O
CTL	O
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	B
epitopes	I
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	B
epitopes	I
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL	O
/	O
10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB	O
/	O
FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB	O
/	O
cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	B
antigen	I
(	O
s	O
)	O
,	O
and	O
the	O
CTL	O
responses	O
were	O
measured	O
.	O

In	O
C57BL	O
/	O
10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	B
antigen	I
in	O
E1A	O
.	O

When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O

or	O
intranasally	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	O
region	O
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	O
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	O
and	O
E1B	O
,	O
no	O
immunorecessive	B
epitopes	I
were	O
recognized	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB	O
/	O
c	O
mice	O
was	O
more	O
complex	O
.	O

CTLs	O
from	O
BALB	O
/	O
c	O
mice	O
inoculated	O
i.p	O
.	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
E1B	O
in	O
the	O
context	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
Dd	O
allele	O
and	O
a	O
region	O
outside	O
E1	O
associated	O
with	O
the	O
Kd	O
allele	O
.	O

When	O
BALB	O
/	O
c	O
mice	O
were	O
inoculated	O
with	O
E1	O
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	B
Kd	I
-	I
restricted	I
epitope	I
was	O
recognized	O
,	O
and	O
Dd	O
-	O
restricted	O
CTLs	O
did	O
not	O
develop	O
.	O

This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	O
against	O
immunorecessive	B
epitopes	I
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	B
-diverse	O
human	O
population	O
.	O

Involvement	O
of	O
Egr-1	B
/RelA	B
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-induced	O
NF	B
-	I
kappa	I
B1	I
transcription	O
.	O

NF	B
-	I
kappa	I
B	I
is	O
an	O
important	O
transcription	B
factor	I
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF	O
-	O
kappa	O
B1	O
gene	O
encodes	O
a	O
105-kD	B
protein	I
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	B
component	I
of	O
NF	B
-	I
kappa	I
B	I
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF	B
-	I
kappa	I
B	I
regulates	O
the	O
NF	O
-	O
kappa	O
B1	O
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	O
cell	O
lines	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	B
(	O
PHA	B
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF	B
-	I
kappa	I
B1	I
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O

Characterization	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
promoter	O
identified	O
an	O
Egr-1	O
site	O
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA	O
/	O
PHA	B
-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Egr-1	B
.	O

Furthermore	O
,	O
Egr-1	B
induction	O
was	O
required	O
for	O
endogenous	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
,	O
since	O
PMA	O
/	O
PHA	O
-	O
stimulated	O
T	O
cell	O
lines	O
expressing	O
antisense	O
Egr-1	O
RNA	O
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF	O
-	O
kappa	O
B1	O
transcription	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	B
and	O
NF	B
-	I
kappa	I
B	I
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
.	O

Jak1	B
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	B
signaling	B
molecules	I
.	O

The	O
Jak1	B
,	I
Jak2	I
,	I
Jak3	I
,	I
and	I
Fes	I
tyrosine	I
kinases	I
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	B
(	I
IL	I
)	I
-4	I
stimulation	O
in	O
different	O
cell	O
systems	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
kinases	O
are	O
responsible	O
for	O
initiating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
of	O
intracellular	B
substrates	I
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	O
Jak1-deficient	O
HeLa	O
cell	O
line	O
,	O
E1C3	O
,	O
and	O
its	O
parental	O
Jak1-expressing	O
counterpart	O
,	O
1D4	O
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	B
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O

IL-4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	B
receptor	I
substrate	I
(	I
IRS	I
)	I
-1	I
and	O
IRS-2	B
in	O
1D4	O
but	O
not	O
in	O
E1C3	O
cells	O
.	O

IL-4	B
-mediated	O
tyrosine	O
phosphorylation	O
of	O
Stat6	B
was	O
pronounced	O
in	O
1D4	O
cells	O
,	O
while	O
no	O
IL-4	B
-induced	O
Stat6	B
phosphorylation	O
was	O
detected	O
in	O
E1C3	O
cells	O
.	O

IL-4	B
also	O
induced	O
Stat6	B
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	O
but	O
not	O
E1C3	O
cells	O
utilizing	O
a	O
radiolabeled	O
immunoglobulin	O
heavy	O
chain	O
germline	O
epsilon	O
promotor	O
sequence	O
(	O
Iepsilon	O
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Reconstitution	O
of	O
Jak1	B
expression	O
in	O
E1C3	O
cells	O
restored	O
the	O
ability	O
of	O
IL-4	B
to	O
induce	O
IRS	O
and	O
Stat6	B
tyrosine	O
phosphorylation	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
Jak1	B
expression	O
is	O
required	O
for	O
mediating	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
crucial	O
molecules	O
involved	O
in	O
IL-4	B
signal	O
transduction	O
.	O

Interleukin-4	B
signaling	O
in	O
B	O
lymphocytes	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Interleukin-4	B
(	O
IL-4	B
)	O
is	O
an	O
important	O
cytokine	O
for	O
B	O
and	O
T	O
lymphocyte	O
function	O
and	O
mediates	O
its	O
effects	O
via	O
a	O
receptor	O
that	O
contains	O
gammac	B
.	O

B	O
cells	O
derived	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	B
-mediated	O
signaling	O
.	O

We	O
found	O
that	O
although	O
IL-4	B
stimulation	O
of	O
X	O
-	O
SCID	O
B	O
cells	O
did	O
not	O
result	O
in	O
Janus	B
tyrosine	I
kinase-3	I
(	O
JAK3	B
)	O
phosphorylation	O
,	O
other	O
IL-4	B
substrates	I
including	O
JAK1	B
and	O
IRS-1	B
were	O
phosphorylated	O
.	O

Additionally	O
,	O
we	O
detected	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
6	I
(	O
STAT6	B
)	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
in	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
a	O
wide	O
range	O
of	O
gammac	B
mutations	O
.	O

However	O
,	O
reconstitution	O
of	O
these	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
gammac	B
enhanced	O
IL-4	B
-mediated	O
responses	O
including	O
STAT6	B
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	B
expression	O
.	O

Thus	O
,	O
gammac	B
is	O
not	O
necessary	O
to	O
trigger	O
IL-4	B
-mediated	O
responses	O
in	O
B	O
cells	O
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL-4	B
-signaling	O
.	O

These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	B
signaling	O
pathways	O
exist	O
.	O

Nuclear	B
Rel	I
-	I
A	I
and	I
c	I
-	I
Rel	I
protein	I
complexes	I
are	O
differentially	O
distributed	O
within	O
human	O
thymocytes	O
.	O

Nuclear	B
factor	I
-	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
)	I
/Rel	I
proteins	I
are	O
inducible	O
transcriptional	B
regulators	I
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF	B
-	I
kappa	I
B	I
proteins	I
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50	B
/	I
p65	I
and	I
p50	I
/	I
c	I
-	I
Rel	I
complexes	I
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	B
Abs	I
allowed	O
visualization	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
proteins	I
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50	B
/	I
c	I
-	I
Rel	I
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50	B
/	I
p65	I
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	B
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c	O
-	O
Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	O
and	O
CD8-positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	B
and	I
c	I
-	I
Rel	I
complexes	I
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	B
-	I
kappa	I
B	I
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Common	O
and	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
human	O
neutrophils	O
utilized	O
by	O
platelet	B
activating	I
factor	I
and	O
FMLP	B
.	O

Stimulation	O
of	O
human	O
neutrophils	O
with	O
chemoattractants	B
FMLP	B
or	O
platelet	B
activating	I
factor	I
(	O
PAF	B
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O

We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O

Stimulation	O
with	O
either	O
PAF	B
or	O
FMLP	B
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	I
MAPk	I
)	I
homologue	I
38-kD	B
murine	I
MAP	I
kinase	I
homologous	O
to	O
HOG-1	B
(	I
p38	I
)	I
MAPk	I
.	O

Neither	O
FMLP	B
nor	O
PAF	B
activated	O
c	B
-	I
jun	I
NH2-terminal	I
MAPk	I
(	O
JNKs	B
)	O
.	O

Under	O
identical	O
conditions	O
,	O
FMLP	B
but	O
not	O
PAF	B
,	O
resulted	O
in	O
significant	O
p42	B
/	I
44	I
(	I
ERK	I
)	I
MAPk	I
activation	O
.	O

Both	O
FMLP	B
and	O
PAF	B
activated	I
MAP	I
kinase	I
kinase-3	I
(	O
MKK3	B
)	O
,	O
a	O
known	O
activator	O
of	O
p38	B
MAPk	I
.	O

Both	O
MAP	B
ERK	I
kinase	I
kinase-1	I
(	O
MEKK1	B
)	O
and	O
Raf	B
are	O
activated	O
strongly	O
by	O
FMLP	B
,	O
but	O
minimally	O
by	O
PAF	B
.	O

Pertussis	B
toxin	I
blocked	O
FMLP	B
-induced	O
activation	O
of	O
the	O
p42	B
/	I
44	I
(	I
ERK	I
)	I
MAPk	I
cascade	O
,	O
but	O
not	O
that	O
of	O
p38	B
MAPk	I
.	O

A	O
specific	O
p38	B
MAPk	I
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	B
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	B
or	O
FMLP	B
.	O

These	O
results	O
demonstrate	O
distinct	O
patterns	O
of	O
intracellular	O
signaling	O
for	O
two	O
chemoattractants	B
and	O
suggest	O
that	O
selective	O
activation	O
of	O
intracellular	O
signaling	O
cascades	O
may	O
underlie	O
different	O
patterns	O
of	O
functional	O
responses	O
.	O

Pivotal	O
role	O
for	O
the	O
NFIL3	B
/	I
E4BP4	I
transcription	I
factor	I
in	O
interleukin	B
3	I
-mediated	O
survival	O
of	O
pro	O
-	O
B	O
lymphocytes	O
.	O

The	O
E2A	B
-	I
HLF	I
(	I
hepatic	I
leukemia	I
factor	I
)	I
oncoprotein	I
,	O
generated	O
in	O
pro	O
-	O
B	O
lymphocytes	O
by	O
fusion	O
of	O
the	O
trans	B
-	I
activation	I
domain	I
of	O
E2A	B
to	O
the	O
basic	B
region	I
/	I
leucine	I
zipper	I
(	I
bZIP	I
)	I
domain	I
of	O
HLF	B
,	O
functions	O
as	O
an	O
anti	B
-	I
apoptotic	I
transcription	I
factor	I
in	O
leukemic	O
cell	O
transformation	O
.	O

When	O
introduced	O
into	O
interleukin	B
3	I
(	O
IL-3	B
)	O
-dependent	O
mouse	O
pro	O
-	O
B	O
lymphocytes	O
,	O
E2A	B
-	I
HLF	I
prevents	O
apoptosis	O
induced	O
by	O
growth	B
factor	I
deprivation	O
,	O
suggesting	O
that	O
IL-3	B
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	B
factor	I
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	B
oncoprotein	I
.	O

We	O
considered	O
four	O
bZIP	B
transcription	I
factors	I
as	O
candidates	O
for	O
this	O
putative	O
IL-3-regulated	B
factor	I
,	O
each	O
of	O
which	O
binds	O
avidly	O
to	O
the	O
DNA	O
consensus	O
sequence	O
recognized	O
by	O
E2A	B
-	I
HLF	I
and	O
is	O
related	O
to	O
the	O
Caenorhabditis	B
elegans	I
CES-2	I
(	O
cell	B
death	I
specification	I
protein	I
)	O
neuron	B
-	I
specific	I
mediator	I
of	I
cell	I
death	I
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	B
protein	I
(	O
also	O
called	O
E4bp4	B
)	O
,	O
but	O
not	O
of	O
Hlf	B
,	O
Dbp	B
,	O
or	O
Tef	B
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	B
in	O
mouse	O
pro	O
-	O
B	O
cell	O
lines	O
(	O
Baf-3	O
and	O
FL5.12	O
)	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
Nfil3	B
/	I
E4bp4	I
is	O
regulated	O
as	O
a	O
`	O
`	O
delayed	O
-	O
early	O
''	O
IL-3-responsive	O
gene	O
,	O
requiring	O
de	O
novo	O
protein	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
IL-3	B
,	O
enforced	O
expression	O
of	O
the	O
human	O
NFIL3	O
/	O
E4BP4	O
cDNA	O
promoted	O
the	O
survival	O
but	O
not	O
the	O
growth	O
of	O
IL-3-dependent	O
pro	O
-	O
B	O
cells	O
.	O

Our	O
results	O
implicate	O
NFIL3	B
/	I
E4BP4	I
(	O
nuclear	B
factor	I
regulated	I
by	I
IL-3	I
/	I
adenovirus	I
E4	I
promoter	I
binding	I
protein	I
)	O
in	O
a	O
distinct	O
growth	O
factor	O
-	O
regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	O
B	O
-	O
cell	O
progenitors	O
,	O
and	O
whose	O
alteration	O
by	O
E2A	B
-	I
HLF	I
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O

ALY	B
,	O
a	O
context	B
-	I
dependent	I
coactivator	I
of	O
LEF-1	B
and	O
AML-1	B
,	O
is	O
required	O
for	O
TCRalpha	O
enhancer	O
function	O
.	O

LEF-1	B
is	O
a	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
alpha	O
)	O
enhancer	O
by	O
facilitating	O
the	O
assembly	O
of	O
multiple	B
proteins	I
into	O
a	O
higher	O
order	O
nucleoprotein	B
complex	I
.	O

The	O
function	O
of	O
LEF-1	B
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	B
domain	I
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	B
domain	I
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer	B
-	I
binding	I
proteins	I
.	O

With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context	B
-	I
dependent	I
activation	I
domains	I
,	O
we	O
cloned	O
ALY	B
,	O
a	O
novel	O
LEF-1-interacting	B
protein	I
.	O

ALY	B
is	O
a	O
ubiquitously	O
expressed	O
,	O
nuclear	O
protein	O
that	O
specifically	O
associates	O
with	O
the	O
activation	B
domains	I
of	O
LEF-1	B
and	O
AML-1	B
(	O
CBF	B
alpha2	I
,	O
PEBP2	B
alpha	I
(	O
B	O
)	O
,	O
which	O
is	O
another	O
protein	O
component	O
of	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
.	O

In	O
addition	O
,	O
ALY	B
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	B
and	O
AML	B
proteins	I
.	O

Overexpression	O
of	O
ALY	B
stimulates	O
the	O
activity	O
of	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
reconstituted	O
in	O
transfected	O
nonlymphoid	O
HeLa	O
cells	O
,	O
whereas	O
down	O
-	O
regulation	O
of	O
ALY	B
by	O
anti	O
-	O
sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
T	O
cells	O
.	O

Similar	O
to	O
LEF-1	B
,	O
ALY	B
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	O
alpha	O
enhancer	O
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	B
DNA	I
-	I
binding	I
domain	I
.	O

We	O
propose	O
that	O
ALY	B
mediates	O
context	O
-	O
dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	B
proteins	I
in	O
the	O
TCR	B
alpha	I
enhancer	I
complex	I
.	O

Estrogen	B
and	O
progesterone	B
receptors	I
in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE	O
:	O
Sex	O
-	O
related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B
and	O
progesterone	B
receptors	I
by	O
using	O
monoclonal	B
antibodies	I
with	O
a	O
peroxidase	O
-	O
antiperoxidase	O
technique	O
.	O

RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	B
receptors	I
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B
and	O
progesterone	B
receptors	I
with	O
eosinophil	B
cationic	I
protein	I
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	O
cells	O
were	O
eosinophils	O
.	O

CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	B
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	O
in	O
patients	O
with	O
VKC	O
.	O

Induction	O
of	O
relA	B
(	I
p65	I
)	I
and	O
I	B
kappa	I
B	I
alpha	I
subunit	I
expression	O
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
subunits	I
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	B
homodimers	I
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
heterodimers	I
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	B
(	I
p65	I
)	I
subunit	I
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
was	O
significantly	O
higher	O
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
heterodimers	I
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50	B
/	I
RelA	I
(	I
p65	I
)	I
complexes	I
that	O
are	O
readily	O
available	O
for	O
inducer	O
-	O
mediated	O
stimulation	O
.	O

Requirement	O
of	O
prestimulated	O
THP-1	O
monocytic	O
cells	O
for	O
endothelial	O
cell	O
activation	O
.	O

Involvement	O
of	O
TNF	O
alpha	O
.	O

Blood	O
monocytes	O
spontaneously	O
activate	O
endothelial	O
cells	O
in	O
culture	O
,	O
leading	O
to	O
adhesion	O
of	O
monocytic	O
cells	O
onto	O
the	O
endothelial	O
surface	O
and	O
overproduction	O
of	O
endothelial	O
proteins	O
such	O
as	O
von	B
Willebrand	I
factor	I
(	O
vWf	B
)	O
and	O
plasminogen	B
activator	I
inhibitor	I
type	I
1	I
(	O
PAI-1	B
)	O
.	O

To	O
overcome	O
the	O
difficulty	O
in	O
obtaining	O
quiescent	O
monocytes	O
,	O
we	O
studied	O
the	O
ability	O
of	O
promonocytic	O
THP-1	O
cells	O
to	O
activate	O
endothelial	O
cells	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
-prestimulated	O
and	O
untreated	O
THP-1	O
cells	O
were	O
cocultured	O
with	O
resting	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
for	O
3	O
and	O
24	O
h	O
in	O
the	O
presence	O
of	O
colimycin	O
to	O
neutralize	O
LPS	O
traces	O
.	O

Addition	O
of	O
untreated	O
THP-1	O
cells	O
had	O
little	O
effect	O
on	O
HUVEC	O
adhesiveness	O
.	O

Addition	O
of	O
prestimulated	O
THP-1	O
cells	O
was	O
followed	O
by	O
a	O
noticeable	O
adhesion	O
after	O
3	O
h	O
which	O
reversed	O
to	O
basal	O
values	O
within	O
24	O
h	O
.	O

Under	O
these	O
conditions	O
HUVEC	B
adhesion	I
molecules	I
,	O
E	B
-	I
selectin	I
,	O
VCAM-1	B
and	O
ICAM-1	B
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	B
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

Diffusible	B
endothelial	I
proteins	I
such	O
as	O
soluble	O
E	B
-	I
selectin	I
,	O
PAI-1	B
and	O
vWf	B
to	O
a	O
minimal	O
extent	O
,	O
increased	O
in	O
supernatants	O
from	O
HUVEC	O
cocultured	O
for	O
24	O
h	O
with	O
prestimulated	O
THP-1	O
cells	O
.	O

In	O
those	O
cocultures	O
,	O
TNF	B
alpha	I
concentrations	O
peaked	O
at	O
3	O
h	O
whereas	O
IL-1	O
beta	O
levels	O
progressively	O
rose	O
until	O
24	O
h	O
.	O

Addition	O
of	O
an	O
anti	B
-	I
TNF	I
alpha	I
antibody	I
decreased	O
by	O
40	O
%	O
E	B
-	I
selectin	I
and	O
ICAM-1	B
induction	O
and	O
suppressed	O
PAI-1	B
overproduction	O
with	O
a	O
weak	O
effect	O
on	O
vWf	B
.	O

An	O
anti	B
-	I
IL-1	I
beta	I
antibody	I
had	O
negligible	O
effects	O
on	O
HUVEC	B
adhesion	I
molecules	I
,	O
PAI-1	B
or	O
vWf	B
production	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
promonocytic	O
THP-1	O
cells	O
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	O
and	O
that	O
TNF	B
alpha	I
contributes	O
to	O
this	O
phenomenon	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	B
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	B
-	I
Jkappa	I
or	O
nuclear	B
localization	I
sequences	I
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP	B
-	I
Jkappa	I
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	B
transmembrane	I
receptor	I
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	B
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	B
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	B
domain	I
(	O
DeltaE	B
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	B
domain	I
(	O
ICN	B
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	B
-	I
Jkappa	I
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	B
factor	I
RBP	I
-	I
Jkappa	I
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP	B
-	I
Jkappa	I
-	I
binding	I
site	I
within	O
the	O
NOTCH1	B
ankyrin	I
repeat	I
region	I
of	O
the	O
intracellular	B
domain	I
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	B
-	I
Jkappa	I
-	I
binding	I
site	I
,	O
which	O
lies	O
within	O
the	O
intracellular	B
domain	I
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	B
-	I
Jkappa	I
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	B
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	B
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	B
localization	I
sequences	I
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	B
-	I
bound	I
DeltaE	I
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	B
-	I
bound	I
DeltaE	I
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	B
ICN	I
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	B
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP	B
-	I
Jkappa	I
at	O
promoter	O
sites	O
.	O

Glucocorticoid	O
-	O
resistance	O
in	O
peripheral	O
-	O
blood	O
lymphocytes	O
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid	B
-	I
receptors	I
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
resistance	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
seriously	O
impairs	O
successive	O
GC	O
therapy	O
after	O
renal	O
transplantation	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
GC	O
-	O
receptor	O
(	O
GC	O
-	O
R	O
)	O
parameters	O
in	O
peripheral	O
-	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
PBMC	O
resistance	O
to	O
GC	O
in	O
21	O
CRF	O
patients	O
and	O
18	O
healthy	O
subjects	O
.	O

Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	O
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng	O
/	O
mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng	O
/	O
mL	O
)	O
groups	O
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC	B
-	I
R	I
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
2.89	O
+	O
/-	O
1.23	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+	O
/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+	O
/-	O
2.02	O
(	O
257.7	O
+	O
/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

The	O
GC	B
-	I
R	I
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.33	O
+	O
/-	O
1.37	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+	O
/-	O
1.39	O
nM	O
,	O
respectively	O
.	O

Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	B
stimulation	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase	O
-	O
ratios	O
(	O
post	O
/	O
pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	B
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
6.04	O
+	O
/-	O
2.35	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+	O
/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.13	O
+	O
/-	O
2.31	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+	O
/-	O
1.62	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	B
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC	B
-	I
R	I
parameters	O
in	O
CRF	O
.	O

We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	O
capacity	O
to	O
amplify	O
GC	B
-	I
R	I
numbers	O
in	O
response	O
to	O
mitogen	B
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC	B
-	I
R	I
parameters	O
.	O

An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC	O
-	O
resistance	O
of	O
CRF	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B	B
-	I
cell	I
-	I
specific	I
activator	I
protein	I
.	O

Germline	B
transcripts	I
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	B
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B	B
-	I
cell	I
-	I
specific	I
activator	I
protein	I
(	O
BSAP	B
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	B
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	B
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	B
plays	O
a	O
role	O
in	O
both	O
IL-4	B
-dependent	O
induction	O
and	O
CD40	B
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	B
is	O
unique	O
among	O
the	O
transcription	B
factors	I
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	B
switching	O
.	O

Molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

The	O
immunoregulatory	B
properties	O
of	O
prolactin	O
,	O
a	O
pituitary	O
peptide	O
hormone	O
,	O
have	O
received	O
renewed	O
attention	O
.	O

The	O
prolactin	B
receptor	I
,	O
a	O
member	O
of	O
the	O
hematopoietin	B
/	I
cytokine	I
receptor	I
superfamily	I
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O

Certain	O
subpopulations	O
of	O
lymphocytes	O
synthesize	O
and	O
secrete	O
biologically	O
active	O
prolactin	O
,	O
which	O
suggests	O
that	O
prolactin	O
can	O
act	O
as	O
an	O
autocrine	O
and/or	O
paracrine	O
factor	O
to	O
modulate	O
the	O
activities	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	B
molecules	I
and	O
prolactin	O
-	O
inducible	O
target	O
genes	O
that	O
participate	O
in	O
these	O
responses	O
.	O

In	O
particular	O
,	O
the	O
prolactin	O
-	O
inducible	O
interferon	O
regulatory	O
factor-1	O
gene	O
and	O
its	O
roles	O
in	O
mediating	O
diverse	O
immune	O
responses	O
.	O

A	O
new	O
mouse	O
gene	O
,	O
SRG3	O
,	O
related	O
to	O
the	O
SWI3	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
in	O
a	O
thymoma	O
cell	O
line	O
.	O

We	O
isolated	O
a	O
new	O
mouse	O
gene	O
that	O
is	O
highly	O
expressed	O
in	O
thymocytes	O
,	O
testis	O
,	O
and	O
brain	O
.	O

This	O
gene	O
,	O
SRG3	O
,	O
showed	O
a	O
significant	O
sequence	O
homology	O
to	O
SWI3	O
,	O
a	O
yeast	O
transcriptional	O
activator	O
,	O
and	O
its	O
human	O
homolog	O
BAF155	O
.	O

SRG3	O
encodes	O
1	O
,	O
100	O
amino	O
acids	O
and	O
has	O
33	O
-	O
47	O
%	O
identity	O
with	O
SWI3	B
protein	I
over	O
three	O
regions	O
.	O

The	O
SRG3	B
protein	I
contains	O
an	O
acidic	B
NH2	I
terminus	I
,	O
a	O
myb	B
-	I
like	I
DNA	I
binding	I
domain	I
,	O
a	O
leucine	B
-	I
zipper	I
motif	I
,	O
and	O
a	O
proline-	B
and	I
glutamine	I
-	I
rich	I
region	I
at	O
its	O
COOH	B
terminus	I
.	O

Rabbit	O
antiserum	O
raised	O
against	O
a	O
COOH	O
-	O
terminal	O
polypeptide	O
of	O
the	O
SRG3	O
recognized	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
155	O
kD	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170-kD	B
protein	I
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	B
BAF170	I
.	O

Immunoprecipitation	O
of	O
cell	O
extract	O
with	O
the	O
antiserum	O
against	O
the	O
mouse	B
SRG3	I
also	O
brought	O
down	O
a	O
195-kD	B
protein	I
that	O
could	O
be	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
human	B
SWI2	I
protein	I
.	O

The	O
results	O
suggest	O
that	O
the	O
SRG3	B
protein	I
associates	O
with	O
a	O
mouse	B
SWI2	I
.	O

The	O
SRG3	B
protein	I
is	O
expressed	O
about	O
three	O
times	O
higher	O
in	O
thymocytes	O
than	O
in	O
peripheral	O
lymphocytes	O
.	O

The	O
expression	O
of	O
anti	B
-	I
sense	I
RNA	I
to	O
SRG3	O
mRNA	O
in	O
a	O
thymoma	O
cell	O
line	O
,	O
S49.1	O
,	O
reduced	O
the	O
expression	O
level	O
of	O
the	O
SRG3	B
protein	I
,	O
and	O
decreased	O
the	O
apoptotic	O
cell	O
death	O
induced	O
by	O
glucocorticoids	O
.	O

These	O
results	O
suggest	O
that	O
the	O
SRG3	B
protein	I
is	O
involved	O
in	O
the	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
thymoma	O
cell	O
line	O
.	O

This	O
implicates	O
that	O
the	O
SRG3	O
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

The	O
IL-4	B
receptor	I
alpha	I
-	I
chain	I
cytoplasmic	I
domain	I
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	B
and	O
STAT6	B
and	O
the	O
induction	O
of	O
IL-4	B
-specific	O
gene	O
expression	O
.	O

The	O
common	B
gamma	I
-	I
chain	I
(	O
gamma	B
(	I
c	I
)	I
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	B
,	O
yet	O
cells	O
lacking	O
gamma	B
(	I
c	I
)	I
are	O
able	O
to	O
respond	O
to	O
IL-4	B
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	B
gamma'-chain	I
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	B
alpha	I
chain	I
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	B
(	I
c	I
)	I
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	B
(	I
c	I
)	I
,	O
the	O
IL-4R	B
alpha	I
chain	I
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	B
receptor	I
containing	O
the	O
extracellular	B
domain	I
of	O
c	B
-	I
kit	I
(	O
the	O
stem	B
cell	I
factor	I
(	I
SCF	I
)	I
receptor	I
)	O
and	O
the	O
cytoplasmic	B
and	I
transmembrane	I
domains	I
of	O
the	O
IL-4R	B
alpha	I
chain	I
was	O
generated	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	B
receptor	I
kit	B
/	I
IL-4R	I
alpha	I
with	O
SCF	B
induces	O
activation	O
of	O
the	O
IL-4R	B
alpha	I
-	I
associated	I
kinase	I
JAK-1	B
and	O
the	O
transcription	B
factor	I
STAT6	B
.	O

However	O
,	O
tyrosine	O
phosphorylation	O
of	O
JAK-3	B
,	O
which	O
associates	O
with	O
gamma	B
(	I
c	I
)	I
,	O
is	O
not	O
induced	O
by	O
SCF	B
in	O
these	O
cells	O
.	O

SCF	B
-mediated	O
ligation	O
of	O
kit	B
/	I
IL-4R	I
alpha	I
is	O
sufficient	O
to	O
elicit	O
IL-4	B
-specific	O
gene	O
expression	O
,	O
including	O
up	O
-	O
regulation	O
of	O
CD23	B
and	O
synthesis	O
of	O
germ	O
-	O
line	O
epsilon	O
transcripts	O
.	O

In	O
the	O
T	O
cell	O
line	O
CTLL2	O
,	O
ligation	O
of	O
kit	B
/	I
IL-4R	I
alpha	I
induces	O
cellular	O
proliferation	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	O
HeLa	O
cells	O
,	O
STAT6	B
activation	O
by	O
IL-4	B
is	O
completely	O
abolished	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	B
alpha	I
cytoplasmic	I
domain	I
is	O
sufficient	O
to	O
activate	O
JAK-1	B
and	O
STAT6	B
and	O
to	O
induce	O
expression	O
of	O
IL-4	O
target	O
genes	O
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	B
signaling	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
JAK-3	B
and	O
gamma	B
(	I
c	I
)	I
.	O

AP-1	B
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV	O
-	O
I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	B
factors	I
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV	O
-	O
I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	O
lines	O
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	B
factors	I
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1	O
-	O
4	O
)	O
.	O

ATF	B
/	I
CREB	I
and	O
Sp	B
family	I
members	I
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA	B
-	I
protein	I
complexes	I
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA	B
-	I
protein	I
complex	I
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	O
MG	O
glioblastoma	O
cell	O
line	O
or	O
the	O
THP-1	O
mature	O
monocytic	O
cell	O
line	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA	B
-	I
protein	I
complex	I
is	O
comprised	O
of	O
the	O
AP-1	B
components	O
,	O
Fos	B
and	O
Jun	B
.	O

Expression	O
of	O
transcription	B
factors	I
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O

During	O
15	O
days	O
of	O
treatment	O
of	O
K562	O
cells	O
with	O
sodium	O
phenylacetate	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cellular	O
hemoglobin	B
concentration	O
with	O
a	O
similar	O
increase	O
in	O
the	O
expression	O
of	O
gamma	O
-	O
globin	O
mRNA	O
.	O

Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O

At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	B
surface	I
antigenes	I
CD33	B
,	O
CD34	B
,	O
CD45	B
,	O
CD71	B
and	O
glycophorin	B
A	I
.	O

Likewise	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
erythroid	B
transcription	I
factors	I
GATA-1	B
,	O
GATA-2	B
,	O
NF	B
-	I
E2	I
,	O
SCL	B
and	O
RBTN2	B
,	O
all	O
expressed	O
in	O
untreated	O
K562	O
cells	O
,	O
did	O
not	O
increase	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
.	O

The	O
expression	O
of	O
the	O
nuclear	B
factors	I
Evi-1	B
and	O
c	B
-	I
myb	I
,	O
known	O
to	O
inhibit	O
erythroid	O
differentiation	O
,	O
did	O
not	O
decrease	O
.	O

We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	O
cells	O
increases	O
gamma	O
-	O
globin	O
mRNA	O
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	B
transcription	I
factors	I
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

c	O
-	O
Myb	O
and	O
Ets	B
proteins	I
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B
.	O

The	O
Zfh	B
family	I
of	O
zinc	B
finger	I
/	I
homeodomain	I
proteins	I
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	B
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	B
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	B
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	B
factors	I
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	B
-	I
Myb	I
and	O
Ets	B
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	B
blocks	O
the	O
activity	O
of	O
c	B
-	I
Myb	I
and	O
Ets	B
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	B
-	I
Myb	I
and	O
Ets	B
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	B
and	O
transcriptional	O
activation	O
by	O
c	B
-	I
Myb	I
/Ets	B
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B
integrin	I
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

Opposite	O
effects	O
of	O
the	O
acute	B
promyelocytic	I
leukemia	I
PML	I
-	I
retinoic	I
acid	I
receptor	I
alpha	I
(	O
RAR	B
alpha	I
)	O
and	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
proteins	I
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	B
alpha	I
(	O
RAR	B
alpha	I
)	O
and	O
the	O
PML	B
or	O
PLZF	B
nuclear	I
protein	I
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML	B
-	I
RAR	I
alpha	I
or	O
the	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
protein	I
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML	B
-	I
RAR	I
alpha	I
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF	B
-	I
RAR	I
alpha	I
do	O
not	O
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML	B
-	I
RAR	I
alpha	I
expression	O
,	O
PLZF	B
-	I
RAR	I
alpha	I
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	O
and	O
HL-60	O
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML	B
-	I
RAR	I
alpha	I
,	O
but	O
not	O
PLZF	B
-	I
RAR	I
alpha	I
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	O
precursor	O
cells	O
and	O
restores	O
RA	O
sensitivity	O
of	O
RA	O
-	O
resistant	O
hematopoietic	O
cells	O
;	O
(	O
iii	O
)	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML	B
-	I
RAR	I
alpha	I
enhances	O
the	O
RA	O
response	O
of	O
RA	O
target	O
genes	O
(	O
those	O
for	O
RAR	B
beta	I
,	O
RAR	B
gamma	I
,	O
and	O
transglutaminase	B
type	I
II	I
[	O
TGase	B
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF	B
-	I
RAR	I
alpha	I
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	B
beta	I
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	B
gamma	I
and	O
type	B
II	I
TGase	I
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA	O
-	O
dependent	O
enhancers	O
or	O
inhibitors	O
of	O
RA	O
-	O
responsive	O
genes	O
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML	B
-	I
RAR	I
alpha	I
and	O
PLZF	B
-	I
RAR	I
alpha	I
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF	B
-	I
RAR	I
alpha	I
fusion	I
protein	I
contains	O
an	O
approximately	O
120-amino	B
-	I
acid	I
N	I
-	I
terminal	I
motif	I
(	O
called	O
the	O
POZ	B
domain	I
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	B
proteins	I
and	O
which	O
mediates	O
protein	O
-	O
protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	B
POZ	I
domain	I
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF	B
-	I
RAR	I
alpha	I
on	O
RA	O
-	O
induced	O
differentiation	O
and	O
on	O
RA	O
-	O
mediated	O
type	B
II	I
TGase	I
up	O
-	O
regulation	O
,	O
suggesting	O
that	O
POZ	O
-	O
mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF	B
-	I
RAR	I
alpha	I
.	O

Regulation	O
of	O
B	O
-	O
cell	O
commitment	O
to	O
plasma	O
cells	O
or	O
to	O
memory	O
B	O
cells	O
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B	O
-	O
lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B	O
-	O
cell	O
pathway	O
.	O

Recent	O
studies	O
suggest	O
that	O
CD40-CD40	B
ligand	I
,	O
OX	B
-	I
OX40	I
ligand	I
,	O
a	O
group	O
of	O
cytokines	B
and	O
intracellular	O
transcriptional	O
factors	O
may	O
all	O
contribute	O
to	O
B	O
-	O
lymphocyte	O
differentiation	O
control	O
.	O

Transcription	B
factor	I
GATA-3	I
is	O
differentially	O
expressed	O
in	O
murine	O
Th1	O
and	O
Th2	O
cells	O
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	O
gene	O
.	O

Interleukin-5	B
(	O
IL-5	B
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	O
by	O
Th1	O
cells	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1-	O
and	O
Th2-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	B
factor	I
GATA-3	B
in	O
IL-5	O
promoter	O
activation	O
in	O
EL-4	O
cells	O
,	O
which	O
express	O
both	O
Th1-	B
and	I
Th2-type	I
cytokines	I
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA-3	B
is	O
critical	O
for	O
expression	O
of	O
the	O
IL-5	B
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	B
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	B
in	O
Th1	O
cells	O
or	O
in	O
a	O
non	O
-	O
lymphoid	O
,	O
non	O
-	O
IL-5-producing	O
cell	O
line	O
activated	O
the	O
IL-5	O
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	B
gene	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
Th1	O
cells	O
,	O
and	O
antigen-	O
or	O
cAMP	O
-	O
activated	O
Th2	O
cells	O
(	O
but	O
not	O
Th1	O
cells	O
)	O
expressed	O
the	O
GATA-3	B
protein	I
.	O

Thus	O
,	O
GATA-3	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA-3	B
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
transcription	B
factors	I
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
ability	O
of	O
BHRF1	B
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas	O
-	O
mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus	O
-	O
infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	B
,	O
an	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
early	I
-	I
lytic	I
-	I
cycle	I
protein	I
with	O
distant	O
homology	O
to	O
Bcl-2	B
,	O
as	O
an	O
anti	B
-	I
apoptosis	I
protein	I
.	O

Expression	O
of	O
BHRF1	B
in	O
MCF	O
-	O
Fas	O
cells	O
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti	B
-	I
Fas	I
antibody	I
and	O
TNF	O
-	O
mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	B
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
ability	O
of	O
BHRF1	B
to	O
protect	O
MCF	O
-	O
Fas	O
cells	O
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	B
resembled	O
that	O
of	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
as	O
it	O
inhibited	O
TNF-	O
and	O
anti	O
-	O
Fas	O
-	O
induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	B
phospholipase	I
A2	I
and	O
caspase-3	B
/	I
CPP32	I
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
-	I
like	I
transcription	I
factors	I
.	O

A	O
putative	O
function	O
of	O
BHRF1	B
in	O
EBV	O
-	O
infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus	O
-	O
infected	O
cells	O
from	O
TNF-	O
and/or	O
anti	O
-	O
Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	B
nor	O
Bcl-2	B
in	O
a	O
B	O
-	O
cell	O
line	O
,	O
BJAB	O
,	O
protected	O
the	O
cells	O
from	O
anti	O
-	O
Fas	O
-	O
mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum	O
-	O
starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	B
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	B
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

Expression	O
of	O
bcl-6	B
protein	I
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

Bcl-6	B
protein	I
is	O
a	O
recently	O
identified	O
novel	O
transcription	B
factor	I
whose	O
deregulated	O
expression	O
is	O
associated	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
.	O

It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	O
center	O
B	O
cells	O
and	O
their	O
neoplastic	O
counterparts	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
expression	O
of	O
bcl-6	B
protein	I
on	O
normal	O
epidermis	O
,	O
benign	O
,	O
and	O
malignant	O
tumors	O
originating	O
from	O
epidermal	O
cells	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
cell	O
lines	O
are	O
investigated	O
.	O

With	O
the	O
use	O
of	O
immunohistochemistry	O
,	O
bcl-6	B
protein	I
was	O
shown	O
to	O
stain	O
intensely	O
on	O
normal	O
prickle	O
cells	O
,	O
but	O
none	O
to	O
only	O
slightly	O
on	O
epidermal	O
basal	O
cells	O
.	O

Papillomas	O
and	O
keratoacanthomas	O
copied	O
their	O
normal	O
counterparts	O
in	O
the	O
mode	O
of	O
expression	O
.	O

Various	O
levels	O
of	O
expression	O
were	O
found	O
on	O
seborrheic	O
keratoses	O
,	O
while	O
the	O
expression	O
level	O
on	O
basal	O
cell	O
epitheliomas	O
was	O
low	O
.	O

Peculiarly	O
,	O
eccrine	O
poromas	O
and	O
undifferentiated	O
spindle	O
-	O
shaped	O
basal	O
cell	O
epitheliomas	O
were	O
totally	O
unstained	O
.	O

Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle	O
-	O
shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	O
cell	O
line	O
remained	O
unstained	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	B
protein	I
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	O
epidermal	O
cells	O
.	O

HIV-1	B
Vpr	I
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
[	O
see	O
comments	O
]	O

The	O
HIV-1	B
accessory	I
gene	I
product	I
Vpr	B
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	B
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	B
modulates	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	B
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	B
-mediated	O
activation	O
,	O
Vpr	B
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	B
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	B
suppression	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
via	O
the	O
induction	O
of	O
I	B
kappa	I
B	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

Further	O
,	O
Vpr	B
suppresses	O
expression	O
of	O
IL-2	B
,	O
IL-10	B
,	O
IL-12	B
,	O
TNF	B
alpha	I
and	O
IL-4	B
,	O
all	O
of	O
which	O
are	O
NF	B
-	I
kappa	I
B	I
-dependent	O
.	O

The	O
effects	O
of	O
Vpr	B
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	B
can	O
regulate	O
NF	B
-	I
kappa	I
B	I
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	B
.	O

Nuclear	O
localization	O
of	O
RelB	B
is	O
associated	O
with	O
effective	O
antigen	O
-	O
presenting	O
cell	O
function	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APCs	O
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

The	O
phenotype	O
of	O
RelB	B
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	B
kappa	I
B	I
/	I
Rel	I
family	I
in	O
DC	O
differentiation	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
RelB	B
in	O
DC	O
differentiation	O
,	O
mRNA	O
,	O
intracellular	O
protein	O
expression	O
,	O
and	O
DNA	O
binding	O
activity	O
of	O
RelB	B
were	O
examined	O
in	O
immature	O
and	O
differentiated	O
human	O
DC	O
,	O
as	O
well	O
as	O
other	O
PB	O
mononuclear	O
cell	O
populations	O
.	O

RelB	B
protein	O
and	O
mRNA	O
were	O
detected	O
constitutively	O
in	O
lymphocytes	O
and	O
in	O
activated	O
monocytes	O
,	O
differentiated	O
DC	O
,	O
and	O
monocyte	O
-	O
derived	O
DC	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	B
within	O
the	O
differentiated	O
lymph	O
node	O
interdigitating	O
DC	O
and	O
follicular	O
DC	O
,	O
but	O
not	O
undifferentiated	O
DC	O
in	O
normal	O
skin	O
.	O

Active	O
nuclear	O
RelB	B
was	O
detected	O
by	O
supershift	O
assay	O
only	O
in	O
differentiated	O
DC	O
derived	O
from	O
either	O
PB	O
precursors	O
or	O
monocytes	O
and	O
in	O
activated	O
B	O
cells	O
.	O

These	O
RelB+	O
APC	O
were	O
potent	O
stimulators	O
of	O
the	O
MLR	B
.	O

The	O
data	O
indicate	O
that	O
RelB	B
expression	O
is	O
regulated	O
both	O
transcriptionally	O
and	O
post	O
-	O
translationally	O
in	O
myeloid	O
cells	O
.	O

Within	O
the	O
nucleus	O
,	O
RelB	B
may	O
specifically	O
transactivate	O
genes	O
that	O
are	O
critical	O
for	O
APC	O
function	O
.	O

Expression	O
of	O
c	O
-	O
fos	O
correlates	O
with	O
IFN	B
-	I
alpha	I
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	O
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN	B
-	I
alpha	I
2c	I
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c	O
-	O
fos	O
,	O
c	O
-	O
myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr	O
/	O
abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	O
-	O
fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	B
-	I
alpha	I
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr	O
/	O
abl	O
,	O
c	O
-	O
myc	O
and	O
p53	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	B
-	I
alpha	I
is	O
accompanied	O
by	O
upregulation	O
of	O
c	O
-	O
fos	O
and	O
downregulation	O
of	O
c	O
-	O
myc	O
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	O
and	O
FHIT	O
genes	O
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Intragenic	O
deletions	O
of	O
TSG101	O
,	O
the	O
human	O
homolog	O
of	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
that	O
acts	O
to	O
suppress	O
malignant	O
cell	O
growth	O
,	O
were	O
reported	O
in	O
human	O
breast	O
tumours	O
.	O

We	O
screened	O
TSG101	O
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV	O
-	O
immortalised	O
B	O
-	O
cells	O
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	O
deletions	O
in	O
RNA	O
transcripts	O
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	O
site	O
sequences	O
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	O
tumour	O
suppressor	O
gene	O
FHIT	O
.	O

We	O
analysed	O
FHIT	O
in	O
the	O
same	O
series	O
of	O
RNA	O
samples	O
and	O
detected	O
truncated	O
FHIT	O
transcripts	O
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
transcripts	O
from	O
TSG101	O
,	O
FHIT	O
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	O
peripheral	O
blood	O
lymphocytes	O
.	O

Large	O
TSG101	O
and	O
FHIT	O
intragenic	O
transcript	O
deletions	O
were	O
detected	O
and	O
these	O
appeared	O
to	O
be	O
the	O
predominant	O
transcript	O
in	O
'	O
aged	O
'	O
lymphocytes	O
.	O

Similar	O
alterations	O
were	O
not	O
detected	O
in	O
transcripts	O
of	O
the	O
other	O
genes	O
which	O
were	O
analysed	O
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	O
TSG101	O
and	O
FHIT	O
transcripts	O
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	O
and	O
FHIT	O
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O

OCA	B
-	I
B	I
is	O
a	O
functional	O
analog	O
of	O
VP16	B
but	O
targets	O
a	O
separate	O
surface	O
of	O
the	O
Oct-1	B
POU	I
domain	I
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1998	O
Apr	O
;	O
18	O
(	O
4	O
)	O
:	O
2430	O
]	O

OCA	B
-	I
B	I
is	O
a	O
B	B
-	I
cell	I
-	I
specific	I
coregulator	I
of	O
the	O
broadly	O
expressed	O
POU	B
domain	I
transcription	I
factor	I
Oct-1	B
.	O

OCA	B
-	I
B	I
associates	O
with	O
the	O
Oct-1	B
POU	I
domain	I
,	O
a	O
bipartite	O
DNA	O
-	O
binding	O
structure	O
containing	O
a	O
POU	B
-	I
specific	I
(	I
POU	I
[	I
S	I
]	I
)	I
domain	I
joined	O
by	O
a	O
flexible	O
linker	O
to	O
a	O
POU	B
homeodomain	I
(	O
POU	B
[	I
H	I
]	I
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
OCA	B
-	I
B	I
alters	O
the	O
activity	O
of	O
Oct-1	B
in	O
two	O
ways	O
.	O

It	O
provides	O
a	O
transcriptional	O
activation	O
domain	O
which	O
,	O
unlike	O
Oct-1	B
,	O
activates	O
an	O
mRNA	O
-	O
type	O
promoter	O
effectively	O
,	O
and	O
it	O
stabilizes	O
Oct-1	B
on	O
the	O
Oct-1-responsive	O
octamer	O
sequence	O
ATGCAAAT	O
.	O

These	O
properties	O
of	O
OCA	B
-	I
B	I
parallel	O
those	O
displayed	O
by	O
the	O
herpes	B
simplex	I
virus	I
Oct-1	I
coregulator	I
VP16	B
.	O

OCA	B
-	I
B	I
,	O
however	O
,	O
interacts	O
with	O
a	O
different	O
surface	O
of	O
the	O
DNA	O
-	O
bound	O
Oct-1	B
POU	I
domain	I
,	O
interacting	O
with	O
both	O
the	O
POU	B
(	I
S	I
)	I
and	I
POU	I
(	I
H	I
)	I
domains	I
and	O
the	O
center	O
of	O
the	O
ATGCAAAT	O
octamer	O
sequence	O
.	O

The	O
OCA	O
-	O
B	O
and	O
VP16	B
interactions	O
with	O
the	O
Oct-1	B
POU	I
domain	I
are	O
sufficiently	O
different	O
to	O
permit	O
OCA	B
-	I
B	I
and	O
VP16	B
to	O
bind	O
the	O
Oct-1	B
POU	I
domain	I
simultaneously	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	B
POU	I
domain	I
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	B
factor	I
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	B
factor	I
(	O
TF	B
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	B
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	B
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	B
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes	O
/	O
macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	B
activity	O
generated	O
by	O
both	O
unstimulated	O
and	O
endotoxin	O
-	O
stimulated	O
cells	O
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	O
monocyte	O
TF	B
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	B
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	B
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	B
-	I
gamma	I
or	O
interleukin-1beta	B
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	O
mRNA	O
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	O
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	B
activation	O
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	B
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	B
expression	O
and	O
NF	B
-	I
kappaB	I
activation	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	B
polymerase	I
II	I
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	O
through	O
XPG	O
.	O

Of	O
these	O
,	O
the	O
XPB	O
and	O
XPD	O
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	B
transcription	I
factor	I
,	O
TFIIH	B
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	O
or	O
XPD	O
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper	O
-	O
sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
cells	O
contained	O
reduced	O
amounts	O
of	O
TFIIH	B
.	O

Extracts	O
prepared	O
from	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
lymphoblastoid	O
cells	O
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	B
for	O
the	O
clinical	O
symptoms	O
in	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
patients	O
,	O
and	O
discuss	O
a	O
'	O
conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Temporal	O
control	O
of	O
IgH	O
gene	O
expression	O
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	O
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	O
3'LCR	O
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	O
gene	O
expression	O
and	O
compare	O
it	O
with	O
the	O
5'LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	B
cytokines	I
and	O
mononuclear	O
cell	O
attracting	O
chemokines	B
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF	B
-	I
kappa	I
B	I
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	O
cytokine	O
genes	O
,	O
but	O
can	O
not	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	O
genes	O
lack	O
respective	O
binding	O
sites	O
in	O
their	O
promoter	O
regions	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	B
factors	I
of	O
possible	O
importance	O
such	O
as	O
CREB	B
,	O
CTF	B
,	O
OTF-1	B
,	O
and	O
OTF-2	B
.	O

To	O
explore	O
long	O
-	O
term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	B
factors	I
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	B
transcription	I
factor	I
proteins	I
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell	O
-	O
type	O
-	O
specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
OFT-2	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
genes	O
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	O
significant	O
changes	O
were	O
detected	O
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	B
,	O
CTF	B
,	O
and	O
OTF-2	B
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	B
factor	I
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	B
factor	I
proteins	I
is	O
required	O
.	O

Genes	O
that	O
regulate	O
interleukin-4	B
expression	O
in	O
T	O
cells	O
.	O

Interleukin-4	B
is	O
an	O
immunomodulatory	B
cytokine	I
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	O
gene	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	B
factors	I
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	O
helper	O
cell	O
cytokine	O
gene	O
expression	O
.	O

Role	O
of	O
cyclic	B
AMP	I
response	I
element	I
-	I
binding	I
protein	I
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
.	O

The	O
NF	B
-	I
kappaB	I
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
elevation	O
of	O
intracellular	O
cyclic	O
AMP	O
inhibits	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
in	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
without	O
preventing	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
complexes	I
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	B
kinase	I
A	I
signaling	O
pathway	O
may	O
inhibit	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	B
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
amino	B
-	I
terminal	I
region	I
(	O
amino	B
acids	I
1	I
-	I
450	I
)	O
of	O
CBP	B
specifically	O
interacts	O
with	O
the	O
carboxyl	B
-	I
terminal	I
region	I
(	O
amino	B
acids	I
286	I
-	I
551	I
)	O
of	O
NF	B
-	I
kappaB	I
p65	B
(	O
RelA	B
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Functional	O
studies	O
using	O
human	O
endothelial	O
cells	O
demonstrated	O
that	O
overexpression	O
of	O
CBP	B
rescued	O
cAMP	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
and	O
transcription	O
mediated	O
by	O
a	O
chimeric	B
protein	I
,	O
GAL4-p65	B
(	I
286	I
-	I
551	I
)	I
,	O
which	O
contained	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
fused	O
to	O
the	O
carboxyl	B
-	I
terminal	I
region	I
of	O
p65	B
(	O
amino	B
acids	I
286	I
-	I
551	I
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	B
inhibited	O
GAL4	B
-p65	O
(	O
286	O
-	O
551	O
)	O
-mediated	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	B
kinase	I
A	I
pathway	O
inhibits	O
NF	B
-	I
kappaB	I
transcription	O
by	O
phosphorylating	O
CREB	B
,	O
which	O
competes	O
with	O
p65	B
for	O
limiting	O
amounts	O
of	O
CBP	B
.	O

Mycobacterium	O
tuberculosis	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
can	O
induce	O
NF	B
-	I
kappaB	I
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	B
-expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR	O
-	O
dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	B
tyrosine	I
kinase	I
(	I
s	I
)	I
,	O
protein	B
kinase	I
A	I
and/or	O
protein	B
kinase	I
C	I
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
-	O
driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappaB	I
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild	O
-	O
type	O
,	O
but	O
not	O
the	O
kappaB	O
-	O
mutated	O
,	O
HIV-1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	B
TNF	I
-	I
alpha	I
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Coactivation	O
by	O
OCA	B
-	I
B	I
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	B
-	I
B	I
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	O
promoters	O
through	O
interaction	O
with	O
octamer	B
-	I
bound	I
Oct-1	I
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	B
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct-1	O
and	O
OCA	O
-	O
B	O
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	B
and	O
the	O
PC4	B
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	B
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	B
/OCA	B
-	I
B	I
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	B
-	I
derived	I
PC2	I
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	B
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	B
in	O
the	O
reconstituted	O
system	O
,	O
OCA	B
-	I
B	I
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	B
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	B
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA	B
-	I
B	I
/	O
Oct-1	B
-dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct-1	B
and	O
OCA	B
-	I
B	I
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	B
coactivators	I
.	O

Differential	O
regulation	O
of	O
the	O
Janus	B
kinase	I
-STAT	B
pathway	O
and	O
biologic	O
function	O
of	O
IL-13	B
in	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
:	O
a	O
comparative	O
study	O
with	O
IL-4	B
.	O

IL-13	B
,	O
a	O
cytokine	O
similar	O
to	O
IL-4	B
,	O
is	O
a	O
regulator	O
of	O
human	O
B	O
cell	O
and	O
monocyte	O
functions	O
.	O

Biologic	O
effects	O
of	O
IL-13	B
on	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
have	O
not	O
been	O
well	O
defined	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
primary	O
NK	O
cells	O
,	O
IL-13	B
,	O
but	O
not	O
IL-4	B
,	O
may	O
induce	O
low	O
levels	O
of	O
IFN	B
-	I
gamma	I
secretion	O
.	O

When	O
NK	O
cells	O
were	O
costimulated	O
with	O
IL-13	B
and	O
IL-2	B
,	O
IL-13	B
generally	O
resulted	O
in	O
two	O
types	O
of	O
reactivity	O
:	O
IL-13	B
synergized	O
with	O
IL-2	B
to	O
stimulate	O
IFN	B
-	I
gamma	I
production	O
or	O
it	O
modestly	O
inhibited	O
IL-2	B
-mediated	O
IFN	B
-	I
gamma	I
production	O
.	O

In	O
both	O
types	O
of	O
donors	O
,	O
the	O
effect	O
of	O
IL-13	B
on	O
IL-2	B
-induced	O
IFN	B
-	I
gamma	I
production	O
was	O
in	O
marked	O
contrast	O
to	O
the	O
strong	O
inhibition	O
seen	O
with	O
IL-4	B
in	O
NK	O
cells	O
.	O

Additionally	O
,	O
IL-13	B
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	B
.	O

In	O
T	O
cells	O
,	O
IL-13	B
inhibits	O
anti	O
-	O
CD3	O
mAb	O
/	O
IL-2-	O
or	O
PHA	O
-	O
mediated	O
IFN	O
-	O
gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	B
,	O
like	O
IL-4	B
,	O
induces	O
distinct	O
STAT6-DNA	B
binding	I
complexes	I
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	B
and	O
Janus	B
kinase	I
3	I
(	O
JAK3	B
)	O
in	O
NK	O
and	O
T	O
cells	O
.	O

We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	B
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	O
cells	O
but	O
not	O
in	O
NK	O
cells	O
,	O
suggesting	O
different	O
STAT6	B
isoforms	I
.	O

These	O
findings	O
show	O
that	O
IL-13	B
and	O
IL-4	B
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	B
is	O
a	O
potent	O
regulator	O
of	O
STAT6	B
and	O
JAK3	B
in	O
these	O
cell	O
types	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	B
factor	I
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	B
expression	O
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA	O
-	O
binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	B
factors	I
:	O
NFkappaB	B
,	O
AP-1	B
and	O
NFAT	B
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	B
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	B
activity	O
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	B
factor	I
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	O
lymphocytes	O
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	B
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	B
factor	I
DNA	O
-	O
binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Macrophages	O
in	O
human	O
atheroma	O
contain	O
PPARgamma	B
:	O
differentiation	B
-	I
dependent	I
peroxisomal	I
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	B
activity	O
through	O
PPARgamma	B
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Mononuclear	O
phagocytes	O
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	B
metalloproteinases	I
(	O
MMPs	B
)	O
,	O
including	O
MMP-9	B
.	O

Peroxisomal	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
,	O
a	O
transcription	B
factor	I
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O

The	O
role	O
of	O
PPARgamma	B
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O

We	O
report	O
here	O
that	O
monocytes	O
/	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	B
PPARgamma	I
.	O

Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	B
immunoreactive	I
PPARgamma	I
.	O

Human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	O
mRNA	O
and	O
protein	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
PPARgamma	O
mRNA	O
expression	O
in	O
U937	O
cells	O
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate	O
-	O
induced	O
differentiation	O
.	O

Stimulation	O
of	O
PPARgamma	B
with	O
troglitazone	O
or	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
inhibited	O
MMP-9	B
gelatinolytic	O
activity	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O

This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	B
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O

Thus	O
,	O
PPARgamma	B
is	O
present	O
in	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	B
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O

PPARgamma	B
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte	O
/	O
macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O

Suppression	O
of	O
human	O
anti	O
-	O
porcine	O
T	O
-	O
cell	O
immune	O
responses	O
by	O
major	O
histocompatibility	O
complex	O
class	O
II	O
transactivator	O
constructs	O
lacking	O
the	O
amino	O
terminal	O
domain	O
.	O

BACKGROUND	O
:	O
The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
is	O
a	O
bi-	B
or	I
multifunctional	I
domain	I
protein	I
that	O
acts	O
as	O
a	O
transcriptional	B
activator	I
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	O
CIITA	O
gene	O
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	B
terminal	I
151	I
amino	I
acids	I
,	O
acts	O
as	O
a	O
potent	O
dominant	O
-	O
negative	O
suppressor	O
of	O
HLA	B
class	I
II	I
expression	O
.	O

Porcine	B
MHC	I
class	I
II	I
antigens	I
are	O
potent	O
stimulators	O
of	O
direct	O
T	O
-	O
cell	O
recognition	O
by	O
human	O
CD4	O
+	O
T	O
cells	O
and	O
are	O
,	O
therefore	O
,	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
rejection	O
responses	O
to	O
transgenic	O
pig	O
donors	O
in	O
clinical	O
xenotransplantation	O
.	O

We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
examining	O
mutated	O
CIITA	O
constructs	O
for	O
their	O
effect	O
on	O
porcine	O
MHC	B
class	I
II	I
expression	O
.	O

METHODS	O
:	O
Stable	O
transfectants	O
of	O
the	O
porcine	O
vascular	O
endothelial	O
cell	O
line	O
PIEC	O
with	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
induction	O
by	O
recombinant	B
porcine	I
interferon	I
-	I
gamma	I
.	O

Transient	O
transfectants	O
of	O
the	O
porcine	O
B	O
-	O
cell	O
line	O
L23	O
with	O
the	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
expression	O
.	O

T	O
-	O
cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

RESULTS	O
:	O
In	O
preliminary	O
studies	O
,	O
we	O
demonstrated	O
that	O
transfection	O
of	O
the	O
PIEC	O
line	O
with	O
full	O
-	O
length	O
human	O
CIITA	O
constructs	O
resulted	O
in	O
strong	O
expression	O
of	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
antigens	O
,	O
thus	O
establishing	O
the	O
cross	O
-	O
species	O
effectiveness	O
of	O
human	B
CIITA	I
in	O
the	O
pig	O
.	O

The	O
mutated	O
human	O
CIITA	O
constructs	O
were	O
,	O
therefore	O
,	O
tested	O
in	O
the	O
pig	O
.	O

PIEC	O
clones	O
stably	O
transfected	O
with	O
one	O
of	O
these	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
SLA	B
-	I
DR	I
and	O
SLA	B
-	I
DQ	I
antigen	O
induction	O
and	O
marked	O
suppression	O
of	O
SLA	O
-	O
DRA	O
mRNA	O
induction	O
.	O

Moreover	O
,	O
transient	O
transfection	O
of	O
the	O
porcine	O
B	O
-	O
cell	O
line	O
L23	O
showed	O
up	O
to	O
90	O
%	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
antigen	O
expression	O
in	O
5	O
-	O
8	O
days	O
.	O

In	O
functional	O
studies	O
,	O
interferon	O
-	O
gamma	O
-	O
stimulated	O
PIEC	O
clones	O
transfected	O
with	O
this	O
mutated	B
CIITA	I
construct	O
failed	O
to	O
stimulate	O
purified	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O

CONCLUSION	O
:	O
Mutated	O
human	O
CIITA	O
constructs	O
are	O
potent	O
suppressors	O
of	O
porcine	O
MHC	B
class	I
II	I
expression	O
.	O

Redox	O
signals	O
and	O
NF	B
-	I
kappaB	I
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL-2	B
,	O
IL-6	B
,	O
IL-8	B
,	O
and	O
several	O
T	B
cell	I
surface	I
receptors	I
.	O

Diminished	O
NF	B
-	I
kappaB	I
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF	B
-	I
kappaB	I
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF	B
-	I
kappaB	I
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV-1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	O
cell	O
lines	O
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF	B
-	I
kappaB	I
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF	B
-	I
kappaB	I
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF	B
-	I
kappaB	I
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF	B
-	I
kappaB	I
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF	B
-	I
kappaB	I
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF	B
-	I
kappaB	I
activation	O
may	O
be	O
relevant	O
to	O
immune	O
-	O
related	O
diseases	O
and	O
to	O
aging	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	B
transduction	I
molecules	I
.	O

The	O
adoptive	O
transfer	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti	B
-	I
CD3	I
and	O
interleukin	B
2	I
(	O
IL-2	B
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	O
modified	O
variant	O
(	O
designated	O
D5G6	O
)	O
that	O
secretes	O
granulocyte	B
/	I
macrophage	I
-	I
colony	I
-	I
stimulating	I
factor	I
.	O

In	O
contrast	O
to	O
anti	O
-	O
CD3	O
/	O
IL-2-activated	O
LN	O
cells	O
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
has	O
no	O
therapeutic	O
activity	O
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	B
kinases	I
p56lck	B
and	O
p59fyn	B
and	O
proteins	O
of	O
the	O
NF	B
-	I
kappaB	I
family	I
were	O
analyzed	O
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	O
of	O
p56lck	B
and	O
p59fyn	B
were	O
lower	O
in	O
tumor	O
-	O
draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine	B
-	I
phosphorylated	I
substrates	I
was	O
markedly	O
depressed	O
following	O
anti	B
-	I
CD3	I
stimulation	O
.	O

After	O
5-day	O
anti	B
-	I
CD3	I
/IL-2	B
activation	O
,	O
levels	O
of	O
p56lck	B
and	O
p59fyn	B
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	B
,	O
p59fyn	B
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c	B
-	I
Rel	I
and	O
Rel	B
A	I
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	B
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	B
-	I
CD3	I
mAb	I
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	B
cell	I
receptor	I
/	I
CD3	I
complex	I
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	O
gene	O
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

MyD88	B
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	B
(	O
IL-1	B
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	B
receptor	I
complex	I
and	O
IL-1	B
receptor	I
-	I
associated	I
kinase	I
(	O
IRAK	B
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	B
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	B
in	O
response	O
to	O
IL-1	B
.	O

Increases	O
in	O
interferon	B
-	I
gamma	I
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	B
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL-18	B
-induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
is	O
blocked	O
in	O
MyD88-	O
/	O
-	O
Th1-developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	B
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	B
receptor	I
as	O
well	O
as	O
IL-18	B
receptor	I
.	O

Characterization	O
of	O
cytokine	B
differential	O
induction	O
of	O
STAT	B
complexes	I
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
.	O

Cytokines	B
,	O
IL-2	B
,	O
IL-4	B
,	O
IL-6	B
,	O
IL-7	B
,	O
IL-12	B
,	O
and	O
IL-15	B
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O

Recent	O
studies	O
reveal	O
that	O
a	O
family	O
of	O
transcription	B
factors	I
,	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STATs	B
)	O
directly	O
mediate	O
many	O
cytokine	B
signals	O
.	O

We	O
analyzed	O
the	O
activation	O
of	O
STATs	B
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
by	O
a	O
variety	O
of	O
specific	O
cytokines	B
.	O

We	O
demonstrate	O
that	O
IL-12	B
induces	O
STAT4	B
only	O
in	O
freshly	O
isolated	O
primary	O
NK	O
cells	O
,	O
but	O
not	O
in	O
primary	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
the	O
IL-12	B
receptor	I
in	O
resting	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
IL-4	B
induces	O
different	O
C	B
epsilon	I
GAS	I
DNA	I
-	I
protein	I
binding	I
complexes	I
in	O
both	O
T	O
and	O
NK	O
cells	O
.	O

Moreover	O
,	O
IL-4	B
costimulation	O
with	O
IL-2	B
or	O
IL-12	B
does	O
not	O
alter	O
their	O
own	O
preferential	O
GAS	O
-like	O
DNA	O
binding	O
patterns	O
when	O
C	O
epsilon-	O
,	O
Fc	O
gamma	O
RI-	O
,	O
and	O
SIE	O
GAS	O
motif	O
containing	O
oligonucleotide	O
probes	O
are	O
compared	O
,	O
suggesting	O
that	O
induction	O
of	O
GAS	B
-	I
like	I
DNA	I
-	I
protein	I
binding	I
complexes	I
by	O
IL-2	B
,	O
IL-4	B
,	O
and	O
IL-12	B
is	O
highly	O
selective	O
and	O
represents	O
one	O
important	O
factor	O
in	O
determining	O
specific	O
gene	O
activation	O
.	O

In	O
addition	O
,	O
IL-6	B
and	O
IL-2	B
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	B
alpha	I
and	O
STAT3	B
in	O
both	O
NK	O
and	O
T	O
cells	O
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	O
gene	O
expression	O
.	O

We	O
further	O
demonstrated	O
that	O
IL-2	B
,	I
-7	I
,	I
and	I
-15	I
induce	O
multiple	B
STAT	I
proteins	I
,	O
including	O
STAT5a	B
,	O
STAT5b	B
,	O
STAT1	B
alpha	I
,	O
STAT3	B
,	O
and	O
another	O
unidentified	O
Fc	B
gamma	I
RI	I
GAS	I
DNA	I
-	I
binding	I
protein	I
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	B
and	O
STAT5b	B
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	O
and	O
NK	O
cells	O
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	O
and	O
T	O
cells	O
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	B
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	B
transcription	I
factors	I
.	O

Interleukin-6	B
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O

Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	B
and	O
recruitment	O
of	O
neutrophils	O
(	O
PMN	O
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	B
(	O
IL-6	B
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	B
and	O
activation	O
of	O
Stat3	B
.	O

Using	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	O
mRNA	O
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Increased	O
IL-6	B
protein	O
expression	O
was	O
localized	O
to	O
bronchial	O
and	O
alveolar	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B
activation	O
with	O
kinetics	O
similar	O
to	O
IL-6	O
mRNA	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B
activation	O
predominantly	O
within	O
alveoli	O
.	O

Intratracheal	O
instillation	O
of	O
IL-6	B
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
.	O

These	O
findings	O
indicate	O
that	O
IL-6	B
production	O
and	O
Stat3	B
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN	O
-	O
mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

Activation	O
of	O
distinct	O
transcription	B
factors	I
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon	B
-	I
gamma	I
,	O
and	O
GM	B
-	I
CSF	I
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	B
proteases	I
.	O

Human	O
neutrophils	O
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early	O
-	O
response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B
,	O
chemokines	B
,	O
and	O
the	O
high	O
-	O
affinity	O
surface	O
receptor	O
for	O
IgG	B
,	O
FcgammaRI	B
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	B
factors	I
,	O
such	O
as	O
members	O
of	O
the	O
NF	B
-	I
kappaB	I
and	O
STAT	B
families	I
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	B
factors	I
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	B
-	I
kappaB	I
/	I
Rel	I
and	O
STAT	B
proteins	I
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	B
induce	O
a	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50	B
/	I
RelA	I
dimers	I
,	O
and	O
that	O
IFNgamma	B
promotes	O
the	O
binding	O
of	O
STAT1	B
homodimers	I
to	O
the	O
IFNgamma	O
response	O
region	O
of	O
the	O
FcgammaRI	O
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM	B
-	I
CSF	I
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	B
-containing	O
DNA	O
-	O
binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	B
proteases	I
.	O

Prostaglandin	O
E2	O
Up	O
-	O
regulates	O
HIV-1	O
long	O
terminal	O
repeat	O
-driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B
and	I
host	I
cellular	I
factors	I
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	B
immunomodulatory	I
molecule	I
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	O
,	O
a	O
Jurkat	O
-	O
derived	O
T	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	O
LTR	O
-mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	B
messengers	I
involved	O
in	O
this	O
PGE2-dependent	O
up	O
-	O
regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B
kinase	I
A	I
,	O
and	O
Ca2	O
+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	O
LTR	O
-	O
based	O
vectors	O
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF	B
-	I
kappaB	I
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB	O
-	O
regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	O
LTR	O
-driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	B
receptor	I
subtype	I
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV-1	O
.	O

Differential	O
regulation	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Coproporphyrinogen	B
oxidase	I
(	O
CPO	B
)	O
catalyzes	O
the	O
sixth	O
step	O
of	O
the	O
heme	B
biosynthetic	O
pathway	O
.	O

To	O
assess	O
the	O
tissue	O
-	O
specific	O
regulation	O
of	O
the	O
CPO	O
gene	O
promoter	O
,	O
mouse	O
genomic	O
DNA	O
clones	O
for	O
CPO	B
were	O
isolated	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
mouse	O
CPO	O
gene	O
spans	O
approximately	O
11	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
,	O
just	O
like	O
its	O
human	O
counterpart	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
by	O
transient	O
transfection	O
assays	O
indicated	O
that	O
synergistic	O
action	O
between	O
an	O
SP-1-like	O
element	O
at	O
-21	O
/	O
-12	O
,	O
a	O
GATA	O
site	O
at	O
-59	O
/	O
-54	O
,	O
and	O
a	O
novel	O
regulatory	O
element	O
,	O
CPRE	O
(	O
-	O
GGACTACAG	O
-	O
)	O
at	O
-49	O
/	O
-41	O
,	O
is	O
essential	O
for	O
the	O
promoter	O
activity	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
.	O

In	O
nonerythroid	O
NIH3T3	O
cells	O
,	O
however	O
,	O
the	O
GATA	O
site	O
is	O
not	O
required	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
specific	O
DNA	B
-	I
protein	I
complexes	I
can	O
be	O
formed	O
with	O
each	O
element	O
,	O
and	O
that	O
there	O
are	O
cell	O
-	O
specific	O
differences	O
in	O
factors	O
,	O
which	O
bind	O
to	O
the	O
SP-1-like	O
element	O
between	O
MEL	O
and	O
NIH3T3	O
cells	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	B
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O

Interleukin	B
1beta	I
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	O
on	O
LNCaP	O
human	O
prostate	O
cancer	O
cells	O
.	O

Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen	O
-	O
sensitive	O
prostate	O
cancer	O
LNCaP	O
cells	O
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation	O
-	O
promoting	O
substances	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	O
blood	O
monocytes	O
that	O
exhibit	O
anti	O
-	O
tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	O
cell	O
line	O
.	O

For	O
this	O
purpose	O
,	O
LNCaP	O
cells	O
were	O
incubated	O
with	O
monocyte	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	B
receptor	I
(	O
AR	B
)	O
and	O
secretion	O
of	O
prostate	B
-	I
specific	I
antigen	I
(	O
PSA	B
)	O
were	O
assessed	O
.	O

Conditioned	O
medium	O
from	O
monocytes	O
reduced	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
40	O
%	O
MCM	O
caused	O
a	O
50	O
%	O
reduction	O
in	O
cell	O
proliferation	O
.	O

AR	B
protein	I
decreased	O
by	O
70	O
%	O
and	O
PSA	B
levels	O
in	O
supernatants	O
from	O
LNCaP	O
cells	O
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	O
,	O
prostaglandin	O
E2	O
and	O
interleukin	B
1beta	I
(	O
IL-1beta	B
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O

LNCaP	O
cells	O
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
levels	O
.	O

The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	B
protein	I
and	O
PSA	B
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti	B
-	I
IL-1beta	I
antibody	I
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	B
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down	O
-	O
regulation	O
of	O
AR	B
and	O
PSA	B
proteins	O
.	O

LNCaP	O
cells	O
were	O
shown	O
to	O
express	O
the	O
IL-1beta	B
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	B
signal	O
.	O

Our	O
findings	O
reveal	O
that	O
monocyte	B
-	I
derived	I
IL-1beta	I
inhibits	O
the	O
proliferation	O
of	O
androgen	O
-	O
responsive	O
prostate	O
tumour	O
cells	O
and	O
reduces	O
AR	B
and	O
PSA	B
levels	O
.	O

p21ras	B
initiates	O
Rac-1	B
but	O
not	O
phosphatidyl	B
inositol	I
3	I
kinase	I
/	I
PKB	I
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	B
is	O
activated	O
by	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	B
lymphocyte	I
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	B
nucleotide	I
binding	I
protein	I
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	B
/	I
threonine	I
kinase	I
Raf-1	B
and	O
the	O
Ras	B
-	I
related	I
GTPase	I
Rac-1	B
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	B
3-kinase	I
(	O
PtdIns	B
3-kinase	I
)	O
.	O

Activation	O
of	O
this	O
lipid	B
kinase	I
is	O
able	O
to	O
induce	O
critical	O
Rac-1	B
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	B
/	I
threonine	I
kinase	I
Akt	I
/	I
PKB	I
.	O

The	O
role	O
of	O
PtdIns	B
3-kinase	I
in	O
Ras	B
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	B
3-kinase	I
to	O
initiate	O
the	O
Rac-1	B
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	B
/	I
PKB	I
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	B
can	O
initiate	O
a	O
Rac-1	B
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	B
complexes	I
.	O

PtdIns	B
3-kinase	I
signals	O
can	O
not	O
mimic	O
p21ras	B
and	O
induce	O
the	O
Rac	B
mediated	O
responses	O
of	O
AP-1	B
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	B
or	O
Ras	B
activation	O
of	O
AP-1	B
is	O
dependent	O
on	O
PtdIns	B
3-kinase	I
.	O

PKB	B
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
;	O
PtdIns	B
3-kinase	I
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	B
response	O
.	O

In	O
contrast	O
,	O
p21ras	B
signals	O
are	O
unable	O
to	O
induce	O
Akt	B
/	I
PKB	I
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	B
function	O
required	O
for	O
Akt	B
/	I
PKB	I
activation	O
in	O
response	O
to	O
the	O
TCR	B
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	B
3-kinase	I
and	O
Akt	B
/	I
PKB	I
are	O
not	O
universal	O
Ras	B
effector	I
molecules	I
.	O

Ras	B
can	O
initiate	O
Rac-1	B
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	B
cell	I
antigen	I
receptor	I
function	O
independently	O
of	O
PtdIns	B
3-kinase	I
activity	O
.	O

Differential	O
effects	O
of	O
protein	B
kinase	I
C	I
inhibitors	O
on	O
fibronectin	B
-induced	O
interleukin	O
-	O
beta	O
gene	O
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
when	O
stimulated	O
with	O
the	O
extracellular	B
matrix	I
glycoprotein	I
,	O
fibronectin	B
(	O
FN	B
)	O
.	O

Protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	B
acts	O
upon	O
to	O
mediate	O
the	O
FN	B
-induced	O
IL-1beta	B
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	B
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	B
-induced	O
IL-1beta	B
response	O
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	B
protein	I
into	O
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	B
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	B
protein	I
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full	O
-	O
length	O
IL-1beta	O
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	B
factor	I
activator	I
protein-1	I
(	O
AP-1	B
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	B
induction	O
of	O
IL-1beta	B
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	B
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	B
,	O
we	O
conclude	O
that	O
PKC	B
is	O
necessary	O
for	O
FN	B
-induced	O
IL-1beta	B
protein	O
production	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL-1beta	B
by	O
unknown	O
mechanisms	O

In	O
situ	O
RT	O
-	O
PCR	O
detection	O
of	O
Epstein	O
-	O
Barr	O
virus	O
immediate	O
-	O
early	O
transcripts	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

AIDS	O
-	O
related	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O

The	O
pathway	O
whereby	O
EBV	O
infects	O
T	O
cells	O
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	O
cells	O
has	O
not	O
been	O
established	O
.	O

In	O
order	O
to	O
shed	O
light	O
on	O
the	O
early	O
events	O
of	O
the	O
EBV	O
infection	O
of	O
T	O
cells	O
,	O
we	O
have	O
used	O
in	O
situ	O
reverse	O
transcription	O
based	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
study	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
homogeneous	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
.	O

Following	O
EBV	O
infection	O
,	O
Epstein	O
-	O
Barr	O
nuclear	O
antigen	O
(	O
EBNA	B
)	O
expression	O
could	O
be	O
detected	O
in	O
T	O
rosetting	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

Only	O
a	O
few	O
cells	O
showed	O
viral	B
capsid	I
antigen	I
(	O
VCA	B
)	O
.	O

EBV	O
immediate	O
-	O
early	O
gene	O
transcripts	O
(	O
BZLF1	O
,	O
BRLF1	O
,	O
and	O
BMLF1	O
)	O
encoded	O
in	O
the	O
BamHI	O
Z	O
,	O
R	O
,	O
and	O
M	O
fragments	O
could	O
be	O
detected	O
by	O
in	O
situ	O
RT	O
-	O
PCR	O
in	O
the	O
EBV	O
producer	O
cell	O
line	O
B95.8	O
.	O

Both	O
BZLF1	O
and	O
BRLF1	O
immediate	O
-	O
early	O
transcripts	O
,	O
but	O
not	O
BMLF1	O
transcript	O
,	O
could	O
be	O
detected	O
in	O
individual	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
infected	O
with	O
EBV	O
.	O

Demonstration	O
of	O
EBV	O
mRNA	O
transcripts	O
encoding	O
immediate	B
-	I
early	I
transcriptional	I
transactivators	I
in	O
EBV	O
-	O
infected	O
T	O
cells	O
provides	O
the	O
first	O
evidence	O
for	O
a	O
possible	O
mechanism	O
whereby	O
EBV	O
could	O
contribute	O
to	O
T	O
cell	O
proliferation	O
and	O
EBV	O
-	O
associated	O
T	O
cell	O
malignancies	O
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	O
human	O
T	O
cells	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
by	O
dendritic	O
cells	O
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APC	O
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	O
DC	O
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	O
CD4	O
+	O
T	O
cells	O
to	O
epitopes	B
of	O
the	O
immediate	B
early	I
62	I
(	I
IE62	I
)	I
protein	I
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

The	O
induction	O
of	O
CD4	B
+	I
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	B
IE62	I
protein	I
was	O
assessed	O
using	O
T	O
cells	O
and	O
DC	O
from	O
VZV	O
-	O
susceptible	O
donors	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	O
T	O
cells	O
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

T	O
cell	O
proliferation	O
was	O
induced	O
by	O
three	O
peptides	O
,	O
P1	O
,	O
P4	O
,	O
and	O
P7	O
,	O
in	O
71	O
-	O
100	O
%	O
of	O
the	O
donors	O
tested	O
before	O
and	O
after	O
vaccination	O
using	O
DC	O
as	O
APC	O
.	O

Monocytes	O
were	O
effective	O
APC	O
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	O
cells	O
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	O
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	O
as	O
APC	O
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	O
as	O
APC	O
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

A	O
novel	O
growth	O
-	O
factor	O
-	O
dependent	O
myeloid	O
cell	O
line	O
derived	O
from	O
mouse	O
bone	O
marrow	O
cells	O
contains	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
.	O

Constitutive	O
expression	O
of	O
human	B
colony	I
-	I
stimulating	I
factor-1	I
receptor	I
(	O
CSF-1R	B
)	O
confers	O
long	O
-	O
lasting	O
CSF-1	B
-dependent	O
proliferation	O
to	O
mouse	O
myeloid	O
cell	O
lines	O
.	O

We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	B
because	O
mouse	O
CSF-1	B
can	O
not	O
activate	O
human	O
CSF-1R	B
.	O

Then	O
bone	O
marrow	O
cells	O
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	B
form	I
of	O
human	B
CSF-1	I
(	O
2M-1	O
cells	O
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	O
cells	O
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	B
.	O

Thus	O
,	O
we	O
were	O
able	O
to	O
derive	O
a	O
hematopoietic	O
cell	O
line	O
,	O
called	O
47.10	O
,	O
that	O
grew	O
indefinitely	O
under	O
these	O
conditions	O
,	O
whereas	O
no	O
cell	O
line	O
could	O
be	O
developed	O
from	O
nontransgenic	O
mice	O
.	O

Proliferation	O
of	O
47.10	O
cells	O
is	O
severely	O
affected	O
by	O
neutralizing	O
anti	B
-	I
CSF-1R	I
monoclonal	I
antibodies	I
.	O

Morphologic	O
and	O
cytofluorometry	O
analysis	O
established	O
that	O
most	O
47.10	O
cells	O
are	O
immature	O
myelomonocytic	O
cells	O
.	O

Consistent	O
with	O
this	O
phenotype	O
,	O
the	O
myeloid	B
transcription	I
factor	I
PU.1	I
,	O
but	O
not	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	I
,	O
is	O
expressed	O
in	O
47.10	O
cells	O
.	O

A	O
few	O
47.10	O
cells	O
(	O
3	O
-	O
5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage	O
-	O
positive	O
cells	O
after	O
replating	O
on	O
2M-1	O
cells	O
.	O

In	O
agar	O
cultures	O
,	O
47.10	O
cells	O
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
2.5	O
ng	O
/	O
mL	O
)	O
,	O
interleukin-3	B
(	O
1	O
ng	O
/	O
mL	O
)	O
,	O
and	O
mouse	O
CSF-1	B
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
about	O
0.5	O
%	O
of	O
47.10	O
cells	O
formed	O
large	O
14-day	O
colonies	O
(	O
>	O
1	O
mm	O
)	O
composed	O
of	O
mature	O
monocytes	O
and	O
granulocytes	O
,	O
reflecting	O
the	O
presence	O
of	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
(	O
HPP-47.10	O
cells	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	O
myeloid	O
cell	O
line	O
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	O
marrow	O
progenitor	O
cell	O
compartment	O
.	O

Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	O
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O

The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	B
hormone	I
receptor	I
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Significantly	O
increased	O
oestrogen	B
receptor	I
expression	O
,	O
bcl-2	B
expression	O
and	O
numbers	O
of	O
CD8	O
+	O
leukocytes	O
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56	O
+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Apoptotic	O
cells	O
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O

In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	B
hormone	I
receptor	I
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	B
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O

The	O
unusual	O
CD56	O
+	O
CD16-	O
eGLs	O
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56	O
+	O
CD16	O
+	O
natural	O
killer	O
cells	O
.	O

eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U	O
/	O
ml	O
interleukin-2	B
over	O
48-h	O
and	O
120-h	O
time	O
courses	O
.	O

eGLs	O
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD+8	O
T	O
-	O
cell	O
numbers	O
and	O
increased	O
oestrogen	B
receptor	I
and	O
bcl-2	B
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	B
or	O
protease	B
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long	O
-	O
terminal	O
repeat	O
transcription	O
in	O
HIV	O
-	O
infected	O
cells	O
and	O
increased	O
NF	B
-	I
kappaB	I
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF	B
-	I
ATc	I
in	O
effector	O
T	O
cells	O
.	O

The	O
transcription	B
factor	I
NF	B
-	I
ATc	I
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	B
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	O
'	O
polyA	O
site	O
to	O
a	O
more	O
proximal	O
polyA	O
site	O
,	O
NF	B
-	I
ATc	I
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	O
T	O
cells	O
to	O
that	O
of	O
short	O
isoform	B
A	I
in	O
T	O
effector	O
cells	O
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	B
stimulation	I
factor	I
CstF-64	B
to	O
the	O
proximal	O
polyA	O
site	O
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	O
T	O
cells	O
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF	B
-	I
ATc	I
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF	B
-	I
ATc	I
for	O
gene	O
induction	O
in	O
effector	O
T	O
cells	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
cell	O
line	O
(	O
UF-1	O
)	O
associated	O
with	O
expression	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all	O
-	O
trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	B
factors	I
:	O
RA	B
receptors	I
(	O
RARs	B
)	O
and	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
.	O

RXRs	B
heterodimerize	O
with	O
1	B
,	I
25-dihydroxyvitamin	I
D3	I
[	I
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
]	I
receptor	I
(	O
VDR	B
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin	B
-	I
dependent	I
kinase	I
(	I
cdk	I
)	I
inhibitor	I
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
has	O
a	O
vitamin	O
D3-responsive	O
element	O
(	O
VDRE	O
)	O
in	O
its	O
promoter	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	O
leukemic	O
cell	O
lines	O
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	O
cell	O
line	O
(	O
UF-1	O
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF-1	O
cells	O
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all	O
-	O
trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-10	O
)	O
to	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	B
(	I
KIP1	I
)	I
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF-1	O
cells	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B
(	I
KIP1	I
)	I
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B
(	I
KIP1	I
)	I
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B
antigen	I
in	O
myeloid	O
leukemic	O
cells	O
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF-1	O
cells	O
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	B
(	I
WAF1	I
/	I
CIP1	I
)	I
and	O
p27	B
(	I
KIP1	I
)	I
transcript	O
and	O
protein	O
expression	O
in	O
RA	O
-	O
resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	B
inhibitors	I
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA	O
-	O
resistant	O
UF-1	O
cells	O
toward	O
mature	O
granulocytes	O
.	O

IL-2	B
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	B
-	I
kappa	I
B	I
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL-2	B
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL-2	B
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and/or	O
activating	B
protein-1	I
(	O
AP-1	B
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	B
factors	I
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	B
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	B
does	O
not	O
induce	O
I	B
kappa	I
B	I
alpha	O
degradation	O
or	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL-2	B
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL-2	B
neither	O
activates	O
JNK	B
nor	O
increases	O
AP-1	B
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	B
factor	I
does	O
induce	O
the	O
activation	O
of	O
STAT3	B
and	O
STAT5	B
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	B
-	I
kappa	I
B	I
nor	O
AP-1	B
activation	O
is	O
required	O
for	O
IL-2	B
-mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitor	O
I	B
kappa	I
B	I
alpha	I
(	O
mut	B
-	I
I	I
kappa	I
B	I
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	B
-	I
I	I
kappa	I
B	I
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B
-CD25	O
+	O
,	O
CD4	B
-	O
CD8	B
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B
beta	I
-	I
chain	I
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	B
-	I
I	I
kappa	I
B	I
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	B
aldosterone	I
receptors	I
outside	O
the	O
acute	O
phase	O
.	O

Pseudo	O
-	O
hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54-year	O
-	O
old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i.e.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80	O
/	O
60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol	O
/	O
l	O
)	O
;	O
hyperkalemia	O
(	O
7.6	O
mmol	O
/	O
l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg	O
/	O
dl	O
)	O
and	O
creatininemia	O
(	O
2.5	O
mg	O
/	O
dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3-	O
:	O
16	O
mmol	O
/	O
l	O
;	O
N	O
:	O
27	O
-	O
30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg	O
/	O
100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8	O
-	O
15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg	O
/	O
ml	O
,	O
N	O
:	O
10	O
-	O
60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng	O
/	O
ml	O
/	O
h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol	O
/	O
l	O
;	O
N	O
:	O
0.5	O
-	O
2.5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol	O
/	O
l	O
(	O
N	O
supine	O
:	O
5	O
-	O
25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1.4+	O
/	O
-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2.7+	O
/	O
-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+	O
/	O
-0.36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+	O
/	O
-0.42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	B
receptors	I
in	O
mononuclear	O
leukocytes	O
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
was	O
reduced	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE	O
/	O
THF	O
and	O
alpha	O
THF	O
/	O
THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	B
mineralocorticoid	I
receptors	I
outside	O
the	O
acute	O
episode	O
.	O

SHP2-interacting	B
transmembrane	I
adaptor	I
protein	I
(	O
SIT	B
)	O
,	O
a	O
novel	O
disulfide	B
-	I
linked	I
dimer	I
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	B
molecular	I
weight	I
transmembrane	I
adaptor	I
proteins	I
that	O
recruit	O
src	B
homology	I
(	I
SH	I
)	I
2	I
domain	I
-	I
containing	I
intracellular	I
molecules	I
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	B
(	O
SHP2	B
interacting	I
transmembrane	I
adaptor	I
protein	I
)	O
.	O

SIT	B
is	O
a	O
disulfide	B
-	I
linked	I
homodimeric	I
glycoprotein	I
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	B
and	O
possibly	O
syk	B
protein	B
tyrosine	I
kinases	I
SIT	B
recruits	O
the	O
SH2	B
domain	I
-	I
containing	I
tyrosine	I
phosphatase	I
SHP2	B
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	B
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	B
C	I
.	O

However	O
,	O
binding	O
of	O
SHP2	B
to	O
SIT	B
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	B
-	I
AT	I
induction	O
,	O
suggesting	O
that	O
SIT	B
not	O
only	O
regulates	O
NF	B
-	I
AT	I
activity	O
but	O
also	O
controls	O
NF	B
-	I
AT	I
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	B
.	O

GrpL	B
,	O
a	O
Grb2	B
-related	O
adaptor	B
protein	I
,	O
interacts	O
with	O
SLP-76	B
to	O
regulate	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	B
domain	I
-	I
containing	I
protein	I
76	I
(	O
SLP-76	B
)	O
interacts	O
with	O
the	O
guanine	B
nucleotide	I
exchange	I
factor	I
Vav	B
to	O
activate	O
the	O
nuclear	B
factor	I
of	I
activated	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	B
adaptor	I
molecule	I
designated	O
as	O
Grb2-related	B
protein	I
of	I
the	I
lymphoid	I
system	I
(	O
GrpL	B
)	O
.	O

Expression	O
of	O
GrpL	B
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	B
by	O
having	O
a	O
proline	B
-	I
rich	I
region	I
.	O

GrpL	B
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	B
but	O
not	O
with	O
Sos1	B
or	O
Sos2	B
from	O
Jurkat	O
cell	O
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	B
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	B
and	O
Sos2	B
but	O
not	O
with	O
SLP-76	B
.	O

Moreover	O
,	O
tyrosine	B
-	I
phosphorylated	I
LAT	I
/	I
pp36	I
/	I
38	I
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	B
but	O
not	O
GrpL	B
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	B
and	O
Grb2	B
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL	B
-	I
SLP-76	I
complex	I
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	B
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	B
to	O
augment	O
NF	B
-	I
AT	I
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Transcription	B
factors	I
Sp1	B
and	O
AP-2	B
mediate	O
induction	O
of	O
acid	B
sphingomyelinase	I
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12-myristate	O
-13-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25-dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	B
enzyme	I
acid	B
sphingomyelinase	I
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	O
cells	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	O
mononuclear	O
phagocytes	O
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	B
protection	O
assay	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell	O
-	O
type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	O
'	O
deletion	O
derivatives	O
of	O
the	O
upstream	O
regulatory	O
region	O
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	O
elements	O
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-319	O
and	O
-219	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	O
factor	O
expression	O
plasmids	O
for	O
AP-2	B
and	O
Sp1	B
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	O
sites	O
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B
and	O
AP-2	B
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP-1	O
cells	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	B
factors	I
AP-2	B
and	O
Sp1	B
is	O
essential	O
for	O
the	O
up	O
-regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

Grf40	B
,	O
A	O
novel	O
Grb2	B
family	I
member	I
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP-76	B
and	O
LAT	B
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	B
family	I
member	I
,	O
named	O
Grf40	B
,	O
containing	O
the	O
common	O
SH3-SH2-SH3	B
motif	I
.	O

Expression	O
of	O
Grf40	B
is	O
predominant	O
in	O
hematopoietic	O
cells	O
,	O
particularly	O
T	O
cells	O
.	O

Grf40	B
binds	O
to	O
the	O
SH2	B
domain	I
-	I
containing	I
leukocyte	I
protein	I
of	O
76	O
kD	O
(	O
SLP-76	B
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B
.	O

Incidentally	O
,	O
Grf40	B
binds	O
to	O
linker	B
for	I
activation	I
of	I
T	I
cells	I
(	O
LAT	B
)	O
possibly	O
via	O
its	O
SH2	B
domain	I
.	O

Overexpression	O
of	O
wild	B
-	I
type	I
Grf40	I
in	O
Jurkat	O
cells	O
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
and	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
(	O
NF	B
-	I
AT	I
)	O
activation	O
upon	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
stimulation	O
,	O
whereas	O
the	O
COOH	B
-	I
terminal	I
SH3-deleted	I
Grf40	I
mutant	I
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
the	O
SH2-deleted	B
Grf40	I
mutant	I
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2-deleted	B
Grb2	I
mutant	I
.	O

Our	O
data	O
suggest	O
that	O
Grf40	B
is	O
an	O
adaptor	B
molecule	I
involved	O
in	O
TCR	B
-mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	B
with	O
SLP-76	B
and	O
LAT	B
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	B
T	I
-	I
cell	I
mitogens	I
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	O
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	B
-	I
kappaB	I
.	O

The	O
activation	O
of	O
NF	B
-	I
kappaB	I
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	B
molecules	I
.	O

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV-1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

HLA	B
class	I
I	I
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	O
E	O
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	B
class	I
I	I
Ags	I
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B
class	I
I	I
molecules	I
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	B
class	I
I	I
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B
protein	I
in	O
the	O
T	O
cell	O
line	O
Jurkat	O
as	O
well	O
as	O
human	O
aortic	O
endothelial	O
cells	O
.	O

HLA	B
class	I
I	I
-mediated	O
inactivation	O
of	O
Rb	B
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	B
Abs	I
to	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	B
receptors	I
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	B
class	I
I	I
molecules	I
induced	O
cyclin	O
E	O
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	O
endothelial	O
cells	O
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	O
-	O
negative	O
cdk2	O
construct	O
prevented	O
HLA	B
class	I
I	I
-mediated	O
inactivation	O
of	O
Rb	B
;	O
in	O
contrast	O
,	O
dominant	O
-	O
negative	O
cdk4	O
and	O
cdk6	O
constructs	O
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	B
D	I
-	I
associated	I
kinase	I
activity	O
upon	O
HLA	B
class	I
I	I
ligation	O
,	O
suggesting	O
that	O
cyclin	B
E	I
-	I
dependent	I
kinase	I
activity	O
mediates	O
Rb	B
inactivation	O
,	O
leading	O
to	O
E2F	B
activation	O
and	O
cell	O
proliferation	O
.	O

Protein	B
kinase	I
B	I
(	O
c	B
-	I
Akt	I
)	O
,	O
phosphatidylinositol	B
3-kinase	I
,	O
and	O
STAT5	B
are	O
activated	O
by	O
erythropoietin	B
(	O
EPO	B
)	O
in	O
HCD57	O
erythroid	O
cells	O
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO	O
-	O
independent	O
,	O
apoptosis	O
-	O
resistant	O
subclone	O
(	O
HCD57-SREI	O
cells	O
)	O
.	O

We	O
found	O
that	O
erythropoietin	B
(	O
EPO	B
)	O
and	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
activated	B
protein	I
kinase	I
B	I
(	O
PKB	B
/	I
Akt	I
)	O
in	O
EPO	O
-	O
dependent	O
HCD57	O
erythroid	O
cells	O
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	O
cells	O
)	O
.	O

Constitutive	O
activations	O
of	O
PKB	B
/	I
Akt	I
,	O
STAT5a	B
,	O
and	O
STAT5b	B
were	O
noted	O
in	O
these	O
EPO	O
-	O
independent	O
cells	O
.	O

PI3-kinase	B
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB	B
/	I
Akt	I
because	O
the	O
PI3-kinase	B
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB	B
/	I
Akt	I
and	O
factor	O
-	O
dependent	O
PKB	B
/	I
Akt	I
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	O
and	O
HCD57	O
cells	O
correlated	O
with	O
the	O
activity	O
of	O
PKB	B
/	I
Akt	I
;	O
however	O
,	O
PKB	B
/	I
Akt	I
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	O
cells	O
with	O
SCF	B
also	O
activated	O
PKB	B
/	I
Akt	I
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB	B
/	I
PI3-kinase	I
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Constitutive	O
STAT5	B
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B
or	O
EPOR	B
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	B
/PKB	B
/	I
Akt	I
pathway	O
to	O
protect	O
the	O
EPO	O
-	O
independent	O
HCD57-SREI	O
cells	O
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta	O
-	O
globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
assumes	O
a	O
transcriptionally	O
-	O
active	O
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta	O
-	O
globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	O
-	O
specific	O
DNase	O
1	O
hypersensitive	O
site	O
-	O
forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF	B
-	I
E2	I
,	O
AP-1	B
,	O
GATA-1	B
and	O
Sp-1	B
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	B
1	I
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta	O
-	O
globin	O
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta	O
-	O
globin	O
gene	O
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	O
-	O
globin	O
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis	O
-	O
acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta	O
-	O
globin	O
gene	O
expression	O
.	O

Modulation	O
of	O
CD28	B
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	B
molecule	I
CD28	B
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

Although	O
CD28	B
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down	O
-	O
regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	B
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein	O
-	O
binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	B
alpha	I
and	I
beta	I
,	O
within	O
the	O
CD28	O
minimal	O
promoter	O
.	O

Both	O
alpha-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	O
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	O
B	O
cells	O
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down	O
-	O
modulation	O
of	O
site	B
beta	I
-but	O
not	O
site	B
alpha	I
-binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta	O
-	O
binding	O
activities	O
.	O

CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
differ	O
in	O
their	O
beta	O
-	O
binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down	O
-	O
regulation	O
of	O
CD28	B
in	O
senescent	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	O
and	O
CD8+CD28null	O
T	O
cells	O
uniformly	O
lack	O
alpha-	B
and	I
beta-	I
bound	I
complexes	I
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	O
activated	O
cells	O
and	O
not	O
of	O
senescent	O
cells	O
.	O

UV	O
-	O
induced	O
CYP1A1	B
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	B
P-4501A1	I
(	O
CYP1A1	B
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah	O
-	O
receptor	O
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B
P4501A1	I
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	O
mRNA	O
by	O
UV	O
irradiation	O
of	O
cultured	O
human	O
keratinocytes	O
(	O
HaCaT	O
cell	O
line	O
)	O
,	O
primary	O
human	O
blood	O
lymphocytes	O
and	O
mouse	O
Hepa-1	O
cells	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20	O
/	O
12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	B
transcriptase	I
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	O
mRNA	O
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	O
cells	O
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	O
receptor	O
ligand	O
,	O
Hepa-1	O
wild	O
-	O
type	O
and	O
Ah	O
receptor	O
deficient	O
c12	O
cell	O
lines	O
were	O
applied	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
cells	O
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6-formylindolo	O
[	O
3	O
,	O
2-b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B
receptor	I
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV	O
-	O
induced	O
CYP1A1	B
gene	O
expression	O
in	O
mammalian	O
cells	O
is	O
mediated	O
by	O
an	O
Ah	B
receptor	I
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B
receptor	I
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell	B
-	I
surface	I
receptors	I
,	O
intracellular	B
signaling	I
molecules	I
,	O
and	O
nuclear	B
transcription	I
factors	I
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	B
cell	I
transcription	I
factors	I
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	B
,	O
LKLF	B
,	O
and	O
GATA3	B
zinc	I
-	I
finger	I
proteins	I
;	O
the	O
Ets	B
,	O
CREB	B
/	I
ATF	I
,	O
and	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
/	I
NFAT	I
transcription	I
factors	I
;	O
the	O
Stat	B
proteins	I
;	O
and	O
HMG	B
box	I
transcription	I
factors	I
such	O
as	O
LEF1	B
,	O
TCF1	B
,	O
and	O
Sox4	B
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

20-Epi	O
analogues	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	B
coactivator	I
complex	I
binding	O
to	O
the	O
vitamin	B
D3	I
receptor	I
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	O
(	O
Waf1	O
,	O
Cip1	O
)	O
,	O
a	O
key	O
VDR	O
target	O
gene	O
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B
interacting	O
proteins	O
:	O
RXR	B
,	O
GRIP-1	B
,	O
and	O
DRIP205	B
,	O
a	O
subunit	O
of	O
the	O
DRIP	B
coactivator	I
complex	I
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B
with	O
RXR	B
or	O
GRIP-1	B
,	O
the	O
differentiation	O
dose	O
-	O
response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand	O
-	O
dependent	O
recruitment	O
of	O
the	O
DRIP	B
coactivator	I
complex	I
to	O
VDR	B
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	B
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	B
binding	O
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
transcription	B
factor	I
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
--	O
although	O
still	O
difficult	O
--	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti	B
-	I
TNF	I
antibody	I
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF	B
-	I
alpha	I
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	B
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	B
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	B
inhibitors	I
.	O

The	O
biological	O
significance	O
of	O
NF	B
-	I
kappaB	I
activation	O
in	O
T.	O
parva	O
-	O
infected	O
cells	O
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite	O
-	O
mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	B
negative	I
mutant	I
forms	O
of	O
components	O
of	O
the	O
NF	B
-	I
kappaB	I
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	B
or	O
p65	B
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	B
-	I
kappaB	I
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	B
-	I
activated	I
toll	I
-	I
like	I
receptor	I
2	I
.	O

Human	B
Toll	I
-	I
like	I
receptor	I
2	I
(	I
TLR2	I
)	I
is	O
a	O
signaling	B
receptor	I
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	B
-	I
kappaB	I
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	B
associates	O
with	O
the	O
high	B
-	I
affinity	I
LPS	I
binding	I
protein	I
membrane	O
CD14	B
to	O
serve	O
as	O
an	O
LPS	B
receptor	I
complex	I
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R	B
-	I
associated	I
kinase	I
(	I
IRAK	I
)	I
is	O
recruited	O
to	O
the	O
TLR2	B
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	B
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	B
-	I
type	I
TLR2	I
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	B
-mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	B
differentiation	I
protein	I
,	O
IRAK	B
,	O
TNF	B
receptor	I
-	I
associated	I
factor	I
6	I
,	O
and	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
,	O
when	O
coexpressed	O
with	O
TLR2	B
,	O
abrogate	O
TLR2	B
-mediated	O
NF	B
-	I
kappaB	I
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B
and	O
IL-1Rs	B
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B
by	O
DN	O
variants	O
.	O

Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA	B
-	I
DR	I
-restricted	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B
interferon	I
-induced	O
class	B
II	I
transactivator	I
expression	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN	B
-	I
gamma	I
)	O
-induced	O
HLA	B
-	I
DR	I
expression	O
in	O
U373	O
MG	O
astrocytoma	O
cells	O
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN	B
-	I
gamma	I
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA	B
-	I
DR	I
synthesis	O
.	O

This	O
defect	O
leads	O
to	O
the	O
absence	O
of	O
presentation	O
of	O
the	O
major	B
immediate	I
-	I
early	I
protein	I
IE1	B
to	O
specific	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
clones	O
when	O
U373	O
MG	O
cells	O
,	O
used	O
as	O
antigen	O
-	O
presenting	O
cells	O
,	O
are	O
treated	O
with	O
IFN	B
-	I
gamma	I
plus	O
HCMV	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	B
can	O
be	O
restored	O
when	O
U373	O
MG	O
cells	O
are	O
transfected	O
with	O
CIITA	O
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN	O
-	O
gamma	O
-	O
responsive	O
promoter	O
of	O
CIITA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
viral	O
inhibition	O
of	O
CIITA	O
expression	O
.	O

Bcl-2	B
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	B
factor	I
of	I
activated	I
T	I
lymphocytes	I
(	O
NFAT	B
)	O
-induced	O
Fas	B
ligand	O
transcription	O
.	O

Bcl-2	B
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	B
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	B
family	I
such	O
as	O
Bax	B
and	O
Bad	B
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	B
/Fas	B
ligand	I
(	O
FasL	B
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	B
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	B
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	B
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	B
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
lymphocytes	I
,	O
a	O
transcription	B
factor	I
activated	O
by	O
microtubule	B
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium	O
-	O
dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	B
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	B
nuclear	O
translocation	O
,	O
the	O
FasL	B
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	B
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	B
.	O

Furthermore	O
,	O
Bcl-2	B
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B
activation	O
,	O
blocking	O
NFAT	B
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	B
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	B
.	O

Phosphorylated	O
Bcl-2	B
can	O
not	O
bind	O
calcineurin	B
,	O
and	O
NFAT	B
activation	O
,	O
FasL	B
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	B
phosphorylation	O
.	O

TCL1	O
oncogene	O
expression	O
in	O
AIDS	O
-	O
related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
AIDS	O
NHL	O
)	O
comprises	O
a	O
diverse	O
and	O
heterogeneous	O
group	O
of	O
high	O
-	O
grade	O
B	O
cell	O
tumors	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	O
or	O
tumor	O
-	O
suppressor	O
genes	O
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O

We	O
identified	O
the	O
TCL1	O
oncogene	O
from	O
a	O
set	O
of	O
AIDS	O
IBLP	O
-	O
associated	O
cDNA	O
fragments	O
generated	O
by	O
subtractive	O
hybridization	O
with	O
non	O
-	O
AIDS	O
IBLP	O
.	O

Aberrant	O
TCL1	B
expression	O
has	O
been	O
implicated	O
in	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
development	O
,	O
and	O
its	O
expression	O
also	O
has	O
been	O
seen	O
in	O
many	O
established	O
B	O
cell	O
tumor	O
lines	O
.	O

However	O
,	O
TCL1	B
expression	O
has	O
not	O
been	O
reported	O
in	O
AIDS	O
NHL	O
.	O

We	O
find	O
that	O
TCL1	B
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

TCL1	B
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Hyperplastic	O
lymph	O
node	O
and	O
tonsil	O
also	O
exhibit	O
strong	O
TCL1	B
protein	O
expression	O
in	O
mantle	O
zone	O
B	O
cells	O
and	O
in	O
rare	O
interfollicular	O
zone	O
cells	O
,	O
whereas	O
follicle	O
-	O
center	O
B	O
cells	O
(	O
centroblasts	O
and	O
centrocytes	O
)	O
show	O
weaker	O
expression	O
.	O

These	O
results	O
establish	O
TCL1	B
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	O
associated	O
with	O
AIDS	O
IBLP	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	B
expression	O
in	O
quiescent	O
mantle	O
zone	O
B	O
cells	O
is	O
down	O
-	O
regulated	O
in	O
activated	O
germinal	O
center	O
follicular	O
B	O
cells	O
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	B
.	O

High	O
-	O
level	O
expression	O
in	O
nonproliferating	O
B	O
cells	O
suggests	O
that	O
TCL1	B
may	O
function	O
in	O
protecting	O
naive	O
preactivated	O
B	O
cells	O
from	O
apoptosis	O
.	O

Induction	O
of	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
expression	O
by	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
Tax	I
through	O
NF	B
-	I
kappaB	I
in	O
apoptosis	O
-	O
resistant	O
T	O
-	O
cell	O
transfectants	O
with	O
Tax	B
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	B
protected	O
the	O
mouse	O
T	O
-	O
cell	O
line	O
CTLL-2	O
against	O
apoptosis	O
induced	O
by	O
interleukin-2	B
(	O
IL-2	B
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	B
dependent	O
to	O
being	O
IL-2	B
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl	B
-	I
xl	I
but	O
not	O
bcl-2	B
,	O
bcl	B
-	I
xs	I
,	O
bak	B
,	O
bad	B
,	O
or	O
bax	B
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	B
deprivation	O
in	O
CTLL-2	O
cells	O
that	O
expressed	O
Tax	B
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	O
-	O
x	O
promoter	O
was	O
transactivated	O
by	O
wild	B
-	I
type	I
Tax	I
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	B
retaining	O
transactivating	O
ability	O
through	O
NF	B
-	I
kappaB	I
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	B
NF	I
-	I
kappaB	I
binding	I
site	I
identified	O
in	O
the	O
bcl	O
-	O
x	O
promoter	O
significantly	O
decreased	O
Tax	B
-induced	O
transactivation	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF	B
-	I
kappaB	I
family	I
proteins	I
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	B
-induced	O
transactivation	O
of	O
the	O
bcl	O
-	O
x	O
promoter	O
was	O
also	O
diminished	O
by	O
the	O
mutant	B
IkappaBalpha	I
,	O
which	O
specifically	O
inhibits	O
NF	B
-	I
kappaB	I
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
induced	O
by	O
Tax	B
through	O
the	O
NF	B
-	I
kappaB	I
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	O
cells	O
after	O
IL-2	B
deprivation	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappaB	I
(	O
NFkappaB	B
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	B
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus	O
-	O
induced	O
degradation	O
of	O
the	O
cytoplasmic	B
factor	I
IkappaBalpha	B
.	O

Tumor	B
-	I
derived	I
soluble	I
products	I
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	B
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus	O
-	O
induced	O
IkappaBalpha	B
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	B
but	O
not	O
protease	B
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	B
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	O
expression	O
of	O
the	O
cytokines	B
IL-2	B
and	O
IFN	B
-	I
gamma	I
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor	O
-	O
derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

